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1. Abstract 
 
1.1. Zusammenfassung 
Die zielgerichtete Therapie mit tumor-spezifischen Antikörpern hat sich im Laufe der Zeit in der klinischen 
Onkologie etabliert, was durch die Vielzahl an zugelassenen Medikamenten belegt ist. Dennoch gibt es 
Limitationen bei Antikörpern, die Zelloberflächenantigene adressieren. Onkologische Therapeutika müssen im 
Rahmen der Tumortherapie in der Lage sein, alle Krebszellen zu erreichen. Wenn unbehandelte Regionen nicht 
therapiert werden, können diese zu einem Tumor-Rezidiv führen. Die verringerte Tumorpenetration und 
Wirkstoffabgabe von herkömmlichen Antikörper-basierten Medikamenten stellen eine große Herausforderung 
für die effektive Behandlung von soliden Tumoren dar. Im Rahmen von Antikörper-Wirkstoff Konjugaten 
(ADCs), fokussierten sich die größten Forschungsaktivitäten auf neuartige Linker Strukturen, Optimierungen 
von zytotoxischen Arzneistoffen und Technologien für Positions-spezifische Konjugationen. Weniger 
Beachtung erhielt die Modifikation des Antikörpergrundgerüsts oder Antikörperalternativen für die 
Optimierung des Arzneistofftransports. In diesem Kontext spielt die Molekülgröße des ADC Transportvehikels 
eine essenzielle Rolle für den Transport des zytotoxischen Wirkstoffs zu den Tumorzellen. 
 
In der vorliegenden Studie wurde die Auswirkung des Molekulargewichts und der Valenz auf die 
Tumorpenetration und die Wirksamkeit untersucht. In diesem Zuge wurde ein neuartiges ADC Design 
ausgearbeitet und dessen Funktionalität experimentell bestätigt. In einen ADC im IgG Format wurde eine 
Protease-Schnittstelle in die IgG1 Hingeregion eingefügt, welche von überexprimierten Enzymen des 
umliegenden Tumorgewebes gespalten werden kann. Die Spaltung resultiert in 2 Fab Fragmente und einen Fc 
Anteil.  
Der Hinge spaltbare ADC wurde hinsichtlich der Tumorpenetration und der Wirksamkeit von Fab-Wirkstoff 
Konjugaten (FDCs) evaluiert, die mittels enzymatischer Spaltung durch Tumorproteasen lokal freigesetzt 
werden können. Im Gegensatz zu der kurzen Halbwertszeit der im Tumorgewebe lokal freigesetzten Fabs, 
behält der ADC im ungespaltenen Zustand in systemischer Zirkulation die für ADCs typischerweise längere 
Halbwertszeit. ADCs und FDCs mit den zytotoxischen Wirkstoffen MMAE und MMAF wurden durch 
Positions-spezifische Konjugation mittels Sortase A an die leichte Kette der Antikörper und Antikörper 
Fragmente hergestellt. Proteolytische Spaltungsreaktionen und Enzymkinetiken offenbarten eine schnelle 
sowie effiziente Freisetzung der jeweiligen FDCs vom Volllängen ADC durch die Tumorproteasen urokinase-
type plasminogen activator (uPA) und matriptase (MT-SP1). Die hergestellten anti-HER2 ADCs und FDCs 
behielten ihre Antigen Bindeeigenschaften, waren im Mausserum stabil und zeigten vergleichbare in vitro 
Potenz und Aktivität gegenüber einem nicht spaltbaren Kontrollkonstrukt auf HER2-überexprimierenden 
Tumorzellen. Um eine bessere Tumorlokalisation beurteilen zu können, wurden Antikörper-Fluorophor 
Konjugate mit Alexa Fluor 488 hergestellt. Im Vergleich zu Volllängen IgG Antikörper zeigen enzymatisch 
hergestellte Fab-Fluorophor Konjugate eine gleichmäßige Penetration und Verteilung in Tumor Spheroid 
Modellen. Hierbei korrelierte eine tiefere Penetration und homogenere Verteilung im Spheroid mit der 
geringeren Molekülgröße des Transportvehikels. 
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Diese Arbeit zeigt vielversprechende Ergebnisse der in situ generierten FDCs aus den Hinge spaltbaren IgG-
ADCs, die einen potenziellen Benefit gegen solide Tumore im Hinblick auf Tumorpenetration und -lokalisation 
bringen könnten. Darüber hinaus ist ein verbessertes Tumor zu Blut Verhältnis von FDCs zu erwarten, dass in 
einem verringertem Auftreten von Nebenwirkungen resultieren könnte. 
Ob sich die in vitro gezeigte verbesserte Tumorpenetration auch in vivo translatieren lässt, kann abschließend 
nur durch ein Tiermodell belegt werden. Die Einblicke einer in vivo Studie kann Aufschlüsse darüber geben, die 
Balance zwischen der optimalen Tumorpenetration und –akkumulation, dem Molekulargewicht des 
Transportvehikels und der Pharmakokinetik zu optimieren.
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1.2. Abstract  
Targeted therapy with tumor-specific antibodies established in clinical oncology over the past decades with a 
variety of approved drugs. However, antibodies targeting cell surface antigens also suffer from limitations. 
Therapeutic agents must reach all tumor cells in cancer therapy, as untreated regions can lead to tumor 
recurrence.  Poor penetration and drug delivery of conventional antibody-based drugs remain a major challenge 
for effective treatment of solid tumors. In the context of antibody-drug conjugates (ADCs), many research 
efforts focused on new linker chemistry, optimization of cytotoxic drugs and site-specific conjugation 
technologies. Less attention was drawn to the underexplored targeting scaffold of the antibody portion or 
antibody alternatives for optimizing drug delivery. Especially, the molecular size of the ADC pharmacodelivery 
vehicle plays a key role to deliver the cytotoxic payload to tumor cells. 
 
In the presented study, the effect of molecular weight and valency on tumor penetration and efficacy was 
investigated, introducing a novel ADC design. In this novel design an additional protease cleavage site was 
engineered into the IgG1 hinge region. This protease site is sensitive to enzymes commonly active in the tumor 
microenvironment, resulting in the release of 2 Fab-drug conjugates from the original ADC. 
The hinge cleavable ADC was evaluated for the tumor penetration ability and efficacy of Fab-drug conjugates 
(FDCs) that are generated locally by extracellular tumor proteases while retaining the half-life of the full-length 
antibody in systemic circulation. Homogeneous ADCs and FDCs with cytotoxic payloads MMAE and MMAF 
were generated by site-specific conjugation to the light chains of antibodies or antibody fragments using 
sortase A. Proteolytic cleavage reactions and enzyme kinetics displayed a fast and efficient release of FDCs from 
the full-length ADC by tumor-associated proteases urokinase-type plasminogen activator (uPA) and matriptase 
(MT-SP1). The designed anti-HER2 Trastuzumab ADCs and FDCs retained antigen binding properties, were 
stable in mouse serum and demonstrated high in vitro potency and cancer cell killing ability in HER2-
overexpressing cell lines. For assessment of a better tumor localization, preparation as antibody-fluorophore 
conjugates for imaging analysis was achieved with Alexa Fluor 488. Enzymatically generated Fab-fluorophore 
fragments were able to penetrate and distribute more evenly within tumor spheroids compared to full-length 
IgG antibodies. A correlation was observed between reduced molecular size of the pharmacodelivery vehicle and 
tumor penetration and distribution ability. In vitro imaging analysis of tumor spheroids demonstrated increased 
molecular size and increased cellular binding resulted in decreased tumor penetration. 
 
Hence, the presented work showed promising results for the in situ generation of FDCs from IgG-ADCs that 
might have a potential benefit against solid tumors in terms of tumor penetration and localization. Moreover, 
an improved tumor to blood ratio with FDCs can be expected that could also result in reduced adverse effects. 
Further in vivo evaluation is necessary to optimize the balance between optimum tumor penetration and 
accumulation, molecular size of the targeting scaffold and pharmacokinetic properties.
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2. Introduction 
 
2.1. Cancer etiology, incidence and mortality 
Cancer represents a devastating disease and is characterized by uncontrolled proliferation and spread of 
neoplastic cells. To fulfill different physiological functions, various types of cells grow and divide. Normally, in 
case that cells grow old or become damaged by a noxe, apoptosis is activated and new cells replace the old and 
dead cells to restore homeostasis.1 However, when multiple cells in a part of the body divide without regulation 
mechanisms, the excess tissue that is formed is called a tumor or neoplasm. The tumor can be classified as 
malignant or benign by applying distinct criteria.2 On the one hand, a benign tumor is characterized by a slow 
proliferation rate with expansive growth without the presence of metastasis. Besides that, the structure of benign 
tumors have a sharp spatial zoning and histological differences compared to the original tissues are small. On 
the other hand, malignant tumors exhibit high proliferation rates, invasive growth and metastasize in distant 
tissues.2 Several types of cancer evolve by a two-step process. First, a single mutation or a series of mutations 
occur that are potentially responsible for carcinogenesis. Followed by the promotion of this genetic damage, a 
recognizable tumor is the result.3,4 In clinical oncology tumors are classified according to their stage in order to 
better estimate tumor progression and prognosis. The ‘TNM Classification of Malignant Tumors’ System arose 
from the observation that survival rates of patients were higher for cases in which the tumor was localized than 
for those in which the tumor has spread. With the underlying principles of the TNM system, three major criteria 
are assessed to describe the extent of a tumor, which are summarized in Table 1.5 
 
Table 1: Staging and grading according to the TNM classification system. 
The three components with corresponding descriptors used for describing a tumor (T), the presence of regional node (N) and presence 
of metastasis (M) are listed. The extent of malignant disease is indicated by increasing numbers with the respective criteria. Table adapted 
from Sobin et al.5 
 
Criteria Description Stage 
T Extent of primary tumor T0, T1, T2, T3, T4 
N Absence/presence and extent of regional lymph node metastasis N0, N1, N2, N3 
M Absence/presence of distant metastasis M0, M1 
 
 
Clinicians evaluate cancer growth and spread according to the three listed criteria: size/extent of the primary 
tumor (T), absence/presence of regional lymph nodes that are involved (N), and absence/presence of distant 
metastasis (M). Each criteria is indicated by a specific number to further characterize the stage of the diseae. In 
general, the different categories demonstrate that with increasing numbers a more advanced stage and a poor 
prognosis can be assumed, where effective treatment is limited. Therefore, for T1-T4 an increasing size of the 
primary tumor is evident, for N1-N3 multiple lymph nodes are involved, and M1 reveals distant metastasis.5 
During decades of intensive research, cancer etiology revealed that many factors are related to an increased 
occurrence of a malignant tumor.3,4 Today, a lot of cancer risk factors are known. These risk factors comprise 
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genetic predisposition and non-genetic factors like lifestyle and environmental risk factors, but also viruses and 
other infections. For example, alcohol abuse and addictive substances like tobacco are related to an increasing 
risk for lung cancer, colorectal cancer, esophageal cancer and stomach cancer, as well as liver cancer and breast 
cancer, respectively. In case of tobacco-induced cancer one of the primary prevention strategies is reduction of 
frequent smoking. Aside from tobacco use, obesity and physical inactivity can cause cancer mainly in parts of 
the gastrointestinal tract, potentially leading to colorectal cancer, kidney cancer, but also to breast cancer and 
prostate cancer. Environmental risks like urban air pollution or indoor smoke from household use of solid fuels 
are attributed to lung cancer, but also workplace exposure with carcinogenic substances like benzene or 
polycyclic aromatic hydrocarbons are attributed to different tumors. Other chemical carcinogens include 
tobacco-specific nitrosamines (N-nitroso derivatives of nicotine and its metabolites), which are also frequently 
used in cosmetic and rubber products. Another substance is Aflatoxin B1, one of the most potent carcinogens 
derived from the pathogenic fungus Aspergillus flavus. A clear relationship exists between the occurrence of 
cervical cancer in women caused by persistent human papillomavirus (HPV) infection, as well as viral infections 
of hepatitis B and hepatitis C leading to the promotion of hepatocellular carcinoma (HCC).3,4 Broad evidence 
shows that for prevention of HPV and hepatitis B infections, vaccination is the most effective way against these 
viruses and reduce significantly the occurrence of the related cancer. Unfortunately, until now there is no 
hepatitis C vaccine available against this virus infection, which could potentially prevent liver cancer caused by 
such a chronic disease.6 Also a bacterial infection with the gram-negative Helicobacter pylori is associated with a 
higher number of cases of gastric cancer. However, more recent studies exhibited that eradication of Helicobacter 
pylori does not result in complete prevention of all gastric cancers, but leads to a retardation of the precancerous 
process of the disease.7 Besides that, usage of pharmacological agents as oral contraceptives (especially hormones 
like estrogen or progesterone) are known to be an evidence-based cancer cause for breast cancer, especially for 
younger and post-menopausal women.8 Also antineoplastic agents like busulfan, melphalan, chlorambucil and 
cyclophosphamide that are commonly used in cancer therapy are associated with an increasing risk for 
developing second cancers. This ability is related to the fact that these substances mainly act by alkylation of 
purine bases in DNA (mostly guanine residues at N7 position) and evolve their genotoxic activity.9 
Although major improvements in cancer therapy are evident over the last decades, cancer is still the second 
leading cause of death in the United States (following cardiovascular diseases like ischaemic heart disease and 
stroke).10,11 Comprehensive data on cancer incidence (new cases) and mortality exhibit that in 2018, an overall 
estimate of 1.74 million new cancer cases and 610 thousand cancer-related deaths are projected in the US.12 
Most common cases and cancer-related deaths (both sexes) are depicted in Figure 1. According to these 
numbers, lung cancer, colorectal cancer and prostate cancer represent the most common cases and deaths in 
men. Prostate cancer accounts for nearly 20% of new diagnoses of cancer in men. Among women, predominantly 
diagnosed are breast cancer and lung cancer as well as colorectal cancer, indicating also a high mortality rate 
for these cancer types. Overall, 30% of all new diagnosed cancer in women account to breast cancer alone. The 
4 most common cancer in men and women (lung cancer, breast cancer, colorectal cancer and prostate cancer) 
constitute for nearly 45% of the majority of cancer deaths, led by lung cancer with 25%.12 
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For a distinct prognosis of a diagnosed cancer, five-year survival rates are estimated. The tumor is characterized 
as localized, regional or distant at the stage of diagnosis. Relative survival rates with a good prognosis are high 
for prostate cancer (99%), melanoma (92%) and breast cancer in women (90%). A poor prognosis with a low 
relative survival rate is attributed to pancreas cancer (8%), lung cancer (18%) and liver cancer (18%).12 
Nowadays, the most promising way to treat cancer comprises an early detection and screening system combined 
with effective treatment. For example, primary prevention of colorectal cancer is pursued with colonoscopy as 
the predominant screening test, and if necessary, surgical removal to eliminate detected premalignant lesions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Estimated new cancer cases and deaths (both sexes) in the United States in 2018. 
Most common cancers that occurred in the US in 2018 are represented with new cases (illustrated with blue bars) and deaths (illustrated 
with red bars). Decreasing order of cancer sites affected is arranged from highest mortality rates (lung & bronchus) to lowest mortality 
rates (thyroid). Figure is adapted from Siegel et al.12 
 
Hematological malignancies (40 - 50% account for leukemias and lymphomas), often termed as childhood cancer, 
occur frequently within the first 15 years in life. Associations between the occurrence of hematological cancers 
and the exposure to ionizing radiation (extremely low-frequency electromagnetic rays) are evidence-based risk 
factors.13 Taken together, many types of cancer with high incidence and mortality rates exhibit preventable risk 
factors and for an efficient treatment of cancer, an interplay between detection at early stages as well as 
appropriate medication is crucial. The following part will be focused on major characteristics of cancer biology 
and the difference between hematological malignancies and solid tumors. Most of the common cancers form 
solid tumors, which are abnormal masses of tissue. In solid tumors no liquid areas or cysts are present. As 
described in this chapter, the majority of most common diagnosed cancers and cancer related deaths are 
attributed to solid tumors, making a high relevance for therapeutic treatment of these cancers inevitable. 
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Particularly, most cases are associated with lung cancer, breast cancer, colorectal cancer and prostate cancer. 
Apart from that, hematological cancers (cancers of the blood), like leukemias, normally do not form solid tumors. 
Leukemia is a cancer that is mainly affecting the bone marrow and blood. The classification into 4 major groups 
is based on the cell type and tumor growth. Leukemia can be subdivided into 4 different groups, namely acute 
lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphoblastic leukemia (CLL) and 
chronic myeloid leukemia (CML).14 Regarding hematological malignancies, the 2 common blood cancers 
leukemia and non-hodgkin lymphoma are surpassed significantly with incidence and mortality rates by solid 
tumors, ranging only in the middle position of the new cancer cases. 
 
2.1.1. Hallmarks of cancer 
In the context of multistep tumorigenesis, several key features of cancer cells related to formation of a 
microscopic and macroscopic tumor with subsequent development were intensively investigated during last 
decades. These key features – termed as hallmarks of cancer – are of major importance to understand the 
complexity of neoplastic diseases. The well-established hallmarks of cancer were postulated by Hanahan and 
Weinberg and initially included the following 6 attributes: sustaining proliferative signaling, evading growth 
suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating 
invasion and metastasis (depicted in Figure 2).15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: The classical hallmarks of cancer with emerging hallmarks and enabling characteristics. 
Illustrated are the key hallmarks of cancer with deregulating cellular energetics and avoiding immune destruction as emerging hallmarks. 
Genomic instability and tumor-promoting inflammation are associated with enabling characteristics and facilitate the development of 
the key hallmarks and emerging hallmarks. Figure is modified from Hanahan and Weinberg.15 
 
As one predominant attribute of cancers cells, sustaining proliferative signaling enforces uncontrolled, chronic 
proliferation. In healthy tissues the growth-and-division cycle is usually regulated by production and release of 
mitogenic factors, ensuring that a sufficient amount of mitogenic factors are delivered to cells in order to obtain 
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a physiological cell function and homeostasis. Many important growth-promoting signals are associated with 
well investigated growth factors and corresponding enzyme-coupled receptors, namely receptor tyrosine 
kinases (RTKs) as key regulators in cell proliferation and differentiation. All RTKs are highly conserved in 
humans and have a similar molecular structure (illustrated in Figure 3).15,16 
 
 
Figure 3: Signaling pathways, various growth factors and receptor formation of members of the HER family. 
Depicted are EGFR/HER1, HER2, HER3 and HER4 as the four RTKs of the HER family. Each member consists of a transmembrane 
receptor with tyrosine kinase domain, except for HER3 which has no tyrosine kinase activity. Growth factor ligands for the different 
receptors that mediate receptor dimerization and activation are shown. No identified ligand exists for HER2, but the constant active 
conformation of HER2 facilitates dimerization with other ligand-activated receptors. In the activated state, autophosphorylation 
(indicated by yellow circle P) of the respective kinase domains with subsequent signal transduction of the PI3K/Akt and 
Ras/Raf/MEK/MAPK pathway, leads to pro-oncogenic signaling and angiogenesis (resulting from VEGF transcription). Approved 
therapeutic interventions are highlighted in red. The chimeric monoclonal antibody Cetuximab targets EGFR and the humanized 
monoclonal antibody Trastuzumab is used for the treatment of HER2-positive cancers. Both act by binding to the extracellular domain 
of the receptor and thus inhibit receptor dimerization, initiating apoptosis and mediate ADCC. Small molecule tyrosine kinase inhibitors 
(TKIs) like Erlotinib, which inhibits phosphorylation in the kinase domains of EGFR, and Lapatinib that also blocks cytosolic tyrosine 
kinase activity in HER2 (and also EGFR), are in clinical use. Figure is modified from Arteaga et al.17 
AR = Amphiregulin, BTC = Betacellulin, EPG = Epigen, EPR = Epiregulin, HB-EGF = Heparin-binding EGF-like ligand, MAPK = 
Mitogen-activated protein kinase, NRG = Neuregulin, PI3K = Phosphatidylinositol 3-kinase, Raf = Rat fibrosarcoma, Ras = Rat 
sarcoma, TGF-a = Transforming growth factor-a 
 
Upon ligand binding of growth factors to extracellular domains of these cell surface receptors, typically receptor 
dimerization is induced and intracellular tyrosine kinase domains amplify downstream signaling leading to 
tremendous and malignant cell growth. This process is driven by the activated, ligand-induced dimeric form of 
the RTK, where one receptor phosphorylates one or multiple tyrosines in an adjacent RTK and other 
intracellular signaling proteins can be phosphorylated. Cancer cells may produce growth-promoting molecules 
by themselves and by expression of corresponding receptors, where they function in an autocrine signaling 
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fashion to potentiate and support tumor formation.16,18,17 Alternatively, fibroblasts and the tumor-associated 
stroma may also produce and supply cancer cells with a source of paracrine growth factors promoting cancer 
progression.19 Moreover, deregulated receptor signaling by increased levels of cell surface receptors on cancer 
cells as well as modifications in the receptor structure leading to ligand-independent signaling, affect cells to be 
more sensitive to normally limiting amounts of growth factor mediators.15 
Additionally to persistent growth stimuli, another major role is related to the evasion of growth suppressors. 
Many tumor suppressor genes limit cell growth and proliferation and are part of large cell cycle regulation 
networks. The prototype of this class is p53, which has central control functions within the growth-and-division 
cycle. p53 navigates cell proliferation or activates senescence (irreversible cell cycle arrest) and apoptotic cell 
death to prevent significant cell damage. Approximately, more than half of all human cancers bearing mutations 
of p53, which leads to inactivation of its crucial protection function. p53 registers within the cell circuit noxe 
like DNA damage, oncogene activation, stress and other abnormal cell functions. In the event of enormous 
genotoxic damage or insufficient supply of nucleotides, growth stimuli, glucose or oxygen, p53 can halt the 
growth-and-division cycle until the damage has been resolved and homeostasis can be restored. If irreparable 
damage is registered by sensors of the p53 system, p53 can act as a nuclear transcription factor and induce 
apoptosis by transactivation of a variety of genes to inhibit potential harmful conditions.20,21 
Resisting cell death belongs also to the core hallmarks and is characterized by an imbalance of proapoptotic 
proteins and antiapoptotic proteins. As mentioned before, programmed cell death by apoptosis is induced in 
response to several cellular stresses and damages. On the one hand, extracellular signals are received and 
processed by a sensor network. On the other hand, intracellular signals are registered by another regulator 
system. Both converge to the activation of a proteolytic cascade that is related to the intracellular cysteine 
proteases caspase 8 and 9, leading eventually to apoptosis and consumption of the damaged cell. The interplay 
between pro- and antiapoptotic proteins regulate programmed cell death. Bcl-2 is the most prominent inhibitor 
of apoptosis and upon binding to proapoptotic proteins like Bax and Bak, their action is suppressed. If not 
blocked by antiapoptotic proteins, Bax and Bak can disrupt the membrane of mitochondria and release the 
important proapoptotic protein cytochrome c.22 Finally, cytochrome c is able to trigger proteolytic actions of 
caspases and activating the apoptotic pathway. In addition, tumor cells may have a higher expression of the 
antiapoptotic factor Bcl-2, and also a decreased expression of proapoptotic signals like Bax and Bak, so that cells 
can resist cell death in order to promote tumor progression. 
Enabling replicative immortality is for the formation of a macroscopic tumor required. It is widely 
acknowledged, that telomere length and telomerase activity play a central role in the context of carcinogenesis, 
where cancer cells acquire the ability for uncontrolled proliferation. Telomeres form with their hexanucleotide 
sequences and associated proteins the end of chromosomes, in order to protect such ends and genetic material 
efficiently from degradation.23 The corresponding enzyme telomerase, is a DNA polymerase and elongates 
telomeres continuously during several growth-and-division cycles. Telomerase is not present in normal, healthy 
tissues, but upregulated in various types of cancer, indicating that telomerase activity plays a cancer-promoting 
role. Subcritical shortening of telomeric structures can have significant impact. In the case that an abnormal 
length is reached, instabilities in chromosomal structures occur, leading to loss of cell viability and eventually 
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to cell arrest or apoptosis. Therefore, progressive telomere shortening during cell division determines the 
lifetime of healthy, nonimmortalized cells. Cancer cells need to circumvent the limited replication process in 
order to be become immortalized with unlimited replication ability.24 
Yet another key hallmark is the ability of cancer cells to induce angiogenesis to deliver an adequate amount of 
nutrients and oxygen, and to eliminate metabolic waste products. Angiogenesis is characterized by the multistep 
formation of new blood vessels from pre-existing vasculature and is triggered by large-scale growth of tumors 
(~ 2 mm³) that ultimately require blood supply.25,26 Proangiogenic proteins initiate and antiangiogenic proteins 
abolish the process of angiogenesis leading to a tightly controlled system. These angiogenesis regulators act by 
binding to corresponding cell surface receptors to fulfill their mode of action. In many tumors the balance 
between proangiogenic and antiangiogenic signals is perturbed, in favor of proangiogenic mediators (Figure 4). 
 
 
 
 
 
 
 
 
 
 
Figure 4: Important pro- (Activators) and antiangiogenic (Inhibitors) signals in the context of angiogenesis. 
The angiogenic balance between various Activators and Inhibitors regulates the formation of new blood vessels, and angiogenesis is one 
of several distinct steps that is observed in cancer progression. Figure is adapted from Bergers et al.25 FGF = Fibroblast growth factor, 
LPA = Lysophosphatic acid, PDGF = Platelet-derived growth factor, VEGF = Vascular endothelial growth factor 
 
Among the five VEGF ligands, the protoype of proangiogenic factors is VEGF-A, which is upregulated by 
several growth factors and also by hypoxia (via HIF-1a). Once secreted from malignant or stromal cells, 
VEGF-A acts by binding to one of the RTKs VEGFR-1-3 on endothelial cells. This interaction between 
activated endothelial cells with tumor cells initiates the secretion of matrix-degrading enzymes like matrix 
metalloproteinases (MMPs) by macrophages. The degradation process of the extracellular matrix by MMPs 
facilitates migration of activated endothelial cells towards the tumor and enables the formation of new blood 
vessels. The main endogenous, inhibitory counterpart of VEGF-A is Thrombospondin-1, which suppresses 
stimuli for angiogenesis.26,27 Furthermore the majority of angiogenesis inhibitors are generated by cleavage of 
structural proteins.28 
The last core hallmark in tumor development is attributed to the activation of invasion and metastasis, and is 
characterized by the spreading of cancer cells from the primary tumor to other, distant sites and organs within 
the body. Many reports suggest that the more local invasion and distant metastasis occur in a cancer disease, 
the more advanced stage is established. One prominent example is the dysregulation and frequent loss of 
E-cadherin in several epithelial tumors, which normally functions as an important mediator for cell-to-cell 
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adhesion.29 Elevated levels of E-cadherin are known to counteract invasion and metastasis, making this adhesion 
molecule a key regulator of this multistage invasion-metastasis cascade. Cancer metastasis can be regarded as 
an interrelated and sequential process that starts with the local invasion of the surrounding tissue by tumor 
cells. Following this starting point, detachment and emboli formation of tumor cells with subsequent circulation 
of such tumor emboli in the lymphatic and vascular system occurs. Finally, the extravasation and proliferation 
of the tumor embolus in distant organs takes place and after establishing its vascularized system, a 
micrometastasis has formed.30,31,32 As metastases account for almost 90% of cancer-related deaths rather than 
the primary tumor itself, the huge impact of this key hallmark is undeniable.33 
As two emerging hallmarks, the deregulated cellular energetics as well as avoidance of immune destruction have 
a considerable influence on tumor cells and hence are of major importance. To adjust a high proliferation and 
growth rate of cancer cells to new conditions within a tumor microenvironment (TME), cellular energy 
metabolism is reprogrammed and altered. Normally, healthy cells convert glucose under aerobic conditions to 
pyruvate by glycolysis and eventually to carbon dioxide in the mitochondria. In turn, anaerobic circumstances 
typically favor the formation of lactate from pyruvate resulting in lower energy efficiency. Even if oxygen is 
present, cancer cells preferentially produce their energy largely by glycolysis over mitochondrial oxidative 
phosphorylation, leading to a higher glucose consumption than in normal cells. The needed glucose is delivered 
by elevated levels of GLUT1 transporters, a common phenomenon observed in cancer cells.34,35 
The variety of activities by immune cells to antagonize, but also to promote cancer progression, is a complex 
interplay that reflects disparate roles of the immune system on carcinogenesis. Incipient cancer cells are 
continuously controlled, recognized and eliminated by various immune cells like T lymphocytes, especially 
CD8+ cytotoxic T lymphocytes or CD4+ TH1 helper cells. But the ability of some cancer cells to actively evade 
such elimination systems show, that a lower tumoricidal activity of immune cells is achieved. This led to the 
assumption that tumors can shut down antitumor activity of immune cells by a molecular switch mechanism. 
Such immune checkpoints represent inhibitory pathways, and inhibitory ligands or receptors are overexpressed 
on tumor cells to regulate T cell activation, therefore limiting antitumor activity. Exemplarily, CTLA4 and 
PD-1 are the prototypic receptors of these pathways and are exclusively expressed on T cells. PD-L1 as an 
inhibitory ligand is expressed on tumor cells and blocks antitumor response by interaction with its 
corresponding receptor PD-1 on T cells. Hence, tumor cells evolved escape mechanisms by which cytotoxic 
activity of T cells is limited.36,37 
Besides the mentioned core and emerging hallmark capabilities, two enabling characteristics support the 
development of several of these hallmarks in most cancers. The first characteristic is genomic instability, which 
results from mutations in genes of DNA repair and occurs mainly in hereditary cancers. One well-known 
example is BRCA1, a germline mutation that is associated with an increasing risk of breast cancer.38 The second 
characteristic is attributed to tumor-promoting inflammation and indicates that chronic, proinflammatory 
signals as well as conditions in selected organs facilitate tumorigenesis. In most neoplastic areas, the 
surrounding TME delivers several proinflammatory cytokines like TNF-a, IL-1, IL-6 and other factors that 
contribute to tumor development and trigger survival and proliferation of cancer cells. Many of such cytokines 
exhibit growth-promoting and antiapoptotic properties, making inflammatory responses highly relevant in the 
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context of tumor development.39 Moreover, tumors comprise a plethora of distinct cell types of recruited, 
ostensibly normal cells that potentially foster most hallmarks by creating the TME, establishing another layer 
of complexity. The tumor microenvironment and related tumor proteases with their function, main 
characteristics and interactions will be elucidated in detail in chapter 2.4. 
Many therapeutic approaches arose by targeting specific elements at different stages of these pathways during 
cancer development, establishing a well-suited, personalized cancer treatment that improves life expectancy and 
quality of life. In the following section, a brief insight into the history of cancer therapy will be given. 
 
2.1.2. History of cancer therapy development: Landmark achievements 
Many treatment options for cancer evolved over decades and tremendous efforts in cancer drug development 
led to effective therapies. The main types of cancer treatment can be subdivided into surgery, radiation therapy, 
chemotherapy, immunotherapy, targeted therapy, hormone therapy and stem cell transplant. 
Surgery remains a very effective treatment for localized primary tumors and can be regarded as classic cancer 
therapy, likewise radiation therapy and hormone therapy.40 More than a century ago, the American surgeon 
William Halsted published his radical mastectomy based on operations to remove breast cancer tissues that were 
performed from 1889 – 1894.41 Only a few years later in 1903, Goldberg and London claimed the first use of 
radiation therapy leading to a cure of a patient with basal cell carcinoma.42 Radiation therapy alone or combined 
with surgery or systemic chemotherapy is of major importance for effective treatment, depending on the specific 
cancer disease. Radiation therapy is also used prior surgery (neoadjuvant setting) to reduce tumor size, but also 
after surgical removal (adjuvant/postoperative) to ensure that undetectable micrometastases or oligometastases 
are not leading to sudden tumor recurrence.43 These therapeutic settings offer the great capabilities to improve 
locoregional control of the tumor as well as overall patient survival in certain cancers. Surgery and radiation 
therapy dominated the area of cancer treatment until the 1960s. However, they were not able to achieve 
eradication of metastatic cancer.44 Hormone therapy for therapeutic approaches against hormone-dependent 
breast cancer consist of reversible aromatase inhibitors like anastrozole and letrozole as well as the prominent 
SERM tamoxifen, which was approved in 1977.40 
The early beginning of chemotherapy can be regarded as dye therapy, because many principles derived from 
histological staining techniques. Paul Ehrlich, the founder of chemotherapy, observed differential staining 
schemes of dye molecules for certain biological structures. Moreover, his important immunological 
achievements like the “side-chain theory of immunity”, which was rewarded in 1908 with the Nobel Prize for 
Physiology or Medicine, paved the way for the “magic bullet” concept. Ehrlich imagined that this “magic bullet”, 
a specific drug, can bind only to the intended cell-structural targets in a highly specific fashion, leaving the 
healthy cells unharmed and thus reducing adverse effects in patients.45 
However, huge efforts were required, until such specific targeting drugs were established. First efforts in 
modern chemotherapy came up accidentally by usage of the chemical warfare nitrogen mustard, a nonspecific 
DNA alkylating agent. Surprisingly, investigations clearly showed that a profound lymphoid hypoplasia and 
myelosuppression in humans who were exposed to nitrogen mustard during World War II, occurred more 
frequently. The two pharmacologists Goodman and Gilman at Yale University investigated anticancer effects 
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of mustine in 1946. They treated patients suffering from non-hodgkin lymphoma with mustine and observed a 
significant tumor regression. Based on this observation Goodman and Gilman established the basic principle, 
that a systemic administration of drugs are able to induce tumor regression.46 Various approaches in the 1950s 
based on the assumption that cancer cells divide more rapidly than normal cells, a quite revolutionary idea at 
that time. Further efforts that led to the elucidation of the DNA structure by Watson and Crick in 1953, inspired 
researchers to develop DNA analogues like 5-fluorouracil, 8-azaguanine as well as additional DNA alkylating 
drugs like the natural compounds bleomycin and mitomycin C.47–49 In 1948 Sidney Farber introduced the 
principle of antimetabolites with the folic acid derivatives methotrexate and aminopterin, both inducing a robust 
antitumor effect in patients with ALL. Methotrexate specifically inhibits the folate requiring enzymes DHFR 
and thymidylate-synthase, leading eventually to inhibition of DNA synthesis.50 With the purine analogon 
6-mercaptopurine George Hitchings established the antimetabolite therapy for DNA bases, where a false 
substrate is introduced to DNA synthesis.51 Subsequently, early observations by Rosenberg in 1965 identified 
that platinum compounds and derivatives are able to inhibit cell division in E. coli, creating interest for a possible 
use as a cytotoxic agent. Further investigations resulted in the FDA approval of cisplatin in 1978, a DNA 
alkylating agent that cross-links purine bases (binding mainly N7 residues) on DNA and finally causing DNA 
damage as well as triggering apoptosis. Until now, cisplatin is well established in the standard treatment of 
different types of cancer. However, it is also associated with many toxic and adverse effects like nephrotoxicity, 
hepatotoxicity, ototoxicity and cardiotoxicity, caused by its unspecific damage to rapidly dividing cells.52,53 
The era of targeted therapy began with the introduction of targeted small molecules, namely TKIs and 
therapeutic monoclonal antibodies. A key landmark in cancer drug development was achieved with the first 
targeted small molecule drug imatinib for the treatment of CML as well as GIST that was approved by the FDA 
in 2001. Imatinib is an ATP-competitive, RTK-inhibitor that specifically blocks the action of BCR-ABL, a fusion 
protein that is formed by chromosomal translocation between tyrosine kinase ABL from chromosome 9 and 
chromosome 22 (BCR).54,55 The clinical success of imatinib initiated a wave of several TKIs like erlotinib 
targeting EGFR for the treatment of NSCLC, gefitinib also targeting EGFR against NSCLC as well as the 
anti-EGFR/HER2 agent lapatinib against breast cancer. Besides that, various multi TKIs as sunitinib and 
sorafenib for the treatment of RCC are approved.56 
Large molecule therapeutics like antibodies have advantages over small molecule drugs like high specificity and 
a better safety profile with reduced adverse events.45 The long-half life of antibodies allows infrequent dosing. 
Antibodies will be discussed in detail in the following chapter. Ehrlich’s vision of a “magic bullet” is virtually 
accomplished by the development of monoclonal antibodies and antibody-drug conjugates that recognize their 
targets with high specificity without harming healthy cells. The production of monoclonal antibodies (mAbs) 
by using the hybridoma technology was enabled by Köhler and Milstein in 1975.57 Further development made 
chimeric and humanized mAbs suitable for therapeutic approaches that resulted in the approval of rituximab 
and Trastuzumab. With introduction of the chimeric mouse-human antibody rituximab in 1997, the first 
therapeutically use of a mAb for the treatment of cancer was achieved. Rituximab is directed against the B-cell 
specific antigen CD20 and is applied for the treatment of non-Hodgkin lymphoma.58,59 In 1998 Trastuzumab 
was approved as the first targeted therapy against solid tumors. The anti-HER2 antibody showed remarkable 
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results in the treatment of HER2-positive metastatic breast cancer.60 Cetuximab is a chimeric mAb that binds 
to EGFR and was granted approval by the FDA in 2004 for the treatment of metastatic colorectal cancer.61 The 
anti-VEGF mAb bevacizumab was also approved in 2004 for the treatment of colorectal cancer and realized a 
new targeting strategy by neutralizing the ability of the ligand VEGF to bind to VEGFR and therefore 
inhibiting tumor angiogenesis.62,63 
 
 
Figure 5: Timeline with selected milestones of cancer drug development. 
The illustrated timeline that shows major milestones and findings of historical achievements in cancer treatment. Blue boxes indicate 
approvals of ADC-based therapies. Abbreviations can be found in the abbreviations section. Figure is adapted from Strebhardt, Chabner, 
Sievers, Wei et al.45,50,64,65 
 
Furthermore, another therapeutic option for cancer treatment that is discussed in this chapter is 
immunotherapy, which emerged in recent years as a powerful tool against multiple types of cancer. In general, 
elimination of inhibitory signals mediated through the immune checkpoint blockade by antibodies, restores 
T cell activation and antitumor activity. Remarkable responses in the field of immunotherapy were observed by 
the anti-CTLA4 mAb ipilimumab, which was granted FDA approval in 2011 and paved the way for a wave of 
several analog compounds. Ipilimumab is used for the treatment of metastatic melanoma. Targeting the 
PD-1/PD-L1 axis was achieved by the 2014 approved anti-PD-1 antibodies pembrolizumab and nivolumab, 
both immune checkpoint inhibitors are used for the treatment of melanoma and other indications.65,66 
By attaching toxins to highly specific antibodies and thus generating antibody-drug conjugates (ADCs), the 
efficacy of antibody-based therapy and the clinical response can be increased. The principles of ADCs will be 
further explained in subsequent chapters. The first ADC gemtuzumab ozogamicin received marketing 
authorization in 2000 and is directed against the CD33 antigen on AML tumor cells. Despite its initial FDA 
approval, further studies showed no clinical benefit of gemtuzumab ozogamicin and addition of the ADC showed 
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a lack of improvement in response rate as well as patient overall survival. Such uncertainties and safety concerns 
impelled Pfizer to voluntarily withdraw gemtuzumab ozogamicin from the market in 2010. Based on subsequent 
trials, that re-investigated the efficacy of gemtuzumab ozogamicin at lower doses in CD33-positive AML 
patients, the ADC was re-approved in 2017. In 2011, the anti-CD30 ADC brentuximab vedotin was approved 
by the FDA for the treatment of HL and ALCL, introducing the now well established cytotoxic drug MMAE 
and a protease-cleavable linker.67,68 With the approval of Trastuzumab emtansine (T-DM1) in 2013, the first 
and only ADC against solid tumors that targets HER2 was introduced to the market. Inotuzumab ozogamicin 
gained FDA approval in 2017 and binds to the antigen CD22. Inotuzumab ozogamicin is used for the treatment 
of NHL and ALL.64,69 Since very recently, polatuzumab vedotin for the treatment of DLBCL was granted 
approval in 2019 and targets the antigen CD79b on B cells.70,71 
In summary, it can be stated that a broad range of different molecules to treat cancer diseases evolved over 
decades and resulted in more specific agents. Approaches in the field of targeted therapy remain of high interest 
for patients, industry as well as for academia. Within the scope of this work, investigations about antibody-drug 
conjugates with special focus on drug delivery will be pursued and in the following chapter antibodies are 
introduced in more detail. 
 
2.2. Antibodies as powerful therapeutic proteins 
The immune system comprises two substantial components divided in the innate and adaptive immune system. 
Both immune responses detect and eliminate potential harmful pathogens like bacteria, viruses, fungi or 
parasites, thereby providing an effective protection system. The innate immune system serves as an initial 
defense mechanism against pathogens and is characterized by a non-specific and immediate immune response 
that recognizes conserved pathogen-associated molecular patterns (PAMPs) through toll-like receptors (TLRs). 
Typical recognized pathogenic structures are proteins, glycoproteins and polysaccharides. TLRs are expressed 
on the cell surface of phagocytes like macrophages and neutrophils, and upon activation initiate a production of 
proinflammatory cytokines.72,73 In contrast, the adaptive immune system is composed of T and B lymphocytes 
and is characterized by a highly antigen specific and delayed immune response, which is also supported by 
immunological memory.74 On the surface of T and B lymphocytes, T-cell receptors (TCRs) and B-cell receptors 
(BCRs) act as antigen specific receptors and the antigen specific response is established by antibodies or 
immunoglobulins that represent the soluble form of the BCRs. The BCR on the B cell surface detects antigens 
by membrane-bound immunoglobulins. After antigen binds to a BCR, lymphocytes differentiate first into short-
lived plasmablasts and then develop to antibody-secreting plasma cells, that have the capacity to secrete large 
amounts of antibodies with the identical antigen specificity.75 The therapeutic potential of antibodies against 
cancer was realized since the mid-1990s and they can virtually be generated against every target substance.76 
Such substances are known as antigens, because they stimulate antibody generation. 
Antibodies are Y-shaped biomolecules that are used therapeutically against a variety of life-threatening diseases 
ranging from cancer, inflammatory diseases, infectious diseases, transplantation and cardiovascular diseases. 
Generally, antibodies are often referred to as monoclonal antibodies (mAbs), which means that a mAb is 
produced from a single B lymphocyte and represents an identical copy.77,78 Five main immunoglobulin classes 
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exist, each with a unique heavy chain and therefore a different isotype: IgG, IgA, IgD, IgE and IgM. In humans, 
IgG and IgA are divided in further subclasses, namely IgG1, IgG2, IgG3, IgG4 and IgA1, IgA2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: General structural features of an antibody illustrated by an IgG molecule and a Fab fragment. 
Schematic representation of an IgG1 (A) molecule and a Fab fragment (B), both with the variable domains of heavy chain (VH) and light 
chain (VL) in cyan. Constant domains of light chain (CL) and heavy chain (CH1, CH2, CH3) are depicted in orange. Both Fab arms in an 
IgG1 (A) are linked by the hinge region to the Fc part, allowing structural flexibility. Glycosylation in the CH2 domain of the heavy 
chain is located at Asn297 (illustrated by green squares) and is responsible for FcR binding as well as complement binding. CDRs in the 
variable domains are represented by red lines, comprising six hypervariable loops for each Fab fragment. Heavy chain constant domains 
are numbered from the amino-terminal part to the carboxy-terminal end. For simplicity, only interchain disulfide bonds are depicted. 
The monovalent Fab fragment (B) binds one antigen with its variable region, but lacks the Fc part and therefore has no effector functions 
and no interaction with FcRn. The crystal structure of IgG1 (C) and Fab fragment (D) shown in a cartoon surface model (generated by 
PyMOL ver. 0.99, PDB: 1IGT). 
 
The majority of therapeutic antibodies consist of the IgG class and IgG1 is the most abundant antibody in 
serum.79 Antibodies are composed as heterodimeric proteins with a molecular weight of 150 kDa, consisting of 
two light chains and two heavy chains connected through disulfide bonds and a hinge region (Figure 6). 
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The polypeptide structure of an antibody can be further distinguished into one amino-terminal part represented 
by the Fab (Fragment antigen binding) arms as the variable region and a carboxy-terminal end known as the 
Fc (Fragment crystallizable) part. The variable domains consisting of VH (H = heavy chain) and VL (L = light 
chain) bind the epitope on the antigen and determines the high specificity of the antibody, whereas the constant 
region with the Fc part mediates effector functions by interaction with different immune cells.80 Six 
hypervariable loops within the variable region, termed complementarity-determining regions (CDRs), are 
crucial for antigen recognition and are situated between 4 constant framework regions. 3 CDRs of the heavy 
chain in association with 3 CDRs from the light chain are responsible for formation of the antigen-binding site 
on the antibody, known as the paratope.81,82 The hinge region with a length of 15 amino acids in IgG1, is located 
between the first (CH1) and second (CH2) domain and allows high flexibility of the Fab arms to bind the antigen. 
Reduction of the disulfide bonds results in a separated heavy chain with 4 immunoglobulin domains and a light 
chain with 2 domains, showing a molecular weight of 50 kDa and 25 kDa, respectively. Besides that, intrachain 
disulfide bonds exist within each domain.83,84 
Enzymatic fragmentation of antibodies with the proteases papain and pepsin facilitated structural elucidation 
and functional analysis. Papain is a cysteine protease that cleaves the IgG molecule at the amino-terminal side 
of the upper hinge region, releasing 2 Fab fragments each with 50 kDa and the corresponding Fc part also with 
50 kDa. Besides that, the aspartic protease pepsin cuts the antibody at the carboxy-terminal lower hinge region, 
yielding one dimeric and bivalent F(ab’)2 fragment as well as smaller fragments of the remaining heavy chain 
(truncated Fc). The F(ab’)2 fragment has the same valency as the antibody, but is lacking the Fc part. 
The most direct mechanism in which antibodies act, is by binding the target structure like a growth factor 
receptor or soluble factor and thus blocking its action and signaling pathways. Such mode of action is referred 
to as receptor blockade or neutralization. Besides that, immune-mediated cell killing mechanisms like antibody-
dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) are related to Fc 
binding of the immunoglobulin. Important effector functions are defined by the heavy chain and mediate the 
interaction of the Fc part with immune cells or the complement system, contributing to therapeutic efficacy. 
One substantial mechanism termed ADCC, is mediated by binding of the Fc portion of the antibody to immune 
cells bearing Fc receptors (FcRs). As a consequence, antibody-bound targets are destroyed by macrophages, 
neutrophils and dendritic cells through phagocytosis, because of FcR binding.85 The family of FcRs that bind 
IgG molecules comprise 3 different FcRs in humans, with FcRII (CD32) and FcRIII (CD16) exhibiting low 
affinity, and FcRI (CD64) binding with the highest affinity to the Fc part of IgG.86,87,88 NK cells as well as 
basophils and mast cells release mediator molecules upon FcR binding. Most importantly, the activating FcRIII 
(CD16) expressed on NK cells and macrophages has the capability to bind the Fc portion of IgG1 and IgG3 
antibodies and by this activation, NK cells and macrophages release granzyme and perforin from their 
intracellular granules, inducing killing mechanisms.89,90 Another significant effector function is CDC, which is a 
result of activation of the complement system. Initiation of the classical complement cascade by several 
proteolytic cleavage reactions is based on Fc binding to C1q complement protein and activates several 
phagocytic cells which destroy the antigen.91 
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A crucial role regarding the Fc-mediated interaction with immune effector cells depends largely on the 
conserved N-glycosylation of IgG located at asparagine 297 (N297) in the CH2 domain. The core of this 
glycosylation consists of a heptasaccharide with N-acetylglucosamine and mannose. Modifications of glycan 
structure in the Fc region can modulate Fc binding to various FcRs. The elimination of a core fucose in the 
glycan composition results in afucosylated antibodies which exhibit significant enhancement in ADCC activity 
by 50-fold increased affinity to FcRIII and thus are more efficacious. Completely aglycosylated Fc regions 
generated by mutations in the CH2 domains or by deglycosylation, show complete loss of binding to all FcRs, 
except FcRI.92,93 By contrast, the interaction of deglycosylated IgG with the neonatal Fc receptor (FcRn) is not 
affected, indicating that FcRn binding is associated to a different region in the Fc part. To maintain the long 
half-life that is generally observed for antibodies in serum, binding of FcRn to the interface of the CH2-CH3 
domains of the antibody Fc part is essential. After internalization into cells, IgG-Fc binds to FcRn in the acidic 
endosome (pH 6.0 – 6.5) with high affinity, protecting IgG from degradation in lysosomes. Afterwards, IgG is 
recycled to the cell surface and released back in circulation, due to dissociation of IgG from FcRn by a pH change 
at physiological pH (pH 7.4). FcRn is expressed in the gut and liver as well as on endothelial cells. Typically, 
IgG molecules exhibit a half-life in the range of 21 days. In contrast to that, single domain antibodies or scFvs 
that are smaller antibody fragments without FcRn binding are characterized by several minutes.94,95,96 
In general, the majority of approved antibodies are humanized or completely human. Human antibodies can be 
derived from transgenic mice and therefore are well tolerated concerning immunogenicity and safety.97 
Modulation of biological activity and pharmacokinetics depend largely on the antibody format (scFv, Fab or 
IgG) and most therapeutic antibodies comprise the full-length IgG format like Rituximab, Adalimumab, 
Cetuximab, Trastuzumab, Bevacizumab and many others.98 Instead of using antibodies in the IgG format, 
antibody fragments exhibit efficient penetration in tumors as well as better tumor-to-non-tumor binding ratios, 
which might offer improvements in certain settings.99 Further potential advantages of smaller formats might be 
a faster clearance from the body leading to a less whole-body exposure to antibody with modified 
pharmacokinetic properties. However, using unmodified antibody fragments significantly reduces the half-life 
from several weeks to a few hours or less, making frequent administration necessary.99 
Approved non-IgG Fab fragments include the chimeric Abciximab targeting gp IIb/IIIa receptor used for 
prevention of clot formation during angioplasty and anti-VEGF Ranibizumab for the treatment of wet AMD. 
To improve the short half-life of Fab fragments polyethylene glycol (PEG) chains can be attached to the 
fragments in order to increase their hydrodynamic radius. Such a PEGylation strategy was realized in the 
PEGylated Fab Certolizumab pegol targeting TNF-a, which shows a prolonged half-life of 14 days and is 
comparable with half-life of IgG.100,101 Idarucizumab is a Fab fragment that is used as an antidote against the 
anticoagulant dabigatran, in case of severe bleedings.102 
Pharmacokinetics of full-length mAbs are attributed to the large size of 150 kDa and are characterized by a slow 
clearance by the liver as well as non-specific accumulation. For therapeutic applications, antibody fragments 
show restrictions like rapid renal clearance from the body with a short half-life due to the missing Fc-FcRn 
interaction. This rapid clearance of smaller fragments is achieved by a size selective barrier in the kidneys, that 
excretes formats with sizes below renal filtration threshold of 60 kDa (Figure 7).103 
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Figure 7: Smaller antibody derivatives generated by enzymatic or genetic approaches with respective clearance routes. 
Various formats of antibody fragments can be either generated enzymatically (upper row) or genetically (lower row). Molecules are 
arranged in order to size. Two main elimination mechanisms are relevant for therapeutic proteins, renal and liver clearance. Clearance 
routes are mainly size-dependent, and for molecules that are smaller than 60 kDa, excretion through the kidneys is achieved. For high 
molecular weight species, generally elimination through the liver takes place. Figure is modified from Kobayashi et al.103 
 
A plethora of marketed antibodies are utilized with their high specificity and favorable pharmacokinetic 
properties for the treatment of various diseases. Despite clinical success, many unmodified antibodies exhibit 
limited activity in the treatment of cancer compared to conventional chemotherapeutic agents. For this reason, 
antibody-drug conjugates (ADCs) are designed to deliver highly potent agents to tumor cells. 
 
2.2.1. Antibody-drug conjugates (ADCs) 
ADCs are emerging as a novel class of oncology therapeutics that combine the antitumor efficacy of highly 
potent small molecule cytotoxic drugs (300 – 1000 Da) with the favorable pharmacokinetic profile and targeting 
ability of antibodies. ADCs consist of a mAb as a vehicle that binds with high specificity to a tumor surface 
antigen. The mAb is linked covalently to a small molecule drug via chemical linkers (Figure 8).104 By combining 
these components into a single new molecular entity, targeted delivery of normally intolerable small molecule 
compounds selectively to diseased tissues can be achieved, thereby increasing efficacy while decreasing potential 
toxicity of the payload compared to traditional chemotherapeutic drugs.105,106,107 To exploit the benefits of armed 
antibodies, target antigens should be overexpressed on tumor cells or show nearly no expression in healthy 
tissue. This would lead to reduced off-target toxicity and an increased therapeutic index (maximum tolerated 
dose/minimum efficacious dose). Moreover, proteomic approaches indicate that in hematological malignancies 
target expression in organ tissues is lower compared to cell populations from the whole blood, while most of 
solid tumor targets are expressed relative broadly in organ tissues.108 
The mechanism of action of ADCs depends on multiple processes, each of these steps are crucial for efficient 
delivery of the cytotoxic payload (Figure 8). At the beginning, it is necessary that sufficient amount of ADC is 
able to enter tumor tissue from vasculature.  
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Figure 8: Schematic structure of an ADC and mechanism of action. 
Depicted is the structure of an ADC (A), with key features represented through the antibody moiety (blue/orange), linker (green) and 
payload (red). Main characteristics of each component are included, but various alternatives exist. In this scheme, two payloads are 
conjugated to the mAb. The assumed mechanism of action (B) of ADCs on tumor cells is illustrated. After entering the tumor tissue, the 
ADC binds to its respective tumor antigen on the cell surface and is internalized into tumor cells. After internalization, the ADC is 
trafficked inside the cell into endosomes and subsequently into lysosomes, where linker cleavage or antibody degradation takes place and 
cytotoxic drugs are released. Afterwards, payloads can fulfill their cytotoxic activity either by disrupting microtubules or damaging 
DNA, leading to cell death. In this case, microtubule inhibiting agents and their binding to microtubules is depicted. Depending on 
payload properties, bystander killing is enabled by diffusion of cell permeable payloads into adjacent cells. Figure is adapted from Lambert 
and Berkenblit.109 
 
 
Upon binding of the antibody moiety to the target antigen on tumor cell surface, internalization of the whole 
ADC-antigen complex through receptor-mediated endocytosis is achieved. During intracellular trafficking, 
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endocytic vesicles fusion leads to formation of early endosomes, subsequently late endosome and eventually 
lysosomes.110 Inside lysosomes, linker cleavage or lysosomal degradation of the ADC takes place and the toxic 
payload is released in the cell, leading to cell death by either microtubule inhibition (e.g. auristatins, 
maytansinoids) or DNA damage (e.g. duocarmycins, PBDs).109 
Current approved ADCs as well as more than 60 ADCs in clinical trials, predominantly target hematological 
malignancies.104,109,111 
At the beginning of ADC development, first attempts with anti-KS1/4 methotrexate conjugate and anti-KS1/4 
vinblastine-based conjugate were tested for NSCLC. In 1993 the anti-Lewis Y BR96-doxorubicin conjugate for 
breast cancer encountered difficulties and demonstrated only a minor therapeutic benefit. Different factors like 
poor target selection as well as immunogenic chimeric and murine antibodies, but also the utilization of payloads 
with lower potency, contributed to clinical failure of such early first-generation ADCs.112–115 A few decades of 
optimization and development were necessary, until the current 5 ADCs received market authorization. In 2000 
the first ADC, gemtuzumab ozogamicin, was approved by the FDA. Gemtuzumab ozogamicin consists of an 
IgG4 anti-CD33 mAb that is linked to the DNA damager calicheamicin via randomly lysine conjugated 
cleavable hydrazone linker. 
 
Table 2: Overview of approved ADCs. 
Main features of approved ADCs like antibodies, linkers, payloads as well as target antigens and indications are listed. Table is modified 
from Hoffmann et al.111 
ADC Developer Indication 
Target 
Antigen 
Antibody 
type/mutations Linker Cytotoxin 
Year of 
approval 
Gemtuzumab 
ozogamicin 
(Mylotarg®) 
Pfizer Acute 
myeloid 
leukemia 
CD33 Humanized 
IgG4  antibody 
hP67.6 
Acid-lablie 
hydrazone 
bifunctional 
linker 
Calicheamicin FDA 
approved 
in 2000, 
withdrawn 
2010,  
re-
approved 
2017 
 
Brentuximab 
vedotin 
(Adcetris®) 
Seattle 
Genetics 
Relapsed 
Hodgkin 
lymphoma 
and systemic 
ALCL 
CD30 Chimeric IgG 
cAC10 
Cathepsin 
B cleavable 
ValCit 
 
MMAE  
DAR 4 
FDA 
approved 
2011 
Trastuzumab 
emtansine 
(Kadcyla®) 
Roche HER2+ 
metastatic 
breast 
cancer 
HER2 Humainzed 
IgG1 
Non-
cleavable 
thioether 
linker 
 
DM1  
DAR 3.5 
FDA 
approved 
in 2013 
 
Inotuzumab 
ozogamicin 
(Besponsa®) 
Pfizer NHL, ALL CD22 Recombinant 
humanized 
IgG4 
Acid-labile 
hydrazone 
Calicheamicin, 
CM1 
FDA 
approved 
in 2017 
 
Polatuzumab 
vedotin 
(Polivy®) 
Roche DLBCL CD79b Engineered 
cysteines 
(THIOMAB) 
Cathepsin 
B cleavable 
ValCit 
MMAE FDA 
approved 
in 2019 
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Figure 9: Selected approved first- and second-generation ADCs.  
Illustration of approved first-generation ADC gemtuzumab ozogamicin (A), and second-generation ADCs Trastuzumab emtansine (B) 
and brentuximab vedotin (C). Drug-linker structures and schematic attachments on the antibodies are depicted. Figure is modified from 
Beck et al.104 
 
Gemtuzumab ozogamicin is indicated for the treatment of patients with CD33-positive AML, who are 60 years 
of age or older and are not considered for further cytotoxic chemotherapy. As already mentioned in chapter 
2.1.2, the first-generation ADC gemtuzumab ozogamicin was withdrawn in 2010 and re-approved in 2017. 
Several reports indicate that gemtuzumab ozogamicin is a heterogeneous mixture of 50% of different drug-to-
antibody ratio (DAR) species of conjugated ADC and of approximately 50% unconjugated mAb.116,117 Moreover, 
the acid-labile hydrazone linker in gemtuzumab ozogamicin was unstable, releasing 50% of conjugated payload 
in 48h.105 In 2011, brentuximab vedotin with the chimeric IgG1 antibody against CD30 established a payload 
class that is widely used in the ADC field. Brentuximab vedotin utilizes MMAE as a cytotoxic drug that is 
attached to the cysteines of the hinge region of the mAb via a valine-citrulline protease cleavable linker. Another 
important approval was achieved with Trastuzumab emtansine (T-DM1) in 2013. T-DM1 consists of the 
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anti-HER2 mAb Trastuzumab that is conjugated to random lysines via a thioether non-cleavable SMCC linker 
with DM1. Trastuzumab emtansine is used for the treatment of HER2-positive metastatic breast cancer 
patients, who previously were treated with Trastuzumab and a taxane (separately or in combination therapy).  
Besides that, T-DM1 shows tumor growth inhibition against cell lines, that are lapatinib-resistant, which is a 
TKI of HER2 and EGFR.118,119 
Furthermore, two other ADCs received FDA approval and an overview of approved ADCs, comprising several 
data like antibodies, linkers and payloads is given in Table 2. Structures of selected approved ADCs are 
illustrated in Figure 9. 
Predominantly, two main categories of cytotoxic warheads are optimized and used for ADCs. Compounds that 
either target DNA (exploiting activity on proliferating and nonproliferating cells) or microtubules (acting on 
proliferating cells). The majority of payloads used in ADCs which are currently in clinical trials consist of the 
microtubule inhibitors auristatins and maytansinoids, both originating from natural sources like marine 
organisms or botanical species.120 
Auristatins belong to a group of powerful microtubule inhibitors and represent the largest group of ADC 
payloads used in clinical trials.121 Auristatins confer their antitumor activity by disrupting microtubules, which 
are crucial cytoskeletal proteins and play a key role in cell proliferation. The two most common auristatin 
payloads, MMAE and MMAF, are synthetic analogues of the pentapeptide dolastatin 10 (Figure 10) that is 
extracted from the sea hare Dolabella auricularia. Due to the fact, that such derivatives exhibit significant toxicity 
for systemic application as a single agent, conjugation of such compounds to carrier molecules is inevitable. 
MMAE and MMAF have been selected among a plethora of potential candidates, because they exhibit 
advantageous properties like high potency, aqueous solubility and stability under physiological conditions, but 
also a suitable attachment site for a chemical linker.122–124 
One major difference between these two auristatins is that MMAF possesses a negatively charged carboxy-
terminal phenylalanine group and after lysosomal cleavage the released metabolite is therefore much less cell 
permeable. By contrast, the uncharged and nonpolar counterpart MMAE is able to cross biomembranes as a 
neutral molecule, conferring also toxicity to cells in vicinity of tumor cells, irrespective of target expression. 
This phenomenon is referred to as the bystander effect and is facilitated for hydrophobic, cell permeable 
cytotoxic metabolites and bystander potency depends on the charge of linker-drug derivatives. MMAE exerts 
toxicity by bystander activity and is also able to diffuse into target-negative cells. For MMAF, no bystander 
effect is achieved because of its charged properties. Bystander killing may be preferred in solid tumors, where 
targets are heterogeneously expressed and eradication of such tumors is less effective when only antigen-
positive cells are targeted.125–128 
The second largest class of ADC payloads are based on the antimitotic agents maytansinoids with the prototype 
maytansine (Figure 10). Maytansinoids belong to a class of natural macrolide antibiotics that were first isolated 
from the bark of the African shrub Maytenus ovatus.129,130 The most frequently used maytansinoids in ADC 
development are DM1 and DM4. Just like dolastatins and vinca alkaloids, maytansinoids bind to the same site 
on tubulin.120 
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Figure 10: Structures of selected microtubule inhibitors of the auristatin and maytansinoid class. 
Illustrated are the chemical structures of auristatin analogues dolastatin 10 (A), auristatin E (B), MMAE (C) and MMAF (D). The 
different C-termini of the auristatines are highlighted with different colors. Dolaphenine (orange), (+)-norephedrine (yellow) and 
phenylalanine (green). N-terminal linker attachment sites in MMAE and MMAF are indicated by blue boxes. Maytansine (E) and DM1 
(F) are derivatives of the maytansinoids class. All compounds belong to microtubule inhibiting agents. Figure is adapted from Maderna 
et al.123,124 
 
Apart from microtubule inhibitors, several DNA damaging agents are widely used as a class of ADC payloads. 
Calicheamicin is a DNA minor groove binder and exerts its cytotoxic activity through inducing double-strand 
breaks, leading subsequent to cell death. Calicheamicin represents a highly potent enediyene antitumor 
antibiotic that was isolated from actinomycete Micromonospora echinospora and despite four monosaccharide 
units, the hydrophobicity of this compound remains a major challenge for conjugation.131,132 
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Likewise DNA damaging agents and minor groove binders, duocarmycins belong to a drug class of highly 
potent cytotoxic drugs composed of a DNA-binding and a DNA-alkylating unit (Figure 11). DNA-binding is 
preferential in AT-rich regions and subsequently adenine residues are irreversible alkylated at the N3 position, 
leading to disruption of nucleic acid architecture and eventually apoptosis. Most of duocarmycins contain a 
reactive cyclopropyl moiety or a promoiety that is converted into an active form, and has a significant impact 
on antitumor effects. One of the first discovered duocarmycin derivatives is CC-1065 and was isolated from 
Streptomyces sp. The Trastuzumab duocarmycin (DUBA) based ADC SYD985 developed by Synthon 
Biopharmaceuticals is conjugated to interchain cysteines via a cleavable valine-citrulline linker. SYD985 is 
currently in phase III clinical evaluation for the treatment of HER2-positive metastatic breast cancer.133–135 
Pyrrolobenzodiazepines (PBDs) represent another powerful DNA damaging agents with potencies in the 
picomolar range. They were developed by Spirogen and are originally derived from the natural product 
anthramycin, which was isolated from Streptomyces refuineus. PBDs bind also in the minor groove of DNA and 
depending on the PBD unit composition, symmetrical and non-symmetrical PBD dimers (Figure 11) can be 
distinguished. PBDs are able to either cross-link DNA strands by alkylating N2 of guanine through two imine 
functionalities or with only one PBD monomer, monoalkylating agents can be utilized that also form covalent 
PBD-DNA adducts. Several studies revealed that PBD dimers generated by the incorporation of an 
odd-numbered linker length between the PBD monomers show a dramatically increased cytotoxic activity. In 
contrast, when using an even-numbered linker length, a decreased PBD dimer activity is observed. One 
advanced PBD dimer-based ADC is rovalpituzumab tesirine (Rova-T) developed by Stemcentrx. Rova-T targets 
DLL3 and is conjugated via a cathepsin B cleavable valine-alanine linker to hinge cysteines. Rovalpituzumab 
tesirine is tested in phase III clinical trials against SCLC.136–138 
To further improve cytotoxicity of PBDs, ImmunoGen developed derivatives termed indolinobenzodiazepine 
(IGNs), which contain a pseudodimer backbone that exerts slightly stronger cytotoxic activity as original PBDs.  
The DNA-crosslinking diimine form of IGNs is associated with several off-target toxicities and was therefore 
converted into an even potent DNA monoalkylating monoimine form which simultaneously attenuates 
off-target toxicities (Figure 11). DGN462 is such an IGN derivative with a single reactive imine group and is 
used in the ADC IMGN779, which is an anti-CD33 ADC currently in clinical phase I against AML and is 
designed to balance efficacy and tolerability.139,140 In addition to microtubule inhibitors and DNA damaging 
agents, there are several other payloads in ADC development also with different mechanisms of action like the 
topoisomerase I inhibitors SN38 and exatecan, the RNA polymerase II inhibitor a-amanitin or tubulysins. 
However, these payloads are less frequently used in ADC generation.106 
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Figure 11: Structures of DNA damaging agents and derivatives used in ADC development. 
Structures of selected DNA damaging agents are depicted. CC-1065 (A) and DUBA (B) belong to the duocarmycin family and DUBA is 
the payload utilized in SYD985, which is in phase III clinical trials. In the DUBA structure the DNA alkylating unit is highlighted in 
red and the DNA binding unit in blue. Anthramycin (C) and SG-3199 (D) are derivatives of the PBD class and the PBD dimer SG-3199 
is used in the ADC rovalpituzumab tesirine. DGN462 (E) and IGN1 (F) belong to the IGN class. DGN462 has a monoalkylating 
functionality with one single reactive imine group whereas IGN1 represents a DNA cross-linker because of the diimine moiety. Imine 
functionalities in DGN462 and IGN1 are illustrated in red and amino moiety that only binds to DNA is indicated by a blue box. DGN462 
is incorporated as a payload in the ADC IMGN779. Figure is adapted from Elgersma, Mantaj, Miller et al.134,137,139 
 
Premature release of the payload often leads to off-target toxicities. Therefore, good stability of the linker is of 
crucial importance while the ADC is present in the bloodstream. However, also a fast and efficient release inside 
the tumor cell is necessary. For attachment of the cytotoxic payload to the antibody, two categories of linker 
technologies can be distinguished: cleavable and non-cleavable linkers. 
Cleavable linkers represent a prominent linker type in ADCs and are differentiated in terms of their distinct 
release mechanism (acid-labile, protease cleavable linker, disulfide linkers). In the case of acid-labile linkers, 
hydrazone structures are utilized that remain stable at physiological pH 7.4, but are hydrolyzed and release the 
payload at acidic pH in the lysosomal compartments. The most common linker format used in ADCs, are the 
protease cleavable linkers that are designed to release the payload upon enzymatic cleavage by lysosomal 
proteases. Activity and overexpression of specific lysosomal proteases was confirmed and these proteases cleave 
a unique dipeptide sequence like valine-citrulline or valine-alanine (Figure 12). Cathepsin B was identified as a 
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key enzyme, responsible for such linker cleavage of valine-citrulline motifs with subsequently 1,6-fragmentation 
across an aryl spacer achieving subsequent drug release. New approaches exploit the presence of 
ß-glucuronidase that also exists within lysosomes and recognizes and cleaves hydrophilic glucuronide linkers 
(developed by Seattle Genetics).141 Besides that, disulfide-linker structures are cleaved upon reduction and make 
use of the different concentration levels of the thiol-containing tripeptide glutathione, which exhibits 
intracellularly concentrations in the millimolar range whereas extracellularly micromolar concentrations are 
present. To increase the stability of disulfide linkers, steric hindrance of the disulfide structure by adjacent 
methyl groups has been reported. Within the category of cleavable linkers, protease cleavable linker provide 
higher stability in systemic circulation compared to hydrazone- and disulfide-linked structures.142–144 
 
Figure 12: Cathepsin B cleavage of ValCit-based ADC and release of payload. 
Schematic cleavage reaction of the ADC brentuximab vedotin by cathepsin B. Lysosomal cathepsin B recognizes and cleaves the ValCit 
motif between citrulline and PABC. The resulting intermediate is unstable and subsequently undergoes 1,6-fragmentation of the self-
immolative PABC spacer that also undergoes decarboxylation leads to iminoquinone and carbon dioxide as byproducts. MMAE as a 
product is released without any further groups and is able to fulfill its cytotoxic mechanism. Figure is adapted from Burke et al.141 
 
The class of non-cleavable linkers provides high stability, but has no specific release mechanism. Within the cell 
and inside the lysosome, complete proteolytic degradation of the antibody is required and linker-drug with 
subsequent free drug is released. Unspecific cleavage in acidic lysosomes relies mainly on hydrolysis of acid-
labile bonds or cleavage of amide and ester bonds by proteases and esterases.145 Generally, ADCs bearing non-
cleavable linkers often provide a better safety profile, but are less efficacious compared to ADCs containing 
cleavable linkers.138 
For construction of ADCs, suitable conjugation methods are necessary that attach the drug-linker to the 
antibody (Figure 13). Traditional conjugation technologies are chemical conjugations based either on lysine 
amide coupling or cysteine coupling. Generated products differ in the conjugation site as well as in number of 
linker-drugs per antibody molecule. Lysine coupling is utilized to link the payload to solvent accessible lysine 
residues on the antibody using linkers with activated groups like NHS ester. Although an IgG1 antibody has 
approximately 90 lysine residues, generally only 8-10 lysine residues are accessible for conjugation, resulting in 
a heterogeneous mixture of different DAR species. Such heterogeneity is typically undesired as it has significant 
impact on the pharmacokinetics, stability, safety and efficacy profile of an ADC.146,147 Cysteine conjugation 
generates ADCs with a higher degree of homogeneity and controlled DAR, because fewer potential conjugation 
sites are available compared to lysine conjugation. IgG1 molecules consist of 4 interchain disulfide bonds and 
12 intrachain disulfide bonds. Selective reduction of the accessible interchain disulfides (usually achieved with 
TCEP) results in up to 8 free reactive thiols whereas the intrachain disulfides remain unaffected. No substantial 
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structural changes are observed. However, for higher amounts of free thiols a lower thermal stability of the mAb 
is observed.148–150 
For cysteine-based conjugation, free cysteine residues on the antibody are connected to a thiol-reactive 
functional group like maleimides through a Michael addition. The use of maleimide affords a thio-succinimide 
group, which is known to undergo side reactions like retro-Michael reaction involving the free thiol group (C34) 
of human serum albumin or gluthathione and thus, potentially leading to premature release of the cytotoxic 
drug. 
Site-specific conjugation technologies have been developed for the generation of homogeneous ADCs and result 
in a controlled DAR, improving the pharmacological properties of ADCs. Cysteine residues can be genetically 
engineered (THIOMAB) into specific sites on the antibody heavy or light chain to provide regioselectivity. 
S239C mutation (developed by Seattle Genetics) or A114C and V205C mutations (developed by Genentech) 
resulted in homogeneous ADCs without interfering native cysteine functionality. 
Additionally, enzyme-assisted ligation is also used for site-specific conjugation of either native or genetically 
engineered antibodies. Originally derived from Staphylococcus aureus, sortase A possesses transpeptidation 
activity and is utilized for site-specific conjugations yielding homogeneous ADCs with controlled DARs. The 
biological function of sortase A is related to anchoring proteins like virulence factors to the cell wall of gram-
positive bacteria. Sortase A recognizes specifically a LPXTG motif (X = any amino acid) and cleaves the 
threonine-glycine bond within this pentapeptide, subsequently connecting an oligo-glycine payload. Beerli et al. 
from NBE Therapeutics introduced the recognition sequence LPETG for sortase A to the C-termini on both 
the heavy and light chain of an antibody and demonstrated the generation of potent anthracycline-based 
ADCs.151,152,153 
An alternative enzymatic conjugation that also catalyzes a site-specific transpeptidation reaction is achieved by 
transglutaminase. Microbial transglutaminase (mTG) was initially discovered for food industry applications and 
was isolated from Streptomyces mobaraensis. mTG attaches calcium-independently a primary amine substrate (like 
lysines) to a glutamine (Q295) on the antibody to form an isopeptide bond. It is known that mTG tolerates a 
broad spectrum of amine substrates. Other natural glutamine residues in the Fc region are not recognized by 
transglutaminase. The biological function of mammalian transglutaminase relies on its ability to cross-link 
proteins like factor XIIIa or extracellular matrix proteins. In general, prior to mTG conjugation for ADC 
generation, deglycosylation of the antibody or mutation of the N297 to alanine are necessary for exposure of 
native Q295, which lead to successful conjugation yielding a DAR of 2. N297Q mutation results in 4 reaction 
sites that are addressable, typically leading to a DAR of 4. Furthermore, Pfizer added a LLQG tag into the 
antibody to the C-terminus of heavy or light chains that is also recognized by an engineered 
transglutaminase.154,155 
Besides that, other conjugation technologies that are used in the ADC field comprise the incorporation of 
unnatural amino acids, click chemistry, enzymatic reaction with formylglycine-generating enzyme (FGE) as 
well as glyco-engineering with glycosyltransferases.156 
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Figure 13: Conjugation technologies for ADC generation. 
Illustrated are commonly used ADC conjugation methods like lysine or cysteine conjugation that result in heterogeneous mixtures. Site-
specific conjugations can be achieved by engineering cysteine residues into the antibody, inserting unnatural amino acids or using tagged 
or modified antibodies for enzymatic conjugations with transglutaminase or sortase. Figure is adapted from Perez et al.106 
 
Clinical success of ADCs is attributed to rational design of new payloads, improvements of chemical linker 
properties and site-specific conjugation technologies. Less attention was payed on the antibody moiety as a 
pharmacodelivery vehicle with alternative formats that may have advantageous properties regarding the 
biodistribution and tumor penetration of ADCs. Such new approaches need to compromise the beneficial PK 
profile of antibodies in the IgG format with its impaired solid tumor penetration, and the potentially improved 
tumor accumulation of smaller fragments, which exhibit by contrast a short half-life. 
The following chapter focuses on aspects of tumor penetration and biodistribution of small molecules and large 
molecules. 
 
2.3. Solid tumor penetration of small molecule and large molecule therapeutics 
Despite advances of emerging therapeutics like ADCs, inefficient treatment and poor penetration of solid tumors 
due to its multi-dimensional complexity remains a formidable challenge for antibody-based therapeutics. In 
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contrast, hematological malignancies appear to be more accessible to antibodies than solid tumors, because 
vascularity is directly accessible by intravenous administration. In hematological cancers, besides the lack of 
requirement for ADCs to penetrate into solid tumor tissue, also low levels of target expression in healthy tissue 
organs and higher drug exposure in the blood are advantageous.108 Multiple factors contribute to the uneven 
distribution of ADCs that are more related to antibody characteristics, antigen properties or features associated 
to the tumor microenvironment. Paradoxically, delivery of drugs is hampered by tumor physiology and as 
angiogenesis is achieved within tumors, new formed blood vessels appear to be leakier and disordered than 
normal blood vessels. This leakiness and heterogeneity of tumor vasculature allows macromolecules to escape 
easily out of the blood vessels and should be ideal for delivery of large molecules. However, unstructured and 
hastily formed blood vessels generate a dense extracellular matrix and an elevated interstitial fluid pressure 
within tumors that opposes convectional flow and limit the diffusion of macromolecules from tumor vasculature 
to tumors.157,158,159 Traditionally, tumor targeting focused on the use of full-length IgG antibodies due to high 
affinity and selectivity to the antigen as well as favorable pharmacokinetic profile. But larger molecules are more 
restricted to penetrate within the tumor than small molecules, due to dependency on convectional flow.160 
Properties of in vivo biodistribution as well as slow penetration rate of conventional full-length antibodies into 
tissues relative to that of small molecules, limit efficacy of antibody therapy.161 Taking into account that small 
molecule agents such as those conjugated to ADCs, distribute extensively in the body but are also rapidly 
cleared, the molecular size is thought to contribute significantly to tumor penetration. Indeed, antibodies only 
reach perivascular tumor cells and are mainly located in the plasma and extracellular fluids. Therefore 
biodistribution properties of small molecules are altered fundamentally when generating an ADC, retaining PK 
characteristics of the mAb.162,163 It was reported that only a small amount of presumably 1% or less of 
administered ADC and antibody reach their final target.158,164,165 
Inefficient drug delivery due to the limited tumor penetration by the full-length antibody component is a 
tremendous challenge for an effective and curative treatment of solid tumors. Various tumor targeting agents 
ranging in size are under development and as tumor accessibility remains a critical issue for ADC delivery, the 
rise of antibody fragments and even smaller protein scaffolds for ADC construction may potentially be a suitable 
solution to enhance the efficacy of ADCs by improving the tumor penetration. Owing to the smaller size of Fab 
fragments and diabodies than IgGs (50 kDa versus 150 kDa), improved extravasation and tumor penetration 
abilities were demonstrated for smaller antibody fragments with higher diffusion coefficients in several 
approaches.166 Dennis and colleagues investigated an albumin-binding Fab fragment (AB.Fab4D5) targeting 
HER2 and showed that a better tumor penetration and localization was achieved with AB.Fab4D5 than with 
full-length IgG Trastuzumab. Furthermore, Trastuzumab showed a slow tumor accumulation, slow clearance 
rate from healthy tissues as well as a heterogeneous tumor distribution resulting in many unreached tumor cell 
regions. AB.Fab4D5 with its unique properties exhibited low normal tissue exposure and superior tumor to 
blood ratios compared to the conventional format.167  
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Figure 14: Comparison of tumor penetration of antibody-based therapy. 
Illustrated are exemplarily the half-life (t ½) of an ADC in the IgG format and of a Fab fragment. Also the tumor penetration and 
localization is schematically shown. Tumor penetration for the IgG format (red triangle) is decreased significantly with increasing 
distance from the blood vessel. For the Fab fragment (blue triangle) the penetration is more evenly within the tumor mass, reaching also 
distant tumor cells. Gradients in oxygen, nutrients and drug concentration that are present in cells distant from blood vessels are listed. 
These properties are commonly observed in sold tumors. Figure is modified from Minchinton et al.159 
 
Compared to IgG molecules, antibody fragments lack the Fc part that interacts with FcRn, which results in a 
short half-life and makes frequent administrations necessary. A relationship model between the molecular size 
of the pharmacodelivery vehicle and tumor uptake was investigated in detail and minimum tumor uptake was 
predicted for intermediate-sized targeting proteins like monovalent binding scFvs (25 kDa), which also exhibit 
poor tumor retention. Smaller or larger agents exhibit higher tumor uptake levels and show better tumor 
accumulation. Molecules that are larger than the kidney filtration cut off undergo sustained circulation in the 
plasma, leading to an increased probability to extravasate into tumor tissuse. Prediction of high tumor 
accumulation for IgG antibodies is mainly associated with the slow clearance rate due to FcRn-mediated 
recycling from lysosomes.168,169 
Ackerman et al. established a model used for the prediction of the maximum penetration distance R (Eq. 1) in 
solid tumors. A lot of variables in the equation are related to antibody properties like the antibody dose [Ab], 
void fraction (ε), and diffusivity (D). The remaining variables are antigen properties like antigen expression 
[Ag] as well as turnover rate (ke) and are intrinsic regarding penetration limitations. Moreover, the equation 
indicates that improved tumor penetration can be achieved with higher diffusivity of the targeting agent, higher 
antibody doses and slower internalization rates. Moreover, the large antibody size reduces tumor penetration 
due to the low diffusivity and permeability. According Graff et al. values of diffusivity for an IgG molecule and 
scFv can be assumed to be D = 80 µm²/s (for scFv) and D = 14 µm²/s (for IgG). As the parameter diffusivity D 
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is a function of antibody size and is inversely proportional to molecular weight, it can be assumed that in a model 
the scFv distributes about six times faster compared to full-length IgG.157,161,166 
 
 
𝑅 ≈ √
𝐷[Ab]surface
𝑘𝑒([Ag]tumor/𝜀)
 
 
Eq. 1 
 
Impressive data in a comparative evaluation of small molecule-drug conjugates (SMDCs) targeting carbonic 
anhydrase IX (CAIX) confirmed that by using a smaller targeting scaffold a homogenous and complete 
penetration within solid tumors is achieved, whereas full-length ADC is limited to perivascular tumor cells and 
fails to localize in deeper structures within the neoplastic mass. Analogous to ADCs, SMDCs utilize a small 
targeting ligand for the delivery of cyotoxic drugs. So far, small targeting ligands for SMDCs are limited to a 
very few targets comprising folate receptor, prostate-specific membrane antigen, somatostatin receptors and 
CAIX. Unfavorable tumor/blood distribution ratios were obtained for radiolabeled preparations of the anti-
CAIX antibody after 48 h with tumor uptake of 4 % ID/g, whereas SMDC derivatives exhibited exceptional 
tumor/blood distribution ratios of 100:1 with 40 % ID/g tumor uptake after 6 h, indicating preferential delivery 
of the SMDC.170–173 
Moreover, small format-drug conjugates with higher diffusion rates are under investigation for improved tumor 
penetration, particularly for solid tumors, where ADCs were not beneficial. For example, BT1718 with a 
conjugate size of just 2 kDa, is a so called bicycle-drug conjugate employing DM1 and targets MMP-14 that is 
currently in phase I. Also PEN-221 uses DM1 and is directed against the somatostatin receptor. PEN-221 has 
a molecular weight of 5 kDa and is in phase II clinical evaluation. 
Regardless of size, the degree of solid tumor penetration and accumulation is particularly affected by antibody 
binding affinity, especially in larger tumors. Many studies showed that high affinity antibody-based molecules 
(fast on-rate/slow off-rate) represent an obstacle for tumor accumulation and distribution within the entire solid 
tumor mass, hence they localize predominantly in perivascular regions of the tumor and would limit therapeutic 
efficacy in clinical studies. Rudnick and colleagues tested different affinity variants and demonstrated with 
radiolabeled high affinity antibodies that only the first encountered tumor antigens are addressed, before further 
penetration occurs. A stronger binding of antibody and its antigen results in a reduced tumor penetration due 
to a lower amount of free, diffusible antibody that is avaible for tumor penetration. These observations indicate 
that increasing antibody affinity leads to a low tumor accumulation, which is not beneficial, while decreasing 
binding affinity increases localization and achieves a more uniform distribution in tumor tissues.99,174,175,176 This 
phenomenon is known as the “binding site barrier” and suggest that three main factors are responsible for 
creating this barrier, namely (A) greater antigen density, (B) higher antibody affinity, and (C) faster antibody 
internalization and metabolism.167 
Ackerman et al. investigated anti-CEA antibodies with different internalization rates and showed that a slower 
internalizing antibody penetrated much deeper into tumor spheroids whereas the rapid internalizing antibody 
was not able to reach distant regions in the tumor spheroid. Furthermore, low antigen density is associated with 
a greater extent of tumor penetration, but is in contradiction to choose high target expression on tumor cells 
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for drug discovery and development. Hence, selection of target antigens with a slow internalization rate and 
low expression level might be beneficial for homogeneous and improved tumor penetration, although both 
represent intrinsic properties. Concerning ADC mechanism and efficacy, slow internalization rates are 
inappropriate, because payload delivery depends on efficient and often fast internalization.157 
To overcome impaired tumor penetration due to the binding site barrier, administered dose of the antibody can 
be simply increased. With increasing amount of available antibody, more antibodies are able to extravasate, 
binding the proximal antigens, whereas additional unbound antibodies can reach tumor cells distant (> 100 µm) 
from blood vessels leading to improved tumor penetration.159 But increasing the administered dose is not 
suitable for all therapeutic modalities, particularly for ADCs, because the toxin associated with the antibody 
drastically decreases the MTD and an increased number of toxic effects is expected.177,178 Many ADCs are dosed 
at MTD and frequent dose-limiting toxicities to the bone marrow and other healthy tissues limit the 
administered dose. Furthermore, some reports showed that coadministration of unconjugated antibody with 
ADC saturates immediate antigen binding sites, allowing deeper tumor penetration of the ADC from 
vasculature.179,180 
As the size of the targeting scaffold is of major importance for the tumor biodistribution and penetration, the 
following chapter discusses proteases that are overexpressed in the tumor microenvironment and are able to 
cleave off fragments from modified, full-length antibodies. 
 
2.4. Tumor-associated proteases: uPA and Matriptase 
The tumor microenvironment (TME) is composed of the cellular and biochemical composition of different 
populations of cancer cells as well as non-cancer cells, soluble proteins, blood vessels and an extracellular matrix 
that also represents a physical barrier for cell movement. Inflammatory cells and cancer-associated fibrolasts 
secrete a variety of proteins and proinvasive matrix-degrading enzymes like MMPs, cathepsins and serine 
proteases that facilitate cell migration by extracellular matrix proteolysis.181,182 Additionally, several other 
cancer-associated enzymes are known like the serine proteases elastase, cathepsin G but also gelatinases, 
collagenases and matrilysins, belonging to MMPs.183 
One well known extracellular tumor protease, the serine protease urokinase-type plasminogen activator (uPA), 
is overexpressed in several types of cancer and is a central component within a larger network.183 The uPA 
system consists of uPA, its corresponding cell surface receptor uPAR and two endogenous inhibitors 
plasminogen activator inhibitor 1 (PAI-1) and 2 (PAI-2) that negatively regulate uPA activity. uPA has 411 
amino acid residues and represents a 53 kDa multidomain glycoprotein with a glycosylation at N302. uPA is 
produced as an inactive protein known as pro-uPA (or single-chain uPA) and is released in the extracellular 
environment, where it is activated through a proteolytic event by other proteases. Plasmin, cathepsin B and L, 
kallikrein, trypsin and also matriptase are able to cleave pro-uPA into the active two-chain uPA form. The 
structural arrangement of uPA is composed of three functional regions. These regions are a carboxyl-terminal 
serine protease domain, a kringle domain and an amino-terminal fragment (ATF) containing an EGF-like 
domain that is responsible for binding to uPAR. The catalytic triade is composed of His57, Asp102 and Ser195 
(Figure 15).184 
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Figure 15: uPA and matriptase structures. 
Cartoon ribbon representation of uPA (A) and matriptase (B) structures, colored according to the spectrum from N-terminus (dark blue) 
to C-terminus (red). In both serine proteases the catalytic triade (sticks) comprising His57, Asp102, Ser195 are highlighted (generated 
by PyMOL ver 0.99, PDB: 1W12 and 1EAX). 
 
The main substrate of activated uPA is the inactive zymogen plasminogen, where uPA converts the proenzyme 
into its active form plasmin. Plasmin has a central role in the degradation and clearance of fibrin blood clots as 
well as other extracellular matrix constituents and is inhibited by a2-antiplasmin. Many studies indicated that 
the involvement of the uPA system has pleiotropic effects in pathophysiological processes like remodelling of 
extracellular matrix in the context of clot lysis, wound healing, tissue regeneration, angiogenesis, tumor cell 
proliferation and metastasis.185,186 Furthermore, uPA is used as an independent prognostic factor for breast 
cancer and overexpression of one component of the uPA system is associated with poor prognosis. Tissue-tpye 
plasminogen activator (tPA) plays a key role in the blood clotting cascade and is a homologous enzyme to 
uPA.187,188 uPA (Rheothromb®) is used in clinical settings as an anti-fibrinolytic agent in the context of 
thrombosis, e.g. myocardial infarction or pulmonary embolism.189 
Another important tumor protease is the type II transmembrane serine protease matriptase (MT-SP1), which 
is also upregulated in multiple malignant diseases (breast cancer, lung cancer, prostate cancer and colorectal 
cancer).190 Main functions of matriptase are associated with extracellular matrix re-modelling as well as tumor 
growth and metastasis. A fundamental role of matriptase relies on activation of numerous pro-oncogenic and 
pro-metastatic factors such as pro-uPA, pro-HGF, protease-activated receptor 2 (PAR-2), and various reports 
indicate that matriptase co-localizes with pro-uPA (Figure 16).191,192,193 The structural composition of the 95 
kDa matriptase features a carboxy-terminal extracellular trypsin-like S1 pocket, a small hydrophobic S2 subsite 
and a negatively charged S4 region, responsible for binding of basic residues. Mature matriptase is a zymogen 
and proteolytic cleavage is necessary to fulfill its biological function that is generally achieved by auto-
activation.190 The active site of matriptase (Figure 15) is also composed of a catalytic triade with His57, Asp102, 
Ser195 and the arrangement is exactly as in trypsin and chymotrypsin.194 But substrate specificity of matriptase 
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differs substantially from that of trypsin, as matriptase cleaves not randomly basic substrates with arginine and 
lysine residues. The requirement of further surrounding amino acids in close proximity to the cleavage site, 
enables matriptase to be a very specific protease.195 The physiological inhibitor of matriptase is hepatocyte 
growth factor activator inhibitor 1 (HAI-1) and regulates matriptase activity. A strong correlation between 
matriptase inhibition and reduced tumor growth was investigated with several agents like the potent protease 
inhibitor ecotin as well as the small molecule inhibitor CVS-3983 and showed a significant reduction in tumor 
size.190,196 
As uPA and matriptase are known to be overexpressed in a variety of cancers, extracellular cleavage of specific 
sequences that are sensitive to these tumor proteases were investigated for different purposes.197 In an excellent 
approach, Desnoyers et al. demonstrated the in vivo tumor-specific activation of an anti-EGFR probody that is 
cleaved locally in the tumor microenvironment and binds to the antigen, whereas in systemic circulation the 
probody remains inactive. Therefore, this probody approach aimed to reduce target-mediated toxicity commonly 
observed for cetuximab-based therapy due to high levels of EGFR in healthy skin. In their study reduced 
cutaneous toxicity was observed, leading to an improved safety profile. The probody design was based on an 
IgG1 sequence with an amino-terminal extension at the light chain containing a masking peptide and a cleavable 
linker sequence. Based on the sensitivity to tumor proteases, the cleavable substrate motif comprised the 8 amino 
acids LSGRSDNH.198 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Activity of matriptase on several factors. 
Illustration shows activation of pro-oncogenic and pro-metastatic components like pro-uPA and pro-HGF by matriptase. Different 
signaling pathways promote tumor growth and metastasis. Figure is adapted from Uhland.190 
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2.5. Aim of the study 
ADCs emerged as novel therapeutics with clinical success mainly for the treatment of hematological 
malignancies, but still considerable challenges exist against solid tumors. Impaired tumor penetration and 
distribution by large therapeutic molecules are a common observation in solid tumors and to overcome this 
issue, antibody fragments are used to corroborate a potential benefit for the preferential delivery of anticancer 
drugs. The aim of this work is to evaluate the improved tumor penetration ability and ADC efficacy of smaller- 
drug conjugates that are generated locally by extracellular proteases in the tumor microenvironment while 
retaining the long half-life of the IgG format in systemic circulation by a novel ADC design (Figure 17). The 
full-length IgG-ADC is able to bind to FcRn, resulting in a prolonged half-life. For this purpose, a tumor 
protease cleavage site is genetically engineered into the hinge region of an IgG-ADC, resulting in the release of 
two 50 kDa Fab-drug conjugates upon proteolytic cleavage. The smaller size of the Fab-drug conjugates 
accomplish an add-on effect to achieve a better localization and penetration within the tumor. As a model 
construct, Trastuzumab and Cetuximab are tested and overexpression of tumor proteases in several tumor cell 
lines was confirmed. For assessment of efficient and selective cleavage as well as accessibility within the hinge 
region, a cleavable construct containing the specific protease site as well as control constructs were generated 
and investigated for different characteristics like antigen and cellular binding, stability, enzyme kinetics, potency 
and in vitro spheroid penetration. Efficacy was tested with toxin-based molecules in several cell lines that 
overexpress HER2 and EGFR and for spheroid penetration studies antibody-fluorophore conjugates were 
generated. As the size of the ADC delivery vehicle is of major importance for efficient drug delivery, the 
investigations of this novel ADC design might showcase a potential benefit for the balance between optimum 
tumor penetration by the released fragments and the maintained pharmacokinetic properties of the IgG format. 
The more efficient tumor killing by such novel ADC design could lead to higher ADC success rates to improve 
patient lifes. 
 
 
 
Figure 17: Strategy for improving tumor penetration by released smaller-drug conjugates while retaining safety and half-life. 
ADC design with protease site in hinge region (highlighted in red) that is recognized and cleaved by tumor proteases uPA and matriptase. 
In systemic circulation the listed advantages of the IgG format are dominating wheres disadvantages in solid tumors of the IgG format 
at the tumor site are mitigated by the benefit from Fab fragments as a vehicle.
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3. Material 
 
3.1. Human cell lines and bacterial strains 
 
Mammalian cell lines 
Cultivation of mammalian cell lines was performed at 37°C, 5% CO2. Cancer cell lines were purchased from the 
American Type Culture Collection (ATCC®, Manassas, VA, USA) or companies as listed below. 
 
 
Table 3: List of mammalian cell lines used in this work. 
Cell type and cell origin are listed for each cell line. 
 
Cell line Cell type Origin 
A-431 human epidermoid carcinoma ATCC® CRL-1555™ 
BT-474 human ductal carcinoma (mammary gland) ATCC® HTB-20™ 
CHO-S Chinese hamster ovary Life Technologies, Darmstadt, Germany 
(R80007) 
Expi293FTM human embryonic kidney Life Technologies, Darmstadt, Germany 
(A14527) 
HCC1954 human ductal carcinoma (mammary gland) ATCC® CRL-2338™ 
MCF-7 human breast adenocarcinoma  
(mammary gland) 
ATCC® HTB-22™ 
MDA-MB-361 human breast adenocarcinoma  
(mammary gland) 
ATCC® HTB-27™ 
MDA-MB-453 human breast metastatic carcinoma 
(mammary gland) 
ATCC® HTB-131™ 
MDA-MB-468 human breast adenocarcinoma  
(mammary gland) 
ATCC® HTB 132TM 
NHEK.f-c. normal human primary keratinocytes PromoCell, Heidelberg, Germany 
NCI-N87 human gastric carcinoma ATCC® CRL-5822™ 
SK-OV-3 human ovary adenocarcinoma ATCC® HTB-77™ 
SK-BR-3 human breast adenocarcinoma  
(mammary gland) 
ATCC® HTB-30™ 
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Bacterial strains 
One Shot™ TOP10 Chemically Competent E. coli (#C4040-10, Life Technologies, Karlsruhe, Germany); 
Genotype: F- mcrA Δ  (mrr-hsdRMS-mcrBC) φ80lacZΔ  M15 Δ lacX74 recA1 araD139 Δ (ara-leu) 7697 galU galK 
rpsL (StrR) endA1 nupG 
 
 
3.2. Antibody sequences 
 
Amino acid sequences (primary structure) of used anti-HER2 antibodies or antibody fragments based on 
commercial Herceptin (Trastuzumab), where genetic modifications are highlighted with bold font. In general, 
antibody light chains carry always a sortase recognition tag for conjugation and are not listed each time. DNA 
sequences of light chain and heavy chain were codon-optimized for mammalian expression and procured from 
GeneArt (Life Technologies). 
 
Trastuzumab CL (cleavable), LC Srt Tag 
Heavy chain with cleavable linker in hinge region: 
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKG
RFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPL
APSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
TYICNVNHKPSNTKVDKKVEPPKSCDKTHTLSGRSDNHCPPCPAPELLGGPSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP
ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
 
Light chain with sortase recognition motif: 
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSG
TDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL
NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSS
PVTKSFNRGECGGGGSGGGGSGGGGSLPETGS 
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Trastuzumab nCL (noncleavable), LC Srt Tag 
Heavy chain with noncleavable linker in hinge region: 
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKG
RFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPL
APSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
TYICNVNHKPSNTKVDKKVEPPKSCDKTHTGGSGGSGGCPPCPAPELLGGPSVFLFPPKPKDTLMIS
RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ
PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
 
Trastuzumab natural, LC Srt Tag 
Heavy chain: 
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKG
RFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPL
APSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
TYICNVNHKPSNTKVDKKVEPPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV
VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL
PAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP 
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
 
Trastuzumab Fab His, LC Srt Tag 
Heavy chain with hexahistidine tag: 
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKG
RFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPL
APSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
TYICNVNHKPSNTKVDKKVEPPKSCDKTHTGGGGSHHHHHH 
 
Trastuzumab oa SEED AG HC His, LC Srt Tag 
Heavy chain SEED AG with hexahistidine tag: 
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKG
RFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPL
APSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
TYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV
DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPFRPEVHLLPPSREEMTKNQVSLTCLARGFYPKDIAVEWESNGQPENNYKTTPS
RQEPSQGTTTFAVTSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKTISLSPGKHHHHHH 
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Heavy chain SEED GA: 
MKLPVRLLVLMFWIPASLSEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV
DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPPSEELALNELVTLTCLVKGFYPSDIAVEWLQGSQELPREKYLTW
APVLDSDGSFFLYSILRVAAEDWKKGDTFSCSVMHEALHNHYTQKSLDRSPGK 
 
Trastuzumab natural, HC and LC Srt Tag 
Heavy chain with sortase recognition motif: 
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKG
RFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPL
APSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
TYICNVNHKPSNTKVDKKVEPPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV
VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL
PAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP 
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGLPETGS 
 
Trastuzumab CL, LC Srt Tag, HC N297A 
Heavy chain with cleavable linker in hinge region and N297A mutation: 
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKG
RFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPL
APSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
TYICNVNHKPSNTKVDKKVEPPKSCDKTHTLSGRSDNHCPPCPAPELLGGPSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP
ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
 
Trastuzumab nCL, LC Srt Tag, HC N297A 
Heavy chain with noncleavable linker in hinge region and N297A mutation: 
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKG
RFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPL
APSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
TYICNVNHKPSNTKVDKKVEPPKSCDKTHTGGSGGSGGCPPCPAPELLGGPSVFLFPPKPKDTLMIS
RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKE
YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ
PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
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Trastuzumab natural, LC Srt Tag, HC N297A 
Heavy chain with N297A mutation: 
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKG
RFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPL
APSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
TYICNVNHKPSNTKVDKKVEPPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV
VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL
PAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP 
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
 
Trastuzumab oa SEED, LC Srt Tag, AG HC N297A RF 
Heavy chain SEED AG with N297A mutation: 
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKG
RFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPL
APSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ
TYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV
DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPFRPEVHLLPPSREEMTKNQVSLTCLARGFYPKDIAVEWESNGQPENNYKTTPS
RQEPSQGTTTFAVTSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKTISLSPGK 
 
Heavy chain SEED GA with RF mutation: 
EPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
TLPPPSEELALNELVTLTCLVKGFYPSDIAVEWLQGSQELPREKYLTWAPVLDSDGSFFLYSILRVAA
EDWKKGDTFSCSVMHEALHNRFTQKSLDRSPGK 
 
Amino acid sequences (primary structure) of used anti-EGFR antibodies or antibody fragments based on 
commercial Erbitux (Cetuximab) are presented, where genetic modifications are highlighted with bold font. 
 
Cetuximab CL, LC Srt Tag 
Heavy chain with cleavable linker in hinge region: 
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSR
LSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPS
SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
CNVNHKPSNTKVDKRVEPKSCDKTHTLSGRSDNHCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE
VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK
VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN 
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
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Light chain with sortase recognition motif: 
DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDF
TLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNF
YPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVT
KSFNRGECGGGGSGGGGSGGGGSLPETGS 
 
Cetuximab nCL, LC Srt Tag 
Heavy chain with noncleavable linker in hinge region: 
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSR
LSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPS
SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
CNVNHKPSNTKVDKRVEPKSCDKTHTGGSGGSGGCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE
VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK
VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN 
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
 
Cetuximab natural, LC Srt Tag 
Heavy chain: 
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSR
LSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPS
SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
CNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV
SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP
IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL 
DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
 
Cetuximab Fab His, LC Srt Tag 
Heavy chain with hexahistidine tag: 
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSR
LSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPS
SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
CNVNHKPSNTKVDKRVEPKSCDKTHTGGGGSHHHHHH 
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Cetuximab oa SEED AG HC His, LC Srt Tag 
Heavy chain SEED AG with hexahistidine tag: 
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSR
LSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPS
SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYI
CNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV
SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP
IEKTISKAKGQPFRPEVHLLPPSREEMTKNQVSLTCLARGFYPKDIAVEWESNGQPENNYKTTPSRQ 
EPSQGTTTFAVTSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKTISLSPGKHHHHHH 
 
Heavy chain SEED GA: 
EPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
TLPPPSEELALNELVTLTCLVKGFYPSDIAVEWLQGSQELPREKYLTWAPVLDSDGSFFLYSILRVAA
EDWKKGDTFSCSVMHEALHNHYTQKSLDRSPGK 
 
 
3.3. Enzymes and proteins 
ADAM10 R&D Systems, Minneapolis, MN, USA 
Antarctic phosphatase, calf intestinal (CIP) New England Biolabs, Beverly, USA 
Benzonase Novagen, Nottingham, GB 
Bovine serum albumin (BSA), fraction V  Merck, Darmstadt, Germany 
BSA standard solution (2 mg/ml) Thermo Scientific, Schwerte, Germany 
CD40 Avi His Acro Biosystems, Newark, USA 
Ecotin Merck, Darmstadt, Germany 
EGF (236-EG/CF), Recombinant Human R&D Systems, Minneapolis, MN, USA 
EGFR (1-618)-His, Recombinant Human Merck, Darmstadt, Germany 
Furin, Recombinant Human (#1503-SE) R&D Systems, Minneapolis, MN, USA 
HAI-1, Recombinant Human (#1048-PI) R&D Systems, Minneapolis, MN, USA 
HER2, murine Fc-His Merck, Darmstadt, Germany 
ILT5-His Merck, Darmstadt, Germany 
Legumain (#2199-CY) R&D Systems, Minneapolis, MN, USA 
Lysozyme Roche, Mannheim, Germany 
Matriptase/ST14 Catalytic Domain (#3946-SE) R&D Systems, Minneapolis, MN, USA 
MMP-2, Recombinant Human (#902-MPN) R&D Systems, Minneapolis, MN, USA 
MMP-9, Active, Recombinant Human (#PF140) Merck, Darmstadt, Germany 
MMP-14/MT1-MMP, Recombinant Human 
(#918-MP) 
R&D Systems, Minneapolis, MN, USA 
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Phosphatase Inhibitor Cocktail Set II (#524625) Merck, Darmstadt, Germany (Calbiochem) 
Phusion DNA polymerase New England BioLabs, Ipswich, MA, USA 
Protease Inhibitor Cocktail Set III, EDTA-Free 
(#539134) 
Merck, Darmstadt, Germany (Calbiochem) 
Rherbb2 murine Fc R&D Novoprotein, New Jersey, USA 
Recombinant Human ErbB2/Her2 His-tag 
Protein (#10126-ER) 
R&D Systems, Minneapolis, MN, USA 
Sortase A, Recombinant Merck, Darmstadt, Germany 
T4 DNA ligase New England BioLabs, Ipswich, MA, USA 
tPA, Recombinant Human (#7449-SE) R&D Systems, Minneapolis, MN, USA 
Trypsin Sigma Aldrich, Steinheim, Germany 
Trypsin-EDTA Life Technologies, Darmstadt, Germany 
Transglutaminase, microbial Merck, Darmstadt, Germany 
u-Plasminogen Activator (uPA)/Urokinase 
(#1310-SE) 
R&D Systems, Minneapolis, MN, USA 
uPAR, Recombinant Human (#807-UK) R&D Systems, Minneapolis, MN, USA 
 
 
3.3.1. Antibodies 
Reference and control antibodies and antibody-drug conjugates 
Anti-Dig (Digoxigenin) Merck, Darmstadt, Germany 
Anti-hen egg lysozyme (HEL) Merck, Darmstadt, Germany 
Cetuximab (Erbitux®, C225) Merck, Darmstadt, Germany 
Trastuzumab (Herceptin®) Roche, Basel, Switzerland 
Trastuzumab emtansine (Kadcyla®, T-DM1) Roche, Basel, Switzerland 
 
All reference antibodies and antibody-drug conjugates were kindly provided by Merck, Darmstadt, Germany. 
 
Primary antibodies for Western Blot 
Goat anti-human IgG Antibody, F(ab’)2 
Fragment specific 
Jackson ImmunoResearch, Suffolk, GB 
Mouse IgG1 anti-human Matriptase Antibody 
(#MAB3946) 
R&D Systems, Minneapolis, MN, USA 
Mouse IgG1 anti-Penta His Antibody (#34660) Qiagen, Hilden, Germany 
Mouse anti-human IgG, F(ab')2 Fragment 
specific 
Jackson ImmunoResearch, Suffolk, GB 
Mouse IgG2A anti-human uPA Antibody 
(#MAB1310) 
R&D Systems, Minneapolis, MN, USA 
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Mouse anti-human uPAR Antibody (#MAB807) R&D Systems, Minneapolis, MN, USA 
Mouse anti-human IgG, Fcg Fragment specific Jackson ImmunoResearch, Suffolk, GB 
Rabbit anti-EGFR mAb, clone D38B1 Cell Signaling Technologies, Cambridge GB 
 
Secondary antibodies for Western Blot 
Goat anti-mouse IgG (H+L) x AP conjugate 
(#115-055-062) 
Jackson ImmunoResearch, Suffolk, GB 
Goat anti-mouse Fc F(ab‘)2 FITC conjugate Jackson ImmunoResearch, Suffolk, GB 
Goat anti-rabbit Alexa Fluor® 680 IgG (H+L), 
A21076 
Life Technologies, Darmstadt, Germany 
Precision Protein™ StrepTactin-HRP conjugate 
(#1610381) 
Bio-Rad, Munich, Germany 
Rabbit anti-goat IgG (H+L) x AP conjugate 
(#305-056-045) 
Jackson ImmunoResearch, Suffolk, GB 
 
Detection antibodies for flow cytometry 
Anti-Alexa Fluor® 488 Rabbit IgG Antibody 
Fraction (Quenching) (#A11094) 
Life Technologies, Darmstadt, Germany 
Goat Anti-Human IgG (H+L) Fab Fragment, 
Alexa Fluor® 488 (#109-547-003) 
Jackson ImmunoResearch, Suffolk, GB 
Goat anti-human IgG, Fc specific, FITC 
conjugate  
Jackson ImmunoResearch, Suffolk, GB 
 
Antibodies for ELISA 
Goat anti-mouse IgG (H+L) peroxidase (HRP) 
conjugate 
Jackson ImmunoResearch, Suffolk, GB 
Goat anti-human IgG, Fcγ fragment specific 
peroxidase (HRP) conjugate  
Jackson ImmunoResearch, Suffolk, GB 
Goat anti-human IgG, F(ab)2-fragment specific 
(#109-035-006) 
Jackson ImmunoResearch, Suffolk, GB 
Rabbit anti-goat IgG (H+L) peroxidase (HRP) 
conjugate  
Jackson ImmunoResearch, Suffolk, GB 
Rabbit Anti-human IgG, anti-Fc  
(#Clone RM116) 
Merck, Darmstadt, Germany 
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3.4. Oligonucleotides 
Oligonucleotides were obtained from Eurofins MWG Operon, Ebersberg, Germany. 
 
Primers for sequencing: 
pTT5_UP CTGCGCTAAGATTGTCAGT 
pTT5_RP CCATATGTCCTTCCGAGTG 
 
3.5. Chemicals 
1-StepTM Ultra TMB-ELISA substrate solution Thermo Scientific, Schwerte, Germany 
Accutase Merck, Darmstadt, Germany 
Acetic acid Merck, Darmstadt, Germany 
Acetonitrile Merck, Darmstadt, Germany 
Agar-agar Merck, Darmstadt, Germany 
Agarose Life Technologies, Darmstadt, Germany 
Albumin fraction V (from bovine serum), BSA Merck, Darmstadt, Germany 
Alexa Fluor 488 Cadaverine (#A30676) Thermo Scientific, Schwerte, Germany 
Alexa Fluor 647 Cadaverine (#A30679) Thermo Scientific, Schwerte, Germany 
Ammonium sulfate Merck, Darmstadt, Germany 
Ampicillin, sodium salt Life Technologies, Darmstadt, Germany 
BHQ-1 Amine LGC Biosearch Technologies, Petaluma, CA, USA 
BHQ-3 Amine LGC Biosearch Technologies, Petaluma, CA, USA 
BHQ-10 Succinimidyl Ester LGC Biosearch Technologies, Petaluma, CA, USA 
Blocking solution for fluorescent Western Blot Biomol, Hamburg, Germany 
Calcium chloride (CaCl2) Merck, Darmstadt, Germany 
Coomassie Plus - Bradford AssayTM Reagent Thermo Scientific, Schwerte, Germany 
1,5-Dansyl-Glu-Gly-Arg Chloromethyl Ketone Merck, Darmstadt, Germany 
Desocyribonucleotide triphosphates (dNTPs) Novagen, Nottingham, GB 
Disodium hydrogen phosphate (Na2HPO4*2H2O) Merck, Darmstadt, Germany 
DM1 Merck, Darmstadt, Germany 
DMSO VWR International, Darmstadt, Germany 
Eagle Minimal Essential Medium (MEM) Sigma-Aldrich, Steinheim, Germany 
EDTA (ethylenediaminetetraacetic acid) Sigma Aldrich, Steinheim, Germany 
Expi293TM expression medium Life Technologies, Darmstadt, Germany 
Gel filtration standards (#151-1901) Bio-Rad, Munich, Germany 
Gel loading dye (6x) Novagen, Nottingham, GB 
GelRedTM VWR International, Darmstadt, Germany 
Gibco® Dulbecco’s Modified Eagle Medium 
(DMEM) 
Life Technologies, Darmstadt, Germany 
 3. Materials  47 
Gibco® Dulbecco’s PBS (DPBS, w/o CaCl2, MgCl2); 
Phosphate Buffered Saline 
Life Technologies, Darmstadt, Germany 
Gibco® Fetal Calf Serum (FCS), Fetal Bovine Serum Life Technologies, Darmstadt, Germany 
Gibco® L-Glutamine Life Technologies, Darmstadt, Germany 
Gibco® Sodium pyruvate Life Technologies, Darmstadt, Germany 
Gibco® RPMI 1640 medium Life Technologies, Darmstadt, Germany 
Glucose Sigma-Aldrich, Steinheim, Germany 
Guava Instrument Cleaning Fluid (ICF) Merck, Darmstadt, Germany 
Glycine Merck, Darmstadt, Germany 
Hydrochloric acid (HCl) Merck, Darmstadt, Germany 
Isopropyl-β,D-thiogalactopyranosid (IPTG) Merck, Darmstadt, Germany (Calbiochem) 
Imidazole Merck, Darmstadt, Germany 
InstantBlue™ Protein Stain Expedeon Ltd, San Diego, CA, USA 
Insulin Sigma-Aldrich, Steinheim, Germany 
Kanamycin sulfate Merck, Darmstadt, Germany 
Magnesium chloride hexahydrate Merck, Darmstadt, Germany 
Methanol Merck, Darmstadt, Germany 
Monomethyl auristatin E (MMAE) Merck, Darmstadt, Germany 
Monomethyl auristatin F (MMAF) Merck, Darmstadt, Germany 
Monomethyl auristatin E (MMAE) linker-drug 
(Gly3-ValCit-PABC-MMAE) 
Merck, Darmstadt, Germany 
Monomethyl auristatin F (MMAF) linker-drug 
(Gly3-ValCit-PABC-MMAF) 
Merck, Darmstadt, Germany 
Nickel(II)sulfate hexahydrate Merck, Darmstadt, Germany 
NuPAGE® LDS sample buffer (4x) Life Technologies, Darmstadt, Germany 
NuPAGE® MES SDS running buffer (20x) Life Technologies, Darmstadt, Germany 
NuPAGE® Sample Reducing Agent (10x) Life Technologies, Darmstadt, Germany 
NuPAGE® Tris-acetate running buffer Life Technologies, Darmstadt, Germany 
Formaldehyde 37% Merck, Darmstadt, Germany 
Formic acid Sigma-Aldrich, Steinheim, Germany 
PageRuler™ Plus Prestained Protein Ladder, 10 to 
250 kDa (#26620) 
Thermo Scientific, Schwerte, Germany 
Peptone Merck, Darmstadt, Germany 
Perfect DNATM markers, 0.1 – 12 kbp Merck, Darmstadt, Germany 
Phusion HF buffer (5x) New England Biolabs, Ipswich, MA, USA 
Polyethylene glycol 8000 Sigma-Aldrich, Steinheim, Germany 
Potassium chloride (KCl) Merck, Darmstadt, Germany 
Potassium di-hydrogen phosphate (KH2PO4) Merck, Darmstadt, Germany 
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Precision Plus Protein™ Unstained Protein 
Standards (#1610363) 
Bio-Rad, Munich, Germany 
ProCHO5 medium Lonza, Basel, Switzerland 
Propidium iodide (PI) Life Technologies, Darmstadt, Germany 
Protein standard HiMarkTM pre-stained Life Technologies, Darmstadt, Germany 
Restriction enzyme buffers CutSmart or NEB1-4 New England Biolabs, Ipswich, MA, USA 
RIPA cell lysis buffer (10x, #9806) Cell Signaling Technologies, Cambridge GB 
Sucrose Merck, Darmstadt, Germany 
S.O.C. medium Life Technologies, Darmstadt, Germany 
SeeBlue® Plus2 Pre-Stained Protein Standard Life Technologies, Darmstadt, Germany 
Skim milk powder Merck, Darmstadt, Germany 
Sodium azide Merck, Darmstadt, Germany 
Sodium chloride (NaCl) Merck, Darmstadt, Germany 
Sodium hydroxide solution (NaOH) Merck, Darmstadt, Germany 
Sodium perchlorate monohydrate (NaClO4*H2O) Merck, Darmstadt, Germany 
Sulfo-Cyanin-5-amin Lumiprobe, Hannover, Germany 
Sulfuric acid (H2SO4) Bernd Kraft, Duisburg, Germany 
SYPRO Orange Life Technologies, Darmstadt, Germany 
T4 DNA Ligation Buffer (10x) New England BioLabs, Ipswich, MA, USA 
TAE buffer Life Technologies, Darmstadt, Germany 
Tetracycline VWR International, Darmstadt, Germany 
Trifluoroacetic acid (TFA) Life Technologies, Darmstadt, Germany 
Tris(hydroxymethyl)aminomethane (Tris) Carl Roth, Karlsruhe, Germany 
Tris-hydrochloride (Tris-HCl) Sigma-Aldrich, Steinheim, Germany 
Tween®20 (Polysorbate 20) Merck, Darmstadt, Germany 
Yeast extract Becton Dickinson, Heidelberg, Germany 
 
3.6. Cell culture media 
A-431, HEK293 adherent, MCF-7, MDA-MB-361, 
MDA-MB-453, SK-BR.3, SKOV-3 
DMEM, 10% (v/v) FCS, 1 mM sodium pyruvate 
MDA-MB-468, HCC1954, NCI-N87 RPMI 1640, 10% (v/v) FCS, 2 mM L-glutamine, 
1 mM sodium pyruvate 
BT-474 DMEM, 10% (v/v) FCS, 2 mM L-glutamine,  
1 mM sodium pyruvate, 10 µg/ml insulin 
CHO-S ProCHO5, 4 mM L-glutamine 
Expi293FTM Expi293TM expression medium 
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3.7. Solutions, media and buffer 
2xTY medium 16 g/l peptone, 10 g/l yeast extract, 5 g/l NaCl, 
pH 7.0 
5xTY medium 10 g/l peptone, 50 g/l yeast extract, pH 7.0 
Analytical Size Exclusion Chromatography (SEC) 
mobile phase 
PBS, pH 7.4 or 50 mM sodium phosphate 
(NaH2PO4, Na2HPO4), 0.4 M sodium perchlorate, 
pH 6.35 
BCIP/NBT Reagent, Blue/purple, AP substrate Merck, Darmstadt, Germany 
EDTA solution 0.5 M EDTA, pH 8.0 
FACS binding buffer 1% (w/v) BSA in DPBS 
Hydrophobic Interaction Chromatography buffer A: 1.5 M Ammonium sulfate, 25 mM Tris, pH 7.5 
B: 20 % Isopropanol, 25 mM Tris, pH 7.5 
Imidazole buffer 2 M Imidazole, pH 7.5 
Kinetics buffer (KB) for BLI 0.1% (w/v) BSA, 0.02% (v/v) Tween®20 in PBS 
LB medium 10 g/l peptone, 5 g/l yeast extract, 
10 g/l NaCl 
LB-A medium LB, 0.1 mg/l ampicillin 
LB-A agar LB-A, 15 g/l agar-agar 
Legumain activation buffer 50 mM Sodium Acetate, 100 mM NaCl, pH 4.0 
MMP-14/MT1-MMP activation buffer 50 mM Tris, 1 mM CaCl2, 0.5% (w/v) Brij-35, 
pH 9.0 
Nickel(II)sulfate solution 0.5 M Nickel(II)sulfate 
Opti-MEM, Reduced Serum Media Life Technologies, Darmstadt, Germany 
Phosphate buffered saline (10x PBS) 1.5 M NaCl, 84 mM Na2HPO4 x 2H2O,  
16 mM KH2PO4, pH 7.4 
Phosphate buffer (8x) 4 M NaCl, 199.5 mM Na2HPO4 x 2H2O, 
201.5 mM NaH2PO4 x H2O, pH 7.4 
Polyethylenelgycol (PEG)/NaCl 200 g/l PEG6000, 2.5M NaCl ad dH2O 
Preparative SEC mobile phase PBS, pH 7.4 
ProSepA binding buffer A 1.5 M Glycine/NaOH, 3 M NaCl, pH 9.0 
ProSepA elution buffer B2 0.2 M Glycine/HCl, pH 2.5 
ProSepA neutralization buffer C 1 M Tris/HCl, pH 9.0 
Protein A Chromatography binding buffer PBS, pH 6.8 – pH 7.0 or  
10 mM Na2HPO4, 10 mM NaH2PO4,  
500 mM NaCl, pH 7.0 
Protein A Chromatography elution buffer 0.1 M sodium citrate, pH 3.0 or  
20 mM acetic acid, pH 3.2  
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Protein A Chromatography neutralization buffer 3 M Tris/HCl, pH 8.5 or 1 M Tris/HCl, pH 9.0 
Sortase conjugation buffer 150 mM NaCl, 50 mM Tris-HCl, pH 7.5 
Transglutaminase conjugation buffer 150 mM NaCl, 25 mM Tris-HCl, pH 8.0 
Tris/HCl 3 M Tris, pH 8.0 
Wash solution/PBS-Tween®20 0.05% (v/v) Tween®20 in 1x PBS pH 7.4 
 
3.8. Kits and consumable materials 
AirPoreTM Tape Sheets, sealing foil Qiagen, Hilden, Germany 
Amicon® Ultra-15 and 0.5 ml centrifugal filter 
devices, 10K and 30K 
Merck, Darmstadt, Germany 
BCA Protein Assay Kit Thermo Scientific, Schwerte, Germany 
Cell culture flasks T25, T75, T175 Greiner Bio-One, Kremsmuenster, Austria 
Cell culture flat and round bottom NucleonTM 
delta surface 96 well plates 
Thermo Scientific, Schwerte, Germany 
Cell culture 24 well plates Costar® Thermo Scientific, Schwerte, Germany 
Cell culture microplate 384 well, white, clear Greiner Bio-One, Kremsmuenster, Austria 
CellTiter-Glo® Luminescent Cell Viability Assay Promega, Mannheim, Germany 
Chromolith Performance RP-18e 100-3mm Merck, Darmstadt, Germany 
Corning 384 well Spheroid microplates, 
black/clear bottom round, ULA (#3830) 
Sigma-Aldrich, Steinheim, Germany 
GenElute™ HP Plasmid Midiprep, Maxiprep Kit Sigma-Aldrich, Steinheim, Germany 
ExpiFectamineTM 293 transfection kit Life Technologies, Darmstadt, Germany 
Falcon® tubes, 15 ml and 50 ml VWR International, Darmstadt, Germany 
FortéBio tips (AHC, FAB2G, ProteinA) Pall ForteBio LLC, Menlo Park, CA, USA 
Gel and PCR clean-up kit NucleoSpin® Macherey-Nagel, Dueren, Germany 
Glas autosampler vials VWR International, Darmstadt, Germany 
Glas autosampler insert micro vials, 100 μl VWR International, Darmstadt, Germany 
HiPrep 26/10 Desalting GE Healthcare, Munich, Germany 
HiLoad Superdex 200 pg 26/60 columns GE Healthcare, Munich, Germany 
HiTrap MabSelect SuRe columns, 1 ml and 5 ml GE Healthcare, Munich, Germany 
His Buffer Kit GE Healthcare, Munich, Germany 
His GraviTrap GE Healthcare, Munich, Germany 
HisTrap™ HP, 1 ml and 5 ml GE Healthcare, Munich, Germany 
Human Serum HIV tested (#S4200) BioWest, Nuaillé, France 
iBind™ Solution Kit (#SLF1020) Life Technologies, Darmstadt, Germany 
iBlot™ Transfer Stack, Nitrocellulose, mini Life Technologies, Darmstadt, Germany 
iBlot™ Transfer Stack, PVDF, mini Life Technologies, Darmstadt, Germany 
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Limulus amebocyte lysate Endosafe®-PTSTM 
cartriges, PTS2001F, FDA-licensed,  
1-0.01 EU/ml 
Charles River Laboratories, Wilmington, MA, 
USA  
MAB PAK Butyl 5 μm 4.6 mm ID x 100 mm Thermo Scientific, Schwerte, Germany 
MaxiSorp®f flat-bottom 96 well micotiter plates Sigma-Aldrich, Steinheim, Germany 
Mini-Sub® Cell GT cell gel chambers Bio-Rad, Munich, Germany 
Montage PROSEP-A spin columns (#P36486) Merck, Darmstadt, Germany 
Mouse Serum (#S2160) BioWest, Nuaillé, France 
NuPAGE® 3-8% Tris-Acetate gels Life Technologies, Darmstadt, Germany 
NuPAGE® 4-12% Bis-Tris gels Life Technologies, Darmstadt, Germany 
Pellicon® 3 Cassette with Ultracel® 10 kDa 
Membrane, D screen, 88 cm² 
Merck, Darmstadt, Germany 
Pierce™ Coomassie Plus (Bradford) Assay Kit Thermo Scientific, Schwerte, Germany 
Pierce™ Fab Preparation Kit Thermo Scientific, Schwerte, Germany 
Pierce™ F(ab´)2 Preparation Kit Thermo Scientific, Schwerte, Germany 
Polypropylene microtiter plates, black Greiner Bio-one, Frickenhausen, Germany 
Polypropylene microtiter plates, clear Greiner Bio-one, Frickenhausen, Germany 
Polystyrene round bottom 96 well microtiter 
plates 
Greiner Bio-one, Frickenhausen, Germany 
PLRP-S 5 µm, 50 x 2,1 mm, 4000A Agilent Technologies, Waldbronn, Germany 
Pur-A-Lyzer™ Maxi Dialysis Kit Sigma-Aldrich, Steinheim, Germany 
PureLink™ Quick Plasmid Miniprep Kit Life Technologies, Darmstadt, Germany 
Qiaprep® Spin Miniprep kit Qiagen, Hilden, Germany 
Quick Ligation Kit New England BioLabs, Ipswich, MA, USA 
Safe-lock tubes 0.2, 1.5, 2.0, 5.0 ml Eppendorf, Hamburg, Germany 
Standard Capillary Chips NanoTemper Technologies, Munich, Germany 
Steriflip® filter device 0.22 µm Merck, Darmstadt, Germany 
SteritopTM bottle top filter 0.22 µm Merck, Darmstadt, Germany 
The Blocking Solution Candor Bioscience, Wangen, Germany 
Tissue culture 24 well plates Greiner Bio-one, Frickenhausen, Germany 
TMB peroxidase substrate solution Vector Laboratories, Burlingame, CA, USA 
TSKgel SuperSW3000 column, 4.6 x 300 mm Tosoh Bioscience, Darmstadt, Germany 
Ultrafree® Centrifugal filter units Merck, Darmstadt, Germany 
ViaFlow pipette 16 channel Integra, Biebertal, Germany 
Wizard® SV Gel and PCR Clean-Up System Promega, Mannheim, Germany 
Zeba Spin desalting PD-10 columns Life Technologies, Darmstadt, Germany 
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3.9. Equipment 
Analytical balance New Classic MF MS3002S Mettler Toledo, Giessen, Germany 
Cell counter Vi-CELL® XR Beckmann Coulter, Brea, CA, USA 
Chromatography systems ÄKTAxpress, 
ÄTKAexplorer 100, ÄKTApure 
GE Healthcare, Munich, Germany 
Cogent® μScale TFF System Merck, Darmstadt, Germany 
Electrophoresis chambers Bio-Rad, Munich, Germany 
Endosafe®-PTSTM reader, PTS100  Charles River, Wilmington, MA, USA  
EnVision 2104 Perkin Elmer, Boston, MA, USA 
EVOS FL Auto 2 Imaging System Life Technologies, Darmstadt, Germany 
Flow cytometer Guava easyCyte HT 2L Merck, Darmstadt, Germany 
Fluoresence reader Odyssey® CLx LI-COR Biosciences, Bad Homburg, Germany 
FortéBio Octet RED Pall ForteBio LLC, Menlo Park, CA, USA 
Gel imaging system GBOX Syngene, Cambridge, GB 
HeraSafe® Clean Bench Thermo Scientific, Schwerte, Germany 
Hot plate magnetic stirrer IKA® RCT basic Sigma-Aldrich, Steinheim, Germany 
HPLC Agilent Technologies 1260 Infinity, 
ChemStation LC 3D 
Agilent Technologies, Waldbronn, Germany 
iBind™ Western System Life Technologies, Darmstadt, Germany 
iBlot® Dry Blotting System Life Technologies, Darmstadt, Germany 
Incubation shaker Minitron Infors HT, Bottmingen, Switzerland 
Incubator Heracell 150 Thermo Scientific, Schwerte, Germany 
IncuCyte® S3 Live-Cell Analysis System Sartorius, Göttingen, Germany 
Megafuge 1.0R, rotor BS4402/A Thermo Scientific, Schwerte, Germany 
Microplate washer, ELx405TM BioTeK, Bad Friedrichshall, Germany 
Microtiter plate reader BioTeK SynergyTM 4 BioTeK, Bad Friedrichshall, Germany 
Microtiter plate reader SpectraMax® Paradigm® Molecular Devices, Wals, Austria 
Multifuge 3 S-R Heraeus, Hanau, Germany 
Nanodrop ND-1000 Spectrophotometer Thermo Scientific, Schwerte, Germany 
Nanodrop One Spectrophotometer Thermo Scientific, Schwerte, Germany 
pH meter 744 Metrohm, Filderstadt, Germany 
Power supply EC 250-90 Thermo Scientific, Schwerte, Germany 
PowerPacTM basic power supply  Bio-Rad, Munich, Germany 
Prometheus NT.PLEX nanoDSF NanoTemper Technologies, Munich, Germany 
Table centrifuge 5415D Eppendorf, Hamburg, Germany 
Tecan D300e Digital Dispenser Tecan, Maennedorf, Switzerland 
ThermoMixer® Eppendorf, Hamburg, Germany 
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Ultracentrifuge Beckmann OptimaTM LE-80K, 
SW41 TI rotor 
Global Medical Instrumentation, Ramsey, MN, 
USA 
Synapt-G2 mass spectrometer Waters, Milford, MA, USA 
XCell SureLockTM gel electrophoresis device Life Technologies, Darmstadt, Germany 
 
Further basic laboratory equipment and instrumentation that are commonly used were also utilized. 
 
3.10. Software 
Accelrys Draw 4.2 Biovia, San Diego, CA, USA 
ÄKTA UNICORN software ver. 5.31 (Build 407) GE Healthcare, Munich, Germany 
ChemBioDraw Ultra 13.0 Perkin Elmer, Boston, MA, USA 
Endosafe®-PTSTM Data logging utility ver. 1.0  Charles River Laboratories, Wilmington, MA, USA  
FortéBio Octet Data Acquisition ver. 8.0 Pall ForteBio LLC, Menlo Park, CA, USA 
FortéBio Octet Data Analysis ver. 8.0 Pall ForteBio LLC, Menlo Park, CA, USA 
Gen5TM microplate reader Software ver. 1.11.5 BioTeK Instruments, Bad Friedrichshall, Germany 
GraphPad Prism ver. 7.00 GraphPad Software, La Jolla, CA, USA 
GuavaSoft ver 2.7 Merck, Darmstadt, Germany 
HPLC Software ChemStation Agilent Technologies, Waldbronn, Germany 
Image StudioTM Software ver. 2.1 LI-COR Biosciences, Bad Homburg, Germany 
Incucyte S3 2018A Sartorius, Göttingen, Germany 
Lasergene ver. 14 DNA Star Inc., Wisconsin, WI, USA 
Mendeley Desktop ver. 1.19.4 Elsevier, New York, NY, USA 
Microsoft Office 2013 Microsoft Corp., Redmond, WA, USA 
ParadigmTM Software SoftMaxPro ver. 6.3 Molecular Devices, Wals, Austria 
Protein Thermal ShiftTM Software ver. 1.0 Life Technologies, Darmstadt, Germany 
PyMOL ver. 0.99 Schrodinger LLC, San Diego, CA, USA 
Reference Manager ver. 12 Thomson Reuters, FFM, Germany 
SnapGene® Viewer ver. 2.6.2 GSL Biotech LLC, Chicago, IL, USA 
Tecan D300e Software Tecan, Maennedorf, Switzerland 
PR.Thermo Control NanoTemper Technologies, Munich, Germany 
Vi-CELL® XR ver. 2.04 Beckmann Coulter, Brea, CA, USA 
Wallac Envision Manager Perkin Elmer, Boston, MA, USA 
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4. Methods 
 
4.1. Molecular biological and microbiological methods 
4.1.1. Determination of DNA concentration 
The concentration of nucleic acids in aqueous solutions was measured by UV spectrophotometer Nanodrop 
ND-1000 or Nanodrop One applying 1.5 or 2.0 µl of sample on the pedestal. As blank measurements the nucleic 
acid formulation buffer was used. The law of Lambert-Beer is the fundamental physical principle as well as the 
absorption of aromatic nucleobases within the DNA at the wavelength 260 nm. The ratios of absorbance 
A260/A280 and A260/A230 can be used as quality criteria for the purity of the DNA and should be in the range 
1.8 and 2.0-2.2, respectively. Lower values indicate a contamination with undesired products (typically proteins). 
 
4.1.2. Purification of DNA 
DNA fragments were purified after PCR reactions using the Wizard® SV Gel and PCR Clean-Up System 
according to the manufacturer’s protocol. Elution of DNA was carried out in 10-50 µl elution buffer from the 
kit or dH2O. DNA concentration was measured by a UV spectrophotometric analysis. 
 
4.1.3. Agarose gel electrophoresis 
Agarose gel electrophoresis was used for size-dependent separation of linear DNA fragments in an electric field. 
Generally, 1-2% (w/v) agarose gels were prepared in TAE buffer supplemented with GelRedTM solution 
(1:10,000). Samples of 10 µl DNA together with 2 µl 6x loading dye buffer were loaded on gels along with 10 µl 
Perfect DNATM marker (0.1-12 kbp) for determination of size and quantity of separated DNA fragments. Gels 
were run for 50 min at 110 V and after the run, DNA bands were visualized under UV light using the gel 
imaging system GBOX.  
 
4.1.4. DNA sequencing 
Sequence analysis of isolated plasmid DNA samples (15 µl with 50-100 ng/µl) or transformed E. coli glycerol 
stocks in 96 well plates was carried out at Eurofins MWG Operon (Ebersberg, Germany) by using pTT5_UP 
and pTT5_RP primers. 
 
4.1.5. Transformation in E. coli 
For plasmid amplification, heat shock transformation of One Shot™ TOP10 Chemically Competent E. coli cells 
with plasmid DNA was performed. Briefly, 50 µl Chemically Competent E. coli cells were thawed on ice for 
5-10 min, subsequently adding 1 µl plasmid DNA and incubating for 30 min on ice. Heat shock was carried out 
at 42 °C in a water bath for 45 sec without shaking. After heat shock, vials were incubated on ice for 2 min, 
transformed cells were immediately mixed with 250 µl pre-warmed S.O.C. medium and incubated at 37 °C and 
450 rpm for 1 h. Afterwards, cell suspensions were plated on pre-warmed LB-Ampicillin selective agar plates 
and incubated overnight at 37 °C. 
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4.1.6. Plasmid preparation 
Single E. coli colonies were picked from the agar plate and inoculated overnight at 37 °C, 250 rpm in E. coli 
cultures in LB-medium. Plasmid preparation was performed according to the manufacturer’s instruction. 
Plasmid DNA was isolated from 5 ml E. coli cultures using the GenElute™ HP Plasmid Miniprep Kit or from 
100-200 ml E. coli cultures applying the GenElute™ HP Plasmid Midiprep Kit or GenElute™ HP Plasmid 
Maxiprep Kit, respectively. DNA elution was carried out with 100-3000 µl dH2O depending on the size of the 
E. coli culture. 
 
4.2. Biochemical methods 
4.2.1. Determination of protein concentration 
Determination of protein concentration was performed by measuring absorbance at 280 nm (A280) according to 
the law of Lambert-Beer by Bradford assay using the Pierce™ Coomassie Plus (Bradford) Assay Kit, BCA 
Protein Assay Kit or applying 1.5 or 2.0 µl of sample on the pedestal of UV spectrophotometer Nanodrop 
ND-1000 or Nanodrop One. As blank measurements the respective protein formulation buffer was used. 
Concentration was determined with the parameters molecular weight (in kDa) and molar extinction coefficient 
(M-1 cm-1; BRAIN, Genedata; Protean Software, Lasergene DNASTAR) of the protein. For the Bradford assay, 
a standard curve with serial dilutions of BSA (0.1-1 mg/ml) were prepared for protein quantitation. Samples 
were diluted (1:2 to 1:40 depending on the concentration), 5 µl of each sample or standard dilution were added 
in duplicates to a microtiter plate well together with 150 µl Bradford reagent. After shaking and incubation for 
30 min in the dark, absorbance is measured at 595 nm with an ELISA reader. Protein concentration of samples 
are calculated by using the calibration curve. For the BCA assay also BSA standard solutions are prepared. 25 µl 
of each sample or BSA standard are added into a microplate well. Afterwards, 200 µl working reagent 
(containing BCA) are added to each well and mixed on a plate shaker for 30 sec. Microplate is incubated for 30 
min at 37 °C and plate is cooled to RT before measuring absorbance at 562 nm. 
 
4.2.2. Protein A affinity chromatography 
For IgG antibody purification from cell free Expi293 supernatants of small scale productions (25-50 ml), 
purification was carried out with PROSEP® A centrifugal Protein A columns. Due to the fact that Protein A 
has a high affinity for the Fc part of an IgG antibody, established purification procedures are used. For this 
approach, recommended buffers binding buffer A, elution buffer B2 and neutralization buffer C were used, 
following antibody purification protocol. In brief, before loading on PROSEP® A columns, samples were 
clarified by filtration through Steriflip® filter device 0.22 µm to remove any debris. Filtered samples were 
diluted with binding buffer A in a ratio of 1:1 (v/v) and were applied on the columns, centrifuged with 150 xg 
for 20 min and followed by two washing steps (500 xg for 2 min) à 10 ml binding buffer A. Elution of bound 
antibodies was achieved by addition of 10 ml elution buffer B2 in tubes containing 1.3 ml neutralization buffer 
C. Eluates containing antibodies were concentrated with Amicon® Ultra-15 centrifugal filter device (with 
10,000 molecular weight cut-off MWCO; 3000 xg, 15 min) and subsequently buffer exchanged to PBS pH 7.4 
using PD-10 desalting columns or Pur-A-LyzerTM Dialysis Kit. 
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Purification of antibodies from cell free Expi293 supernatants of large scale productions (200 ml) was performed 
by using affinity chromatography with a 1 ml or 5 ml HiTrap MabSelect SuRe column on an ÄKTAxpress or 
ÄKTApure system. Column equilibration was achieved with 5 column volumes (CV) binding buffer PBS pH 7.4 
at a flow rate of 2.5 ml/min, subsequently sample was loaded (2.5 ml/min) on MabSelect column using active 
air sensor and wash out with 5 CV binding buffer. Isocratic elution was carried out with 5 CV using 20 mM 
acetic acid, pH 3.2. Eluate is buffered through HiPrep 26/10 Desalting column with PBS ph 7.4. 1 ml fractions 
were collected in 96 deep well plates and fractions from the target protein peak were pooled and checked for 
purity with SDS PAGE and analytical SEC. Samples were concentrated with Amicon® Ultra-15 centrifugal 
filter device with 10,000 MWCO (3000 xg, 15 min) and subjected to preparative size exclusion chromatography, 
if necessary. 
 
4.2.3. Immobilized metal ion affinity chromatography (IMAC) 
Purification of antibody fragments from cell free Expi293 supernatants of small scale productions (25-50 ml) 
was achieved with single-use columns His GraviTrap and His Buffer Kit based on immobilized metal ion affinity 
chromatography (IMAC) according to the manufacturer’s protocol. Before purification the supernatants were 
dialyzed using Pur-A-Lyzer™ Maxi Dialysis Kit to exchange buffer to PBS pH 7.4. The gravity-flow 
purification was carried out by equilibration of the column using 10 ml binding buffer 20 mM sodium phosphate, 
500 mM NaCl, pH 7.4, sample application, washing step and elution of the sample with 3 ml elution buffer 
containing 500 mM imidazole. 
Prior to purification, cell free Expi293 supernatants of large scale productions (200 ml) were diafiltrated and 
concentrated using the Cogent® μScale Tangential Flow Filtration (TFF) System with three Pellicon® 3 88 cm² 
cassettes and a MWCO of 10 kDa. The retentate was buffer exchanged to PBS pH 7.4. To facilitate purification 
of histidine-tagged antibody fragments, IMAC was designed to capture the protein with hexahistidine tag based 
on high selective affinity for Ni2+ (in Ni sepharose medium). Buffer-exchanged and concentrated supernatants 
were loaded on a HisTrap™ HP, 1 ml or 5 ml column using an ÄKTAexplorer or ÄKTApure system. Column 
equilibration was achieved with 5 column volumes (CV) 1x phosphate buffer pH 7.4 at a flow rate of 5.0 ml/min, 
subsequently sample was loaded (5.0 ml/min) on HisTrap column using active air sensor and wash out with 
5 CV binding buffer. Stepwise elution was carried out with a gradient 10 CV using 20 mM, 50 mM, 100 mM, 
200 mM, 300 mM, 500 mM imidazole, pH 7.4 and 1x phosphate buffer (5.0 ml/min). 1 ml fractions were 
collected in 96 deep well plates and fractions from target protein peaks were pooled and checked for purity with 
SDS PAGE and analytical SEC. Samples were concentrated with Amicon® Ultra-15 centrifugal filter device 
with 10,000 MWCO (3000 xg, 15 min) and subjected to preparative size exclusion chromatography. 
 
4.2.4. Preparative size exclusion chromatography (SEC) 
Antibodies and antibody fragments were purified using chromatography techniques that separate them 
according to differences in size, hence obtaining pure antibody monomer separating from high molecular weight 
protein aggregates. Preparative size exclusion chromatography (SEC) was carried out using HiLoad 26/60 
Superdex 200 pg with PBS pH 7.4 or other desired buffer as mobile phase. Columns were equilibrated with 5 CV 
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buffer at 10.0 ml/min, before 2 ml concentrated protein solution was loaded with a sample loop. 1 ml fractions 
were collected in a 96 deep well plate and selected fractions were pooled (2.5 ml/min). Antibody samples were 
concentrated with Amicon® Ultra-15 centrifugal filter device (10 kDa MWCO) resulting in final concentrations 
of 6-7 mg/ml protein. Determination of protein concentrations and purity was achieved by A280 spectroscopy, 
gel electrophoreses and analytical SEC. Endotoxin levels were assessed for final protein samples by Limulus 
amebocyte lysate (LAL) Endosafe® PTS cartridges and Endosafe® PTS reader according to the manufacturer’s 
instructions. 
 
4.2.5. Analytical size exclusion chromatography 
Evaluation of protein purity, molecular size and relative amount of high molecular weight protein aggregates 
was performed by using analytical size exclusion high performance liquid chromatography (SE-HPLC) with 
TSK Super SW3000 column and HPLC Agilent 1260 (ChemStation LC 3D). Briefly, columns were equilibrated 
with mobile phase buffer at 0.35 ml/min until obtaining stable baseline (~45 min). The gel filtration standard 
(Bio-Rad) that was used contains a mixture of 5 molecular weight markers. 10 µg of protein samples (typically 
10 µl of a solution with a concentration of 1.0 mg/ml) in PBS was applied per run. The following sequence was 
injected: mobile phase, gel filtration standard, protein samples, gel filtration standard, mobile phase. 
Chromatograms recorded with UV detection at 214 nm (or alternatively 254 and 280 nm) and were analyzed 
by the ChemStation software by peak area integration and target purity as well as other species were determined. 
 
4.2.6. SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) represents an established method for 
analysis of protein purity of samples and cell lysates. The intrinsic charge of proteins is masked by addition of 
the anionic detergent SDS or lithium dodecyl sulfate (LDS) that denatures the protein and creates a relatively 
uniform negative charge distribution. SDS-PAGE separates proteins primarily according to molecular weight 
(sieving effect), migrating to the anode in an electric field. For this purpose, protein samples or cell lysates were 
mixed with 4x LDS sample buffer and 10x sample reducing agent (optional, if reduction of disulfide bonds was 
necessary), followed by incubation in a ThermoMixer for 10 min at 70°C for protein denaturation. Samples were 
centrifuged shortly and subjected to NuPAGE® Bis-Tris gels (4-12%), installed in a gel electrophoreses 
chamber. Generally, an amount of 2 µg/lane for Coomassie staining or 1 µg/lane for Western blotting was 
loaded on the gel. As molecular weight markers for antibody samples, SeeBlue® Plus2 Pre-Stained Protein 
Standard or Precision Plus Protein™ Unstained Protein Standards and for cell lysates PageRuler™ Plus 
Prestained Protein Ladder were used. Bis-Tris gels were run for 40 min at 200 V. Afterwards, gels were rinsed 
with deionized water and analyzed with Coomassie staining or Western blotting. 
 
4.2.7. Coomassie staining 
Coomassie staining was performed for detection of proteins that were previously separated by SDS-PAGE using 
InstantBlue™ Protein Stain. Gels were stained for at least 10-30 min on an orbital shaker, the staining solution 
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was discarded and the gels were rinsed 3 times with deionized water, according to the manufacturer’s 
instructions. 
 
4.2.8. Western blotting 
Detection of proteins through Western blotting was carried out by detection antibodies conjugated to enzymes 
(e.g. AP, Alkaline phosphatase; HRP, horseradish peroxidase). Blotting was performed with the iBlot® Dry 
Blotting System according to the manufacturer’s instructions. Briefly, proteins from SDS-PAGE gels were 
electro-transferred to polyvinylidene difluoride (PVDF) membranes (program 3, 7 min, 20 V) and immobilized 
proteins were detected with labeled antibodies. 
 
4.2.9. Labeled antibodies 
After transfer of proteins or ADCs to PVDF membrane, western blot workflow was achieved with the iBind™ 
Western System. This platform is based on sequential lateral flow technology and offers the advantage that 
simply all reagents like primary antibody, secondary antibody and wash solution are added sequentially to the 
system. Briefly, blotted membrane was immersed in 1X iBind™ Solution, primary and secondary antibodies 
were diluted in 1X iBind™ Solution. Afterwards, the iBind™ Card was prepared and the membrane was applied 
with the protein-side down. Finally, all solutions were added to the wells and the system was incubated for at 
least 2.5 h or overnight. After incubation, membrane was rinsed with deionized water and immunodetection 
protocol was performed by addition of BCIP/NBT Alkaline Phosphatase Substrate following the manufacturer’s 
instructions. 
 
4.2.10. Enzyme cleavage reactions and kinetics 
For enzymatic hinge cleavage, cleavable antibodies and ADCs were incubated with respective enzymes 
recombinant human uPA and matriptase (R&D Systems). Protease cleavage was performed by adding antibody 
solutions at 500 nM to protease samples uPA (50 nM) or matriptase (20 nM), and incubation of the mixture at 
37°C for 24 h in DPBS pH 7.4 under nonreduced conditions. The cleavage of antibody was analyzed by SDS-
PAGE and ESI-MS. For enzyme kinetics, modified ADCs where incubated with uPA and matriptase at a ratio 
25:1 (ADC:enzyme) and samples were taken at different time points. To stop the reaction, the irreversible 
inhibitor 1,5-Dansyl-Glu-Gly-Arg Chloromethyl Ketone was added at 10 µM and samples were stored at -80°C 
until analysis. Time points were analyzed by RP-HPLC using an Agilent PLRP-S 5 µm, 50 x 2,1 mm, 4000A 
column with water/0,1% TFA and acetonitrile/0,1% TFA as mobile phase (1.0 ml/min), where pre-assignment 
of fragments was achieved by RP coupled to MS in a previous run. 
 
4.2.11. Total antibody enzyme-linked immunosorbent assay (ELISA) for serum stability 
Prior to analysis, antibody or ADC samples were incubated at 0.5 mg/ml in human or mouse serum for 96 h at 
37°C, 5% CO2. Sampling at different time points was achieved and samples were frozen at - 80°C. Determination 
of antibody concentrations in complex matrices like human or mouse serum was achieved by enzyme-linked 
immunosorbent assay (ELISA). Prior to the main assay, antibodies were titrated for determining the linear 
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range for the concentration dependent reduction in ELISA signal in order to prevent signal saturation for the 
assay antibody concentration. Calibration standards and serum samples were diluted in The Blocking Solution. 
96 well MaxiSorp® polystyrene microtiter plates were coated with 100 µl/well HER2, murine Fc-His at 2 µg/ml 
overnight at 4°C. Additionally, ILT5-His was included as an unrelated antigen to detect possible non-specific 
binding. After incubation and washing steps with 300 µl/well 1x DPBS/0.5 % Tween®20 using microplate 
washer ELx405TM, calibration standards or analytes were added with 100 µl/well for 1 h at RT. Then, after 
washing steps 100 µl/well goat-anti human F(ab’)2 x POD antibody was added and plate was washed again. 
The peroxidase was detected by addition of 100 µl 1 step Ultra TMB ELISA substrate solution and the reaction 
was stopped with 100 µl 2 N sulfuric acid. Absorbance was measured at 450 nm using the BioTek Synergy4 
reader and respective software. The initial concentration time point at the beginning served for each antibody 
as 100% control and based on this, reduction in protein functionality was determined. In addition to total 
antibody concentration, free payload analysis of serum samples was measured with LC-MS. 
 
4.2.12. Sortase-mediated toxin conjugation 
Several conjugation technologies are established for site-specific conjugation of antibodies with linker payloads. 
Sortase-mediated antibody conjugation technology was performed with triple-glycine modified linker payloads 
to tagged light chains of the antibody or antibody fragment, resulting in a homogeneous and site-specific 
product. Triple-glycine modified linker payloads and sortase A were kindly provided by Merck KGaA. 
Antibodies were diluted to a concentration of 5 mg/ml in sortase conjugation buffer (150 mM NaCl, 50 mM 
Tris-HCl, pH 7.5). Briefly, tagged antibodies carrying a sortase recognition motif LPETGS with a (Gly4-Ser3)-
spacer C-terminally on light chains were generated and purified by affinity chromatography. Afterwards, the 
reaction was carried out by using one equivalent of antibody construct and incubated with 10 equivalents of 
Gly3-ValCit-PABC-MMAE substrate per sortase conjugation site, in the presence of 5 µM (0.37 eq) sortase and 
5 mM CaCl2 for 90 min at 25°C. Other used linker-payloads comprised Gly3-ValCit-PABC-MMAF, as well as 
Gly3-C5-Alexa Fluor 488. The reaction was stopped by addition of 10 mM EDTA as calcium ion chelator, 
removing calcium ions and the resulting ADC reaction mix was purified by SEC with HiLoad Superdex 200 pg 
increase as described before. Purified ADC was concentrated with Amicon® Ultra-15 centrifugal filter device 
with 10,000 MWCO (3000 xg, 15 min) and analyzed by HIC and ESI-MS. 
 
4.2.13. Transglutaminase conjugation 
For conjugation of N297A mutated, deglycosylated antibodies, transglutaminase conjugation was achieved for 
site-specific modification of Q295. For this purpose, antibodies were diluted at 5 mg/ml in transglutaminase 
conjugation buffer (150 mM NaCl, 25 mM Tris-HCl, pH 8.0) and antibody-fluorophore conjugates were 
generated by attaching the quencher Gly3-C3-BHQ-10 to Q295 of the antibody. In this case, as described above, 
sortase conjugation was used to attach the fluorophore Gly3-C5-Alexa Fluor 488 to the light chain. To the 
antibody solution 10 equivalents linker quencher per transglutaminase site were added and incubated with 
transglutaminase (75 U/ml) at 37°C for 16 h. After incubation the reaction was cooled down to 10°C and 
resulting conjugates were purified by SEC as described before. 
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4.2.14. Intact mass analysis 
ESI-MS analysis was performed using a Dionex U3000 HPLC system coupled to a Synapt-G2 mass 
spectrometer. 10 µg of protein solution was applied on a Proteomix RP-1000 4.6 mm x 100 mm (Sepax) column 
with mobile phase water/0.1% formic acid (0.5 ml/min). Detection at 214 nm was achieved for protein fragments 
and identification was done by the online coupled mass spectrometer.  
 
4.3. Cell biological methods 
4.3.1. Thawing of mammalian cells 
Cells provided as cryovials at -180 °C were thawed rapidly in a water bath at 37 °C until the ice was dissolved. 
Resuspension of cells with 10 ml of pre-warmed medium was achieved and transferred into a 50 ml falcon tube. 
Cells were centrifuged for 10 min, 250 xg at RT. The supernatant was removed and the pellet was resuspended 
in 10 ml cell culture medium and seeded in a cell culture flask, incubating 3-4 days at 37°C, 5% CO2, 180 rpm . 
 
4.3.2. Cultivation of mammalian cells 
Mammalian cell lines were cultured in cell culture flasks of appropriate sizes (T25-T175 for adherent cells or 
alternatively Erlenmeyer flask) using the recommended media formulations in an incubator with sterile 
conditions at 37°C, 5% CO2 under humidified atmosphere. Cells were passaged usually every 3-4 days and cells 
were certified mycoplasma-free and never exceeded passage 20. Adherent cells were detached by 0,05% trypsin-
EDTA (1 ml) or accutase for 3-5 min at 37°C after washing with pre-warmed DPBS to remove residual serum 
components. Trypsin activity was stopped by addition of FCS-containing medium and cell number as well as 
viability of detached adherent cells or suspension cells were measured by Vi-CELL® XR device by calculating 
the average of 20 images of trypan blue treated cells. Depending on cell growth and density, a sufficient amount 
of cells was re-seeded in a new cell culture flask with fresh medium. For further experiments, cells with a viability 
> 95% were pelleted (250 xg, 10 min, RT), supernatants were discarded and cells were diluted in pre-warmed 
medium yielding appropriate cell numbers (dependent on cell line). 
 
4.3.3. Transfection of mammalian cells and antibody expression 
Antibody expression was performed through transient transfection of antibody chains in Expi293FTM cells using 
the corresponding ExpiFectamineTM 293 transfection kit and media according to the manufacturer’s instruction. 
Briefly, Expi293FTM cells were cultivated in 200 ml in Erlenmeyer flasks at 37°C, 5% CO2 and 90 rpm orbital 
shaking. For passaging, cells were counted and diluted with fresh medium resulting in final cell number of 
0.5 x 106 viable cells per ml. Two days before expression, Expi293F cells were diluted to a concentration of 
1.3 x 106 viable cells per ml. On the day of transfection, cells with a viability > 96% were seeded with a final 
density of 2.9 x 106 viable cells per ml in pre-warmed Expi293™ Expression Medium. 
For small scale expression (25 ml), 25 µg plasmid DNA (plasmid ratio: 1:1 HC:LC for mAbs and Fab fragments 
or 3:3:1 AG:LC:GA for one-armed SEED molecules) and 67.5 µl ExpiFectamineTM293 Reagent were 
preincubated each in 1.25 ml OptiMEM® Reduced Serum Medium and subsequently mixed and incubated for 
5 min. Afterwards, the diluted DNA solution was added to the ExpiFectamine™ 293 Reagent solution. After 
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20-30 min incubation, the DNA-transfection mix was added to 22 ml cells. 16-18 h post transfection, 150 µl of 
Enhancer 1 and 1.5 ml of Enhancer 2 were added. Supernatants were harvested 120 h post transfection by 
centrifugation (3500 xg, 15 min) and supernatants were clarified by sterile filtration through 0.22 µm Steriflip 
devices. For mid scale expression, the transfection volume was adjusted to 200 ml and the transfection mix was 
scaled up proportionately adjusting the amounts of the reagents used to 200 µg DNA and 540 µl 
ExpiFectamineTM293. The overall procedure was analog to the description above. Supernatants were harvested 
by centrifugation (3500 xg, 15 min) and sterile filtration using Stericup devices. 
 
4.3.4. Flow cytometry binding analysis 
Flow cytometric analysis for antibody cellular binding to HER2-positive and EGFR-positive cell lines was 
carried out with a Guava easyCyte HT cytometer using corresponding software Guava ExpressPro. FACS 
binding buffer 1x PBS-1% BSA was prepared freshly and stored at 2-8°C. All washing and sample incubation 
steps were performed in FACS binding buffer. All incubation steps were performed darkened on ice during the 
whole experiment. Adherent cell lines were detached with trypsin-EDTA and cells were counted with the Vi-
CELL®. Cells were centrifuged at 250 xg, 4°C for 10 min. The volume used for incubation and washing steps 
was 100 µl/well, final volume for flow cytometry measurement was 200 µl/well. Antibody binding to cellular 
targets by flow cytometry analysis was achieved by seeding 1x105 vc/100 µl in a 96 microtiter plate and incubate 
with dilution of respective antibody and antibody fragments for 1 h (10 µg/ml). After washing with FACS 
binding buffer (3 times), antibody binding through incubation with polyclonal detection antibody goat anti-
human IgG (H+L) Fab Fragment, Alexa Fluor® 488 was carried out at 20 µg/ml, 100 µl/well and incubated for 
1 h. Fixation of the cells was achieved with 4% formaldehyde solution for 20 min (100 µl/well). Finally, 
microtiterplate was transferred to Guava easyCyte HT cytometer and 5,000 counts/well were measured per 
sample. Overlays of respective antibodies, positive and negative controls were compared on several cancer cell 
lines, indicating binding to the target. 
 
4.3.5. Cellular internalization assay 
Evaluation of internalization of antibody and antibody fragments was determined by flow cytometry using a 
quenching anti-Alexa Fluor® 488 Rabbit IgG Antibody to quench the fluorescence outside of the cell and to 
detect the amount of antibody that was internalized in the cell. The internalization assay has the same 
preparation and procedure as flow cytometry binding assay with additional internalization and quenching steps. 
For this approach, 1x105 vc/well were incubated for 1 h with 10 µg/ml of analyte followed by detection with 
polyclonal antibody goat anti-human IgG (H+L) Fab Fragment, Alexa Fluor® 488 (20 µg/ml, 100 µl/well, 1 h.). 
After washing steps, cells were incubated at either 37°C, 5% CO2 for the internalization step or at 4°C as a 
control preventing internalization for 1 h and 48 h. Afterwards, residual surface binding of analyte was quenched 
by anti-Alexa Fluor® 488 Rabbit IgG Antibody. Control samples were not quenched. Finally, fixation of cells 
with 4% formaldehyde solution was performed and subjected to Guava easyCyte HT cytometer. The relative 
internalization rate was quantified from the x-geometric mean fluorescence based on the following equation: 
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𝑟𝑒𝑙. 𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛 [%] =
(𝑀𝐹𝐼 37°𝐶 𝑞𝑢𝑒𝑛𝑐ℎ𝑒𝑑) − (𝑀𝐹𝐼 4°𝐶 𝑞𝑢𝑒𝑛𝑐ℎ𝑒𝑑)
(𝑀𝐹𝐼 37°𝐶 𝑢𝑛𝑞𝑢𝑒𝑛𝑐ℎ𝑒𝑑)
∗ 100 
 
4.3.6. Preparation of cell lysates 
For cell lysis of cultured mammalian cells, RIPA buffer was used to facilitate protein extraction from 
cytoplasmic, membrane and nuclear proteins and subsequently screen cells for western blotting. Culture 
medium was removed and cells were washed with ice-cold 1x PBS pH 7.4. Cells were lysed with 1 ml of RIPA 
buffer supplemented with Phosphatase Inhibitor Cocktail Set II (1:100), Protease Inhibitor Cocktail Set III 
(1:100), Benzonase (1:1000) and MgCl2. The solution was added to a T75 flask and incubated on ice for 5 min. 
After incubation, lysate was collected and centrifuged in a tube at 14.000 xg for 15 min to pellet cell debris. 
Supernatant was transferred to a new tube for further analysis comprising Bradford assay, SDS-PAGE and 
Western Blot. 
 
4.3.7. Cell Cytotoxicity Assay or Cell Viability Assay 
Evaluation of the cytotoxic effect of ADCs on the viability of cancer cell lines was quantified using the ATP-
based CellTiter-Glo® Luminescent Cell Viability Assay according to the manufacturer’s instructions. ATP 
present in cell culture represents the metabolically active cells. In brief, cells were detached as described before 
and seeded (40 µl/well) in an opaque cell culture 384 well microplate to let cells settle down for 24 h at 37°C, 
5% CO2. Cells were seeded (only listed for HER2 cell lines) at the following densities: SKBR-3 (6000 vc/well), 
HCC1954 (3000 vc/well), MDA-MB-468 (2500 vc/well), BT-474 (7000 vc/well), NCI-N87 (2000 vc/well), 
SKOV-3 (2000 vc/well). ADCs as well as proteins were diluted at 1 µM in PBS/0.3% Tween®20 and small 
molecule compounds at 40 µM in DMSO. All samples were added in serial dilution by using Tecan D300e 
Digital Dispenser. ADC treatment (starting concentration 100 nM) was performed in duplicates in cell line 
specific medium. After 72 h incubation, viability of cells was detected by adding 30 µl/well of CellTiter-Glo® 
reagent with subsequent plate shaking for 2 min at 350 rpm and followed by 10 min incubation in the dark at 
RT. The luminescence was measured with Envision 2104 plate reader and data was processed using Genedata 
Screener. Luminescence values were normalized to values of untreated cells. Data were plotted as percentage of 
untreated cell viability versus the logarithm of antibody concentration and fitted using GraphPad Prism 7. At 
least three independent experiments with duplicates were used to calculate mean IC50 ± standard deviation (s.d.). 
 
4.3.8. Tumor spheroid distribution/penetration 
Tumor spheroids were grown for tumor penetration analysis by antibodies and antibody fragments in a 3D 
model. Before spheroid formation, cell culture medium was sterile filtered and cell line development was 
performed with cancer cell lines by seeding cells (40 µl/well) at different cell densities in 384 well spheroid 
microplates (Corning). After seeding cells, the plate is centrifuged twice at 1000 xg for 4 min, turning the plate 
180 ° after first centrifugation step to make sure cells are centered in the middle of the well. The plate was 
incubated for at least 48 h at 37°C, 5% CO2. After incubation, 3D spheroid formation was checked with the 
IncuCyte® S3 Live-Cell Analysis System using the spheroid scan type. Spheroid treatment was carried out with 
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6.25 nM of antibody-fluorophore conjugate and imaging of tumor spheroid penetration was carried out with the 
IncuCyte device over time using green fluorescence detection. 
 
4.4. Biophysical methods 
4.4.1. Biolayer interferometry (BLI) 
For kinetic characterization of biomolecular interactions of antibodies, biosensor experiments using biolayer 
interferometry (BLI) were performed on an Octet Red96 platform using Octet Data Acquisition and Analysis 
software. In BLI experiments, the increase in layer thickness on biosensors tips by association and dissociation 
of bound molecules is measured, creating a shift in the interference pattern at the detector. In brief, anti-human 
Fab-CH1 (FAB2G) biosensor tips were pre-equilibrated in DPBS for 10 min before measurement. 200 µl/well 
of antibody solution at 3 µg/ml in DPBS was added in black 96 well plates and measurement was carried out at 
25°C, 1000 rpm orbital sensor agitation. A baseline was established for the biosensors in DPBS for 60 sec and 
for the loading step, antibodies were immobilized on biosensor tips for 180 sec. Association and dissociation of 
the rherbb2-Fc analyte diluted in KB buffer was measured for 400 sec and 800 sec, respectively. Binding 
parameters were analyzed assuming a 1:1 Langmuir binding and model performing global curve fitting with 
Octet Data Analysis software. As negative controls, unrelated isotype control antibody anti-hen egg lysozyme 
(anti-HEL) and unrelated antigen CD40 Avi His were implemented to exclude unspecific binding effects. 
 
4.4.2. Nano Differential Scanning Fluorimetry (nanoDSF) 
Thermal unfolding analysis and thermal stability of antibodies was measured to determine the melting point 
and aggregation of proteins using Prometheus NT.PLEX nanoDSF according to the manufacturer’s instruction. 
With nanoDSF technology no fluorescence labeling is required and the system detects the intrinsic fluorescence 
of tyrosine and tryptophane residues at 330 nm and 350 nm under native conditions. In brief, in a 384 well plate 
15 µl of 1 mg/ml protein formulation (1x PBS pH 7.4) was dispensed, in order to fill up Standard Capillary 
Chips with at least 10 µl of protein sample. Before starting the measurement, an initial discovery scan is 
necessary to adjust the excitation power that detects the initial fluorescence in the capillaries. Protein unfolding 
characteristics were analyzed from 20-95°C with excitation power 11% and a temperature gradient 1.0°C/min 
by monitoring the change of intrinsic protein fluorescence. Data acquisition and analysis was processed with 
Software PR.Thermo Control (NanoTemper Technologies) and melting points were determined by measuring 
the maximum of the first derivative curve of F330nm/F350nm ratios. 
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5. Results 
 
5.1. Design and generation of cleavable antibodies and ADCs 
To investigate the specific hinge cleavage by tumor-associated proteases uPA and matriptase, a cleavable linker 
design was utilized to introduce an additional 8 amino acids protease site in the IgG1 hinge region of 
Trastuzumab and Cetuximab.199 The anti-HER2 antibody Trastuzumab and the anti-EGFR antibody 
Cetuximab were used as model antibodies because both molecules are well characterized in several studies and 
many development efforts in the field of ADCs are using these antibodies. Cleavable antibodies are denoted 
Trastuzumab CL (cleavable) and Cetuximab CL, containing the cleavable protease site LSGRSDNH in the hinge 
region, adjacent to the natural papain cleavage site (Figure 18).198 As negative controls Trastuzumab nCL 
(noncleavable) and Cetuximab nCL constructs were designed that replace the protease site by a GGSGGSGG 
linker. 
 
 
Figure 18: Design of cleavable protease site in hinge region of IgG antibody and Trastuzumab ADC variants. 
Depicted are the hinge amino acids with the upper, core and lower hinge region. Additional protease site that is sensitive to tumor 
proteases is highlighted in green (A). Cleavage sites for natural occuring proteases are indicated with numbers below amino acid sequence 
and responsible amino acids for FcR binding are highlighted in red. ADC variants (B) with Trastuzumab CL (with cleavable hinge 
region), Trastuzumab nCL (noncleavable hinge), Trastuzumab natural (native antibody), Trastuzumab Fab fragment and Trastuzumab 
oa SEED. Payloads are attached to the light chains via sortase-mediated antibody conjugation technology. Figure is modified from 
Brezski et al.199 CL = cleavable, nCL = noncleavable, oa = one-armed 
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For comparison of key antibody characteristics, different antibody formats were generated and included in 
further experiments. In the present study, in addition to the constructs Trasutuzmab CL, Trastuzumab nCL, 
also Trastuzumab natural (native antibody), Trastuzumab Fab fragment and Trastuzumab oa (one-armed) 
SEED were used as references (Figure 18). By analogy, Cetuximab variants and also Trastuzumab N297A 
mutated antibodies were utilized with the same design. All constructs carry the sortase A recognition tag 
LPETGS C-terminally on the light chain that is used for site-specific conjugation of cytotoxic drugs and only 
the Trastuzumab Fab fragment is lacking the Fc-part. Generally, two routes enable Fab fragment production 
and purification, namely papain digestion of an IgG antibody and transient mammalian expression. For papain 
digestion protein A affinity chromatography can be used, whereas for his-tagged Fab fragments IMAC is 
utilized.200 Due to insufficient yields with papain digestion of Trastuzumab (data not shown), expression of 
Trastuzumab Fab was preferred. The different antibody variants were produced by transient expression in 
Expi293 cells, purified by protein A affinity chromatography and analyzed by SDS-PAGE as well as analytical 
SEC (Appendix 1, 2 and 7). Trastuzumab Fab and Trastuzumab oa SEED were purified using IMAC and anti-
penta His Western Blot confirmed present His-Tag (Appendix 3 and 4). Besides the Trastuzumab variants, 
Cetuximab-based antibodies and Trastuzumab N297A mutated constructs were also expressed in Expi293 cells 
and purified (Appendix 5 and 6). The expression yields as well as protein purity by analytical SEC of the 
generated antibodies are summarized in Table 4. 
 
Table 4: Expression yields of different antibody constructs and purity as monomeric protein. 
Purified antibody yields after transient expression in Expi293 cells using protein A affinity chromatography for mAbs or IMAC for 
antibody fragments. Yields are calculated as mg/200ml or mg/l. Protein purity was determined by analytical SEC and is indicated as 
percentage [%] monomeric product. CL = cleavable, nCL = noncleavable, oa = one-armed 
 
Antibody construct Yield [mg/200 ml] Yield [mg/l] Purity after SEC [%] 
Trastuzumab CL 26.9 134.5 97.9 
Trastuzumab nCL 37.6 188.0 93.7 
Trastuzumab natural 34.0 170.0 100.0 
Trastuzumab Fab 32.8 164.0 100.0 
Trastuzumab oa SEED 25.1 125.5 100.0 
Trastuzumab CL N297A 19.9 99.5 100.0 
Trastuzumab nCL N297A 39.5 197.5 97.2 
Trastuzumab natural N297A 33.1 165.5 97.4 
Trastuzumab oa SEED N297A 16.4 82.0 95.8 
Cetuximab CL 20.5 102.5 97.2 
Cetuximab nCL 19.8 99.0 99.8 
Cetuximab natural 18.9 94.5 99.6 
Cetuximab Fab 6.6 33.0 98.5 
Cetuximab oa SEED 5.2 26.0 87.4 
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Separate sterilcontrols of used plasmids were prepared by adding plasmid DNA in Expi293 expression medium 
alone and incubating at 37°C, 5% CO2. Expression yields of Trastuzumab variants ranged from 82 to 197 mg/l 
after purification, whereas for Cetuximab antibodies values from 26 to 102 mg/l were achieved. Generally, 
expression of Cetuximab constructs showed lower yields compared to Trastuzumab. Especially, monovalent 
Cetuximab Fab and Cetuximab oa SEED showed low protein amounts after purification. Highest yields were 
obtained for the Trastuzumab nCL and Trastuzumab natural constructs (also deglycosylated N297A variants), 
but also Trastuzumab CL showed good expression values. Regarding protein purity, almost all constructs were 
monomeric and showed purity > 95%, indicating that no high molecular weight species like protein aggregates 
are present. This is of particular importance for cell based assays because aggregates lead to unexpected results 
and bias.  
 
5.1.1. Preparation of ADCs 
As an initial experiment, the protease cleavage of the designed Trastuzumab CL was assessed by tumor 
proteases uPA and matriptase, to determine the selective cleavage site within the hinge region. On the 
assumption that the cleavable sequence is still accessible buried in the hinge region, Trastuzumab CL was 
incubated with and without uPA and matriptase for 24 h and 37°C, and also with negative controls. As it is 
obvious, that only the Fab and Fc band occurred for unconjugated Trastuzumab CL with tumor proteases, 
specific enzymatic cleavage occurred and the accessibility to the cleavage site was demonstrated (Appendix 8). 
Based on the first results, unconjugated antibodies were proceeded to ADC conjugation. The general ADC 
design is depicted in Figure 18 B, and is structural illustrated for MMAE-based constructs in Figure 19. 
 
Figure 19: General ADC structure with MMAE as payload. 
Illustration shows generic structural composition of generated ADCs (Antibody-Gly3-ValCit-PABC-MMAE). Site-specific conjugation 
was achieved by sortase A mediated antibody conjugation technology by attaching triple-glycine drug-linker to sortase A recognition 
motif LPETGS C-terminally to light chain of the antibody. The drug-linker consists beside the triple-glycine of valine-citrulline, PABC 
and MMAE as the cytotoxic compound. 
 
ADCs were generated based on the anti-HER2 antibody Trastuzumab and anti-EGFR antibody Cetuximab. In 
general, in the course of this work, an ADC is denoted by describing the mAb and the conjugated payload as 
mAb x payload (e.g. Trastuzumab CL x MMAE). Payloads that were used for toxin-based ADCs were mainly 
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microtubule inhibiting agents like MMAE and MMAF. The basic structure of the linker drugs comprised a 
valine-citrulline dipeptide motif that is cleaved within the lysosomes by cathepsin B. The dipeptide linker is 
connected to a self immolative PABC portion that is fragmented upon cleavage and releases efficiently the 
payload. The triple-glycine motif is utilized for sortase conjugation and is attached to the LPETGS recognition 
motif on the antibody. An overview of the generated ADCs and monovalent FDCs (Fragment-drug conjugates) 
used in this work is given in Table 5. 
 
Table 5: Overview of ADCs and monovalent FDCs conjugated by sortase A technology. 
Generated ADCs and FDCs (Fragment-drug conjugates) with respective DAR after conjugation reaction using sortase A. Listed are the 
ADC constructs with the used payloads and the linker structure. Protein purity was determined by analytical SEC and is indicated as 
percentage [%] monomeric product. AF488 = Alexa Fluor 488, BHQ-10 = Black Hole Quencher-10, CL = cleavable, nCL = 
noncleavable, oa = one-armed, Gly3-ValCit-PABC = triple-glycine valine-citrulline para-aminobenzyloxycarbonyl, N297A = mutation 
of asparagine (N) to alanine (A) at position 297 
 
ADC construct Payload Linker DAR Purity after SEC [%] 
Trastuzumab CL x MMAE MMAE Gly3-ValCit-PABC 1.9 98.6 
Trastuzumab nCL x MMAE MMAE Gly3-ValCit-PABC 1.8 99.2 
Trastuzumab natural x MMAE MMAE Gly3-ValCit-PABC 1.8 99.1 
Trastuzumab Fab His x MMAE MMAE Gly3-ValCit-PABC 0.9 99.1 
Trastuzumab oa SEED x MMAE MMAE Gly3-ValCit-PABC 0.8 99.0 
Trastuzumab CL x MMAF MMAF Gly3-ValCit-PABC 1.7 99.5 
Trastuzumab nCL x MMAF MMAF Gly3-ValCit-PABC 1.8 99.3 
Trastuzumab natural x MMAF MMAF Gly3-ValCit-PABC 1.9 100.0 
Trastuzumab Fab His x MMAF MMAF Gly3-ValCit-PABC 0.7 88.9 
Trastuzumab oa SEED x MMAF MMAF Gly3-ValCit-PABC 0.8 98.8 
Trastuzumab CL N297A x AF488 x BHQ-10 AF488 Gly3-C5, Gly3-C3 3.3 100.0 
Trastuzumab nCL N297A x AF488 AF488 Gly3-C5 1.6 97.1 
Trastuzumab natural N297A x AF488 AF488 Gly3-C5 1.6 96.3 
Trastuzumab Fab His x AF488 AF488 Gly3-C5 0.8 98.8 
Cetuximab CL x MMAE MMAE Gly3-ValCit-PABC 1.1 99.4 
Cetuximab nCL x MMAE MMAE Gly3-ValCit-PABC 1.3 99.4 
Cetuximab natural x MMAE MMAE Gly3-ValCit-PABC 1.1 99.5 
Cetuximab Fab His x MMAE MMAE Gly3-ValCit-PABC 0.8 99.5 
Cetuximab oa SEED x MMAE MMAE Gly3-ValCit-PABC 0.8 99.4 
 
Conjugation of antibody constructs with (G4S)3-LPETGS tag C-terminally on the light chain was performed 
using sortase A technology. After conjugation reaction, the purified ADC formulated in PBS pH 7.4 was 
analyzed by analytical SEC and HIC as well as ESI-MS to evaluate conjugation reactions. The Drug-to-antibody 
ratio (DAR) of ADCs is used to describe how many molecules are conjugated to the antibody. As Fab fragments 
and one-armed (oa) SEED molecules have only one light chain, also only one conjugation site is available, 
reaching at most a DAR of 1. The DAR of Fab fragments and oa SEEDs ranged from 0.7 to 0.9. For the other 
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formats, conventional IgGs were used that have two intact light chains present each with a sortase A tag. 
Therefore a possible DAR of 2 can be reached. The Trastuzumab IgG variants yielded DAR species from 1.6 to 
1.9. Cetuximab ADCs exhibited a poor conjugation efficiency, reaching a DAR of approximately 1.1 to 1.3. 
Therefore, the conjugation reaction with Cetuximab ADCs was incomplete. Regarding protein purity, almost 
all constructs exhibited a monomeric content of > 95%. Successful conjugation was confirmed by ESI-MS and 
HIC indicating attached toxin to the light chains (Appendix 9). The general structure of MMAF-based ADCs 
is displayed in Appendix 10 and SEC chromatograms are depicted in Appendix 11. In the following, 
investigations regarding the protease cleavage of the hinge region, the exact cleavage site and the selectivity of 
the protease site were pursued. 
 
5.1.2. Characterization of hinge cleavable ADCs and determination of cleavage site 
In the context of ADC generation, it was tested if tumor proteases uPA and matriptase are still able to cleave 
the modified hinge region, when a drug-linker is attached to the antibody. For this purpose, Trastuzumab CL x 
MMAE, Trastuzumab nCL x MMAE and Trastuzumab natural x MMAE were incubated with catalytic 
amounts of uPA, tPA and matriptase at 37°C for 24 h. The same ADC samples were also incubated without 
respective enzymes. Semi-quantitative evaluation was carried out with SDS-PAGE analysis and demonstrated 
specific protease cleavage within the hinge region. Only Trastuzumab CL x MMAE incubated with uPA showed 
a Fab band at approximately 50 kDa as well as a Fc band at 53 kDa, whereas incubation of the ADC sample with 
matriptase exhibited a much faster and quantitative reaction compared to the sample with uPA because no intact 
ADC band is observed at 150 kDa (Figure 20). Trastuzuman nCL x MMAE and Trastuzumab natural x MMAE 
were unaffected by enzyme activity. 
 
 
Figure 20: SDS-PAGE analysis of Trastuzumab x MMAE ADCs incubated with tumor proteases uPA and matriptase. 
Protease cleavage of ADC variants with MMAE by uPA (A) and matriptase (MT-SP1) (B). Incubation of tPA, a homologous enzyme to 
uPA was also tested. Samples Tmab CL x MMAE, Tmab nCL x MMAE and Tmab natural x MMAE were incubated with (+) or without 
(-) enzyme at 37°C for 24 h and were non-reduced. After SDS-PAGE run, InstantBlue stain was performed at least for 30 min. Tmab = 
Trastuzumab, + = with enzyme, - = without enzyme 
 
Hence, specific hinge cleavage of Trastuzumab CL x MMAE by extracellular tumor proteases corroborated that 
smaller fragment-drug conjugates were released. Incubation with tPA, a homologous enzyme to uPA, displayed 
a slightly, unspecific cleavage of Trastuzumab CL x MMAE that is only observed to a minor extent. To 
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determine whether protease cleavage could be transferred to different antibodies as well as other linker-payload 
structures, Trastuzumab x MMAF ADCs, deglycosylated Trastuzumab x AF488 conjugates and Cetuximab x 
MMAE ADCs were tested. As observed with Trastuzumab x MMAE constructs, the same pattern for other 
cleavable antibodies based on Cetuximab or N297A mutated Trastuzumab variants was obtained as well as for 
different linker-payloads (Appendix 12). Therefore, independent of the antibody as well as for various linker-
payloads, no sterical hindrance is assumed for the protease site. For evaluation whether the selectivity of the 
linker cleavage is solely related to uPA and matriptase, a broader panel of proteases including proteases not 
restricted to the tumor microenvironment (like MMPs) were tested for enzymatic cleavage. These proteases 
comprised prominent matrix metalloproteinases MMP-9, MMP-14, but also ADAM-10, Legumain and 
Kallikrein. These experiments indicated that none of the proteases was capable to cleave the protease site 
LSGRSDNH in Trastuzumab CL x MMAE, therefore suggesting a high selectivity for this sequence. In order 
to verify the observed bands from the cleavage reactions and to determine the exact cleavage site within the 
hinge region, ESI-MS analysis was utilized. Analysis of cleavage site was carried out with intact protein analysis 
by using non-reduced samples. As with the SDS-PAGE samples, Trastuzumab CL x MMAE and Trastuzumab 
CL x MMAF were incubated with uPA or matriptase at 37°C for 24 h and mass fragments were determined. 
For the cleavable ADC the most important fragments are the FDC and Fc fragments, because this will give 
valuable information about the exact cleavage site within the engineered hinge region. As the MS spectra 
illustrate, the selective cleavage site of the proteases is between arginine and serine within the 8 amino acid 
sequence (Figure 21). The expected mass from the FDC and Fc part match perfectly with the observed mass 
that was measured by ESI-MS. The released FDC of Trastuzumab CL x MMAE was found to have a mass of 
50.91 kDa whereas the Fc part shows a mass of 53.64 kDa. The higher molecular weight of the Fc portion can 
be attributed to the N-glycosylation that is represented by N-glycan type G0F, which accounts for 1445.3 Da 
and consists of a core structure with 4 N-acetylglucosamine (2 terminal), 3 mannose and 1 fucose residue. 
Moreover, another crucial information extracted from ESI-MS analysis is that the Fab fragment is still intact 
and the linker-drug is attached to it. Therefore, the tumor proteases have no impact on the linker-drug structure. 
Besides tested MMAE-based constructs, Trastuzumab CL x MMAF as well as Cetuximab CL x MMAE were 
analyzed by ESI-MS for protease cleavage and obtained results indicate that in accordance with Trastuzumab 
CL x MMAE, expected mass of fragments could be verified (Appendix 13, 14 and 15). In the case of Cetuximab-
based ADCs, different glycoform species are present that comprise various sugar derivatives and thus make this 
ADC a more heterogeneous product. To summarize the cleavage experiments, it was proved that the 
modification of the hinge region including a protease site can be successfully used to generate a FDC originating 
from an ADC upon incubation with tumor proteases. This FDC should be capable to deliver the cytotoxic 
compound and induce a pronounced cytotoxic activity as the payload is conjugated to the fragment. 
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Figure 21: Mass confirmation of FDC and verification of uPA/MT-SP1 cleavage site by ESI-MS. 
MS spectra of Trastuzumab CL x MMAE that was incubated with MT-SP1 (A) and uPA (B) and cleaved fragments were analyzed by 
ESI-MS. In accordance with the expected mass, hinge cleavage releases FDC fragment that correlates with observed mass. 
 
As it was observed by SDS-PAGE analysis that the two tumor proteases seem to have different cleavage rates, 
enzyme kinetic studies will be achieved. In the following chapter, experiments regarding the fast cleavage 
reaction by the two tumor proteases will be investigated. 
 
5.1.3. Enzyme kinetics and release of FDC 
For quantification of released FDCs over time, Trastuzumab CL x MMAE was incubated with uPA and 
matriptase at 37°C for 24 h and samples were taken at different time points. Prior to analysis, experiments with 
enzyme inhibitors revealed that enzyme activity is abrogated by addition of Ecotin, HAI-1 and 1,5-
Dansyl-Glu-Gly-Arg Chloromethyl Ketone. As the reaction was stopped most efficiently with the irreversible 
inhibitor 1,5-Dansyl-Glu-Gly-Arg Chloromethyl Ketone (Appendix 16), this small molecule was used at 10 µM 
to stop the reaction of uPA and matriptase at 10 different time points and samples were analyzed by RP-HPLC 
(Appendix 17). Assignment of fragment peaks was achieved in a previous run by RP coupled to MS, where the 
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first peak was attributed to the Fc part, the second unconjugated Fab and the third peak was the FDC carrying 
the payload (Appendix 16). After cleavage reaction with uPA and matriptase the resulting DAR was determined 
and was 0.8, hence indicating intact FDC with payload. Besides Trastuzumab CL x MMAE cleavage, this peak 
pattern was also obtained by Trastuzumab CL x MMAF with tumor proteases (data not shown). 
Enzyme kinetic studies exhibited a high conversion of the cleavable substrate Trastuzumab CL x MMAE. uPA 
showed a slower cleavage reaction compared to matriptase, because the catalytic reaction of uPA reaches its 
plateau at approximately 4 h after incubation, whereas matriptase converts all substrate completely after 1 h 
(Figure 22). 
 
Figure 22: Enzyme kinetics of uPA and matriptase incubated with Trastuzumab CL x MMAE. 
Enzyme kinetic studies of uPA (A) and matriptase (MT-SP1) (B) exhibited high conversion of substrate Trastuzumab CL x MMAE. 
Quantification of cleaved fragments was achieved by using RP-HPLC with respective peak assignment. Plotted are the percentage [%] 
of initial concentration of different species against the time points. Curves are depicted of Trastuzumab CL x MMAE (red), Trastuzumab 
CL x MMAE with DAR 1 (brown), Fc part (green) and FDC (blue). Each time point was measured in duplicates. For simplicity reasons, 
the 24 h time point was excluded. Tmab = Trastuzumab 
 
In both cases, the reactions show a proportional decrease of substrate as well as an increase of respective 
products that was also confirmed by SDS-PAGE analysis (Appendix 18). For the uPA reaction after 24 h, 2.4% 
of the Trastuzumab CL x MMAE construct and 1.3% for Trastuzumab CL x MMAE (1 toxin) are remaining, 
whereas 31.6% of the Fc part and 53.5% of the FDC are released. Matriptase conversion resulted in 1.9% 
remaining Trastuzumab CL x MMAE and 0.8% Trastuzumab CL x MMAE (1 toxin) after 24 h. Released Fc 
portion accounts for 38.3% and 53.2% FDC is released. 
Consequently, the high turnover rate of the catalytic reactions indicate that the sequence of the protease site in 
the hinge region is well suited for a fast and efficient release of FDCs. To investigate whether the modified hinge 
region affects antibody binding and internalization properties, molecular interactions with the target as well as 
cellular binding and internalization of the antibodies are tested. 
 
5.2. Characterization of antibody binding affinity and internalization 
To assess the influence of the engineered hinge region on antibody function and binding, kinetic parameters of 
conventional IgG antibodies and antibody fragments were evaluated by biolayer interferometry (BLI). For this 
biophysical method, antibodies were immobilized on anti-human Fab-CH1 (FAB2G) biosensor tips and 
association and dissociation of the antigen HER2 is analyzed. Kinetic parameters of unconjugated antibodies 
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and antibody fragments are summarized in Table 6 and association and dissociation graphs are exemplarily 
shown in Figure 23. BLI experiments showed that no significant alteration in functional binding of modified 
antibodies to the antigen is observed and monovalent fragments maintained nanomolar affinity values in the 
same range like IgG antibodies. The commercial product Herceptin was included for the experiments as the 
benchmark molecule and had an affinity of 0.51 nM, likewise for the Trastuzumab CL construct a binding 
affinity to recombinant HER2 was in the subnanomolar range with 0.46 nM. Trastuzumab nCL exhibited KD 
values of 0.70 nM. For Trastuzumab Fab His, a binding affinity of 0.27 nM was determined and for Trastuzumab 
natural the affinity was 0.06 nM. 
 
Table 6: Overview of kinetic parameters for engineered antibodies and monovalent fragments determined by BLI. 
Affinities are shown as equilibrium dissociation constant (KD), association (ka) and dissociation rates (kd) were measured by BLI. 
Antibodies were immobilized on FAB2G biosensor tips followed by association and dissociation of the antigen HER2. For each 
measurement, six analyte concentrations were measured ranging from 1.56 nM to 50 nM. Trastuzumab CL, Trastuzumab nCL, 
Trastuzumab natural and commercial Herceptin are bivalent IgGs and Trastuzumab Fab His represents a monovalent binder. 
 
Antibody construct Analyte KD [M] ka [M-1s-1] kd [s-1] 
Herceptin HER2 5,13E-10 1,35E+05 6,94E-05 
Trastuzumab CL HER2 4,63E-10 1,24E+05 5,74E-05 
Trastuzumab nCL HER2 7,01E-10 1,38E+05 9,64E-05 
Trastuzumab natural HER2 5,60E-11 1,38E+05 7,70E-06 
Trastuzumab Fab His HER2 2,70E-10 1,39E+05 3,76E-05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Comparison of affinity and kinetic analysis of produced antibodies and antibody fragments determined by BLI. 
Bivalent Trastuzumab CL (A), Trastuzumab nCL (B) and Trastuzumab natural (D) and monovalent Trastuzumab Fab His (C) were 
analyzed with anti-human Fab-CH1 (FAB2G) biosensors. For KD values the association and dissociation were monitored for 400 sec and 
800 sec, respectively. Interference pattern shift [nm] is monitored with varying concentrations of analyte over the time [sec]. 
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Anti-HEL antibody was used as an isotype control and CD40 Avi His as an unrelated antigen to test unspecific 
binding behavior (Appendix 19). In both cases, no binding was detected. Taken together, molecular interactions 
of antibodies to its cognate antigen was verified, exhibiting high affinity for all produced constructs and to test 
antibodies in a more appropriate setting, cellular binding was investigated. 
 
5.2.1. Flow cytometry binding analysis of antibodies and antibody fragments 
As antibodies and antibody fragments displayed suitable kinetic parameters with high affinities in the 
subnanomolar range to HER2, as a following step cellular binding to target expressing cells was determined. 
In a FACS binding assay, it was tested if the modified hinge region is affecting cellular binding of the antibodies. 
For this purpose, antibodies at a concentration of 10 µg/ml were incubated with cancer cell lines and detected 
by goat anti-human IgG (H+L) Fab Fragment, Alexa Fluor 488 conjugate. HER2-expressing cancer cell lines 
with different receptor expression levels were selected for FACS binding analysis. According to Li et al., for the 
HER2-negative cell line MDA-MB-468 no detectable HER2 level is achieved. Whereas for MCF-7, low HER2 
expression levels are known to be 3.646 relative HER2 density on a cell. SKBR-3 was used as a high expressing 
HER2-positive cell line that expresses 1.517.135 relative HER2 molecules on a cell.201 Different receptor 
expression of used cell lines was also confirmed in previous studies (personal communication, Merck, Darmstadt, 
Germany). 
 
 
Figure 24: Cellular binding of designed antibodies and antibody fragments to several cancer cell lines. 
Cells were seeded with 1 x 105 vc/well, incubated with antibodies at 10 µg/ml and detected with goat anti-human IgG (H+L) Fab 
Fragment, Alexa Fluor 488 conjugate via flow cytometry. Antibodies and antibody fragments displayed no binding to HER2-negative 
MDA-MB-468 cells for bivalent (A) and monovalent antibodies (D). On the low-expressing HER2 cell line MCF-7, binding of all 
antibodies is increased (B), whereas monovalent Trastuzumab Fab His shows a slightly weaker binding compared to IgG antibodies (E). 
For SKBR-3 cells a strong binding effect is obtained for conventional antibody format (C) and antibody fragments (F). In all cases, 
binding is comparable to commercial Herceptin. Measurement was carried out with Guava easyCyte HT cytometer using the green 
fluorescence channel. FSC (forward scatter) and SSC (side scatter) were adjusted, samples were measured in duplicates. 
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Also for flow cytometry, anti-HEL was utilized as isotype control and other controls comprised unstained cancer 
cells or cells incubated with goat anti-human IgG (H+L) Fab Fragment, Alexa Fluor® 488 conjugate. Overlay 
of histograms for relative fluorescence intensities of produced Trastuzumab-based antibodies are exemplarily 
shown in Figure 24. The results exhibited a slight binding of antibodies to low-expressed HER2 on MCF-7 
cells, whereas a strong cellular binding was observed on HER2-overexpressing cell line SKBR-3, indicated by 
the pronounced shift. As a reference antibody Herceptin was also tested and overlays of produced antibodies are 
identical with this control, suggesting similar binding properties on the cell surface. Trastuzumab Fab His 
shows a slightly weaker binding compared to IgG antibodies. Moreover, on HER2-negative cells MDA-MB-468 
no unspecific binding of IgG antibodies and antibody fragments was detected and also with the anti-HEL 
antibody no target-dependent binding to HER2-positive and HER2-negative cells was observed. 
For Cetuximab-based constructs (Appendix 20) and for deglycosylated Trastuzumab N297A mutated variants 
(data not shown) FACS binding results reveal also similar binding to benchmark antibody Erbitux or Herceptin, 
respectively. To summarize cellular binding experiments, binding properties are similar to commercial 
Herceptin or Erbitux on target positive and negative cells and antibodies with hinge modification exhibit similar 
binding to cancer cell lines. 
 
5.2.2. Cellular internalization assay 
As antibodies bind to cell surface targets on cancer cells, subsequent internalization should be sufficient and is 
a critical parameter particularly in the context of ADC delivery and trafficking. Therefore, investigations 
regarding internalization rates of the different antibody formats were carried out. Generally, upon binding to 
HER2, receptor mediated endocytosis is induced and vesicle formation from the cell surface is achieved. 
Afterwards, transport to endosomes proceeds at which point the receptor can be recycled back to the cell surface 
or alternatively, receptor is trafficked to lysosomes and degradation is achieved. For the cellular internalization 
assay, fluorescence of each internalized antibody was measured by flow cytometry after quenching with 
anti-Alexa Fluor® 488 Rabbit IgG Antibody cell surface bound Alexa Fluor 488-labeled antibodies. The 
percentage of internalization of antibodies and antibody fragments was calculated by the difference of quenched 
samples at 37°C and 4°C and normalized by unquenched samples as indicated by the equation in the Methods 
chapter. Percentage of internalization of the different formats were determined in time for 1 h and 48 h using 
flow-cytometric analysis in cell lines with different HER2 expression: MDA-MB-468 (negative), MCF-7 (low), 
and SKBR-3 (high). 
Internalization experiments displayed sufficient rates for all antibody formats after 48 h. Internalization results 
are consistent for the different antibody formats and are comparable with previous internalization experiments 
based on Herceptin (personal communication, Merck, Darmstadt Germany). After 1 h incubation, the 
internalization rates on MCF-7 cells range from 9 to 17 % for the constructs, whereas on SKBR-3 cells less 
internalization is observed with values from 0 to 5 % relative internalization. Apart from that, after 48 h on 
MCF-7 about 34 to 39 % of the antibodies are internalized and on SKBR-3 even 38 to 52 % are achieved. 
Furthermore, as a control no internalization was observed with HER2-negative MDA-MB-468 cells. 
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Figure 25: Comparison of relative internalization of produced antibodies and antibody fragments measured by flow cytometry. 
Cellular internalization assay using flow cytometry analysis was carried out by incubation of cancer cell lines MDA-MB-468, MCF-7 
and SKBR-3 with antibodies at 10 µg/ml. After incubation, secondary antibody goat anti-human IgG (H+L) Fab Fragment, Alexa Fluor 
488 was added and cells were either incubated for 1 h and 48 h at 37°C allowing internalization or at 4°C preventing internalization. Cell 
surface bound Alexa Fluor 488-labeled antibodies was quenched with an anti-Alexa Fluor® 488 Rabbit IgG Antibody. Percentage of 
internalization was calculated by comparing MFI of cells incubated at 37°C and those at 4°C. Tmab = Trastuzumab 
 
Table 7: Overview of internalization rates in percentage [%] after 1 h and 48 h incubation. 
Different antibody formats were analyzed for internalization rates by flow cytometry. Cancer cell lines MCF-7, SKBR-3 and MDA-
MB-468 (HER2-negative) were tested and MDA-MB-468 is not listed due to no internalization. 
 
  MCF-7 SKBR-3 
Antibody construct Target 1 h 48 h 1 h 48 h 
Herceptin HER2 17 39 5 52 
Trastuzumab CL HER2 9 36 1 45 
Trastuzumab nCL HER2 13 37 0 44 
Trastuzumab natural HER2 13 35 6 40 
Trastuzumab Fab His HER2 12 38 3 44 
Trastuzumab oa SEED HER2 15 34 0 38 
 
 
5.3. Antibody and ADC thermal stability analysis 
To analyze the influence of the modified cleavable hinge region in the IgG format, nano Differential Scanning 
Fluorimetry (nanoDSF) was performed. NanoDSF was used for thermal stability analysis and investigates 
parameters that contribute to forced degradation of therapeutic proteins and might indicate long-term stability 
during storage of biologics. For this purpose, unconjugated antibodies, deglycosylated antibodies and ADCs 
were tested. In the course of thermal denaturation of proteins, the change of intrinsic protein fluorescence 
(mainly based on tyrosine and tryptophane residues) is monitored and the melting point is determined. Raw 
data of the measurements are shown in Appendix 21. Melting temperature (Tm) of produced glycosylated 
antibodies ranged from 65.5°C to 71.2°C for the CH2 domain, whereas results for the Fab domain were 
consistent for all constructs ranging from 79.5 to 81.7°C (Figure 26). In contrast to that, deglycosylated N297A 
antibodies were thermally less stable with melting temperatures from 61.3 to 63.3°C for the CH2 domain, 
making them more susceptible to unfolding.  
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Figure 26: Thermal stability of Trastuzumab-based antibody variants and ADCs measured by nanoDSF. 
Melting temperatures (Tm) in °C of Trastuzumab glycosylated antibodies (A), ADCs (B) and deglycosylated antibodies (C) were 
measured with nanoDSF for thermal unfolding using 15 µl of protein solution per capillary. Values were calculated as means and samples 
were measured in duplicates. 
 
Values of deglycosylated antibodies are approximately 10°C lower compared to glycosylated IgGs and 60°C is 
considered as critical Tm for therapeutic antibodies. An overview of the melting temperatures of tested 
constructs is given in Table 8. 
In conclusion, thermal unfolding experiments exhibited no alteration of thermal stability of antibodies as well 
as ADCs due to modified hinge region. Antibodies with N297A mutation bearing no glycosylation show uniform 
results with melting temperature 10°C lower than conventional glycosylated antibodies Moreover, sortase 
toxin-conjugation has also no impact on biophysical properties of ADCs. 
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Table 8: Overview of melting temperatures (Tm) of antibodies and ADCs. 
Listed are melting temperature values of the CH2 domain (first derivate) and Fab domain of unconjugated and deglycosylated antibodies 
as well as ADCs. 
 
Antibody 
Tm [°C]  
(CH2 domain) 
Tm [°C]  
(Fab domain) 
Herceptin 71,2 81,7 
Trastuzumab CL 69,9 79,5 
Trastuzumab nCL 70,1 79,8 
Trastuzumab natural 69,7 79,5 
Trastuzumab oa SEED 67,2 79,5 
Trastuzumab Fab His - 80,7 
Trastuzumab CL x MMAE 69,0 79,9 
Trastuzumab nCL x MMAE 68,9 79,7 
Trastuzumab natural x MMAE 68,6 79,7 
Trastuzumab Fab His x MMAE - 80,2 
Trastuzumab oa SEED x MMAE 66,7 79,6 
Kadcyla 65,5 80,9 
Trastuzumab CL HC N297A 61,3 80,2 
Trastuzumab nCL HC N297A 61,1 80,3 
Trastuzumab natural HC N297A 61,4 80,4 
Trastuzumab oa SEED HC N297A RF 63,3 79,7 
 
As a next step, the stability of ADC constructs in mouse and human serum will be evaluated. 
 
5.3.1. In vitro mouse and human serum stability of ADCs 
Trastuzumab x MMAE constructs were incubated in mouse or human serum at 37°C, 5% CO2 for 96 h to 
evaluate stability in these matrices due to concerns regarding the stability of the hinge region. Thus, 
investigations of the ADC constructs in serum from species that are relevant for preclinical testing was achieved. 
Sampling time points were 0 h, 2 h, 4 h, 6 h, 24 h, 48 h, 72 h and 96 h. The concentration of ADCs used for 
incubation was 0.5 mg/ml. The stability of the total antibody was analyzed by ELISA by coating HER2 murine 
Fc-His and detection with goat-anti human F(ab’)2 x POD. 
As a reference value the first time point at 0 h was used and set as 100% at the beginning. Illustrated are the 
serum stability time curves of the different ADCs as percentage of concentration remaining (Figure 27). The 
concentration profiles of Trastuzumab CL x MMAE and Trastuzumab nCL x MMAE remained almost constant 
for the duration of the experiment and show similar results. Therefore, the stability of the ADCs in mouse and 
human serum indicate that no hinge cleavage is expected. 
For mouse serum analysis, nearly all constructs exhibited high stability and stable concentration profiles ranged 
from 90 to 100 % at 96 h. Apart from that, human serum stability revealed slightly less concentration for IgG-
based Trastuzumab CL x MMAE, Trastuzumab nCL x MMAE and Trastuzuman oa SEED x MMAE with 
values from 78 to 95%, whereas Trastuzumab Fab His x MMAE exhibited a more pronounced decrease in 
concentration of 54% only in human serum. 
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Figure 27: Mouse and human serum stability analysis of Trastuzumab x MMAE ADCs. 
Samples were incubated in mouse serum (A) or human serum (B) at 37°C, 5% CO2 for 96 h. HER2, murine Fc-His was coated in microtiter 
plates and detection was achieved with goat-anti human F(ab’)2 x POD antibody. Aliquots were removed at different time points and 
concentration analysis was performed by ELISA. Depicted are total antibody concentration profiles as triplicates over time. 
 
An overview of the remaining total antibody concentration in percentage of the tested constructs at 96 h is 
shown in Table 9 and terminal drug load as well as time curves of MMAE for mouse and human serum are 
shown in Appendix 22 and 23. For drug load experiments, all constructs (except Trastuzumab Fab His x 
MMAE) remained unchanged in human serum over time and payload loss was not detected by LC-MS. Unlike 
mouse serum stability, all constructs display MMAE toxin release that is contributed to the well known activity 
of carboxylesterase 1c, exclusively present in rodent species. 
 
 
Table 9: Overview of percentage of total antibody concentration in percentage of Trastuzumab MMAE ADCs. 
Samples were incubated in mouse or human serum and remaining total antibody concentrations at 96 h are listed. 
 
ADC 
[%] remaining at 96 h 
in mouse serum 
[%] remaining at 96 h 
in human serum 
Trastuzumab CL x MMAE 90 95 
Trastuzumab nCL x MMAE 100 78 
Trastuzumab Fab His x MMAE 100 54 
Trastuzumab oa SEED x MMAE 99 88 
 
 
Taken together, Trastuzumab Fab His x MMAE tended to be less stable in human serum, but stability in mouse 
serum was similar to all other constructs for total antibody analysis. IgG-based ADCs showed high total 
antibody concentrations in mouse and human serum, indicating appropriate stability of these constructs that is 
necessary for exploiting long half-life of antibody molecules. 
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5.4. Matriptase expression in multiple solid tumor cell lines 
Surface expression of matriptase is evident in a variety of solid tumors, including breast cancer, gastric cancer, 
colorectal cancer and lung cancer. To identify suitable cell lines that express matriptase as it is necessary for 
hinge cleavage of the ADC, western blot analysis was performed with tumor cell lysates. Oberst et al. detected 
matriptase in various cancer cell lines, mainly by using northern blotting and western blotting was performed 
with tumor samples from patients.202 As the model ADC is based on Trastuzumab, different HER2-positive and 
HER2-negative cell lines were selected. Tumor cell lines that were used for matriptase detection comprised 
MDA-MB-468, MCF-7, SKBR-3, HCC1954, BT-474, SKOV-3, adherent HEK293. In brief, cultivated cells were 
lysed using RIPA buffer to facilitate protein extraction and tumor cell lysates were separated by SDS-PAGE 
applying a protein amount of 20-40 µg protein. Detection of matriptase was carried out by using as a primary 
antibody mouse IgG1 anti-human Matriptase Antibody with the recommended concentration 1 µg/ml that 
detects human matriptase/ST14 catalytic domain. As a secondary antibody goat anti-mouse IgG (H+L) x AP 
conjugate (1:1000) was used. Western blot results of cell lysates are shown in Figure 28. 
 
 
 
 
 
 
 
 
 
Figure 28: Western blot analysis of tumor cell lysates with detection of human matriptase. 
Different cancer cell lines were cultivated and cell lysates were subjected to SDS-PAGE and Western blotting. Detection was achieved 
with anti-human matriptase antibody directed at matriptase/ST14 catalytic domain and adding goat anti-mouse IgG (H+L) x AP. For 
Immunodetection, BCIP/NBT was added. 
 
Expression of matriptase in several tumor cell lines was verified and as a reference control recombinant 
matriptase/catalytic domain (MT-SP1) was utilized. The results reveal that mature matriptase displays a 
molecular weight of 95 kDa and in all cancer cell lines the catalytic domain of matriptase was dectected. Hence, 
these cell lines are suitable for further cell experiments. In another attempt, detection of the other tumor protease 
uPA with mouse IgG2A anti-human uPA Antibody could not be detected in cell lysate samples. No detection of 
uPAR using mouse anti-human uPAR Antibody was observed. 
 
5.4.1. Detection of cleaved Fab fragment on tumor cells 
For evaluation of hinge cleavage by tumor proteases uPA and matriptase present on tumor cells, cancer cell 
lines MDA-MB-468, HCC1954 and SKBR-3 were used. These cell lines were incubated with Trastuzumab CL, 
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Trastuzumab nCL, Trastuzumab CL + MT-SP1 and Trastuzumab Fab His at 37°C, 5% CO2 for 72 h. ensure 
ted  
 
 
Figure 29: Western Blot analysis of trastuzumab-based antibodies incubated with cancer cell lines. 
Detection of cleaved Fab fragments was carried out with goat anti-human IgG Antibody, F(ab’)2 specific. Samples and controls comprised 
Tmab Fab His, Tmab CL + MT-SP1, Tmab CL and Tmab nCL and were incubated with SKBR-3 (A), HCC1954 (B, D) and MDA-MB-
468 cells (C) at 37°C for 72 h. Western Blots of different time points are depicted and Tmab CL + MT-SP1 was preincubated with 
supplmented MT-SP1. For Immunodetection, BCIP/NBT was added. Tmab = Trastuzumab 
 
 
Trastuzumab CL + MT-SP1 was preincubated 24 h to ensure that a quantitative cleavage by supplemented 
matriptase is attained. Protein samples were resolved by SDS-PAGE and anti-F(ab’)2-Fragment specific 
Western Blot was performed to detect the cleaved Fab fragment. As a primary antibody goat anti-human IgG 
Antibody, F(ab’)2 specific (1:1000) and as a secondary antibody rabbit anti-goat IgG, (H+L)-Alk. Phos (1:1000) 
were used. Samples were removed at different time points and stored at -80°C until analysis.  
As the results reveal, detection of antibodies with Fab bands was achieved and proteolytic cleavage on tumor 
cell surface was evident (Figure 29 and Appendix 24). Cleavage was observed on HER2-positive cell lines 
HCC1954 and SKBR-3 and indicate that longer incubation times only slightly increased the amount of cleaved 
Fab fragment at 50 kDa. 
As positive controls Trastuzumab Fab His and preincubated Trastuzumab CL + MT-SP1 were used and in 
comparison to Trastuzumab CL + MT-SP1, similar amounts of protein were detected by the solely incubated 
Trastuzumab CL. For the negative control Trastuzumab nCL, no (only unspecific in the case of SKBR-3) specific 
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detection at 50 kDa was observed, displaying that intact IgG antibody without a cleavable sequence remains 
unchanged. On HER2-negative cell line MDA-MB-468 also Fab fragment detection was achieved, suggesting 
that matriptase is also present as observed in a previous experiment. 
Therefore, in situ Fab fragment generation by the tumor cells that express matriptase could be confirmed for 
the hinge cleavable Trastuzumab CL construct. In order to test that released toxin-conjugated Fab fragments 
still exert sufficient cytotoxic activity, cell based cytotoxicity assays were performed with several cancer cell 
lines. 
 
5.5. Cytotoxic activity of hinge cleavable ADCs and FDCs in vitro 
The confirmed specific hinge cleavage and efficient release of FDCs by tumor proteases, as well as maintained 
stability and cellular binding and internalization properties of the intact ADC, are essential criteria that pave 
the way for cytotoxic assessment related to the potency of these constructs. 
In a first attempt, ADCs based on the highly potent cytotoxic compound MMAE were tested in cytotoxicity 
assays on HER2-overexpressing cell lines, measuring the cell viability. 
 
 
Figure 30: Cytotoxicity of Trastuzumab x MMAE ADCs on cancer cell lines. 
Trastuzumab antibodies and antibody fragments generated by enzyme-assisted, site-specific conjugation of cleavable ValCit-PABC-
MMAE to light chains were incubated on HER2-overexpressing SKBR-3 (A), HCC1954 (B) and BT-474 cells (C) as well as on HER-2 
negative cells MDA-MB-468 (D) for 72 h. Cell viability was analyzed by measurement of ATP-levels using the CellTiter-Glo assay. 
High cytotoxic activity was observed on HER2-overexpressing cells with subnanomolar potencies (IC50 values), whereas cell killing by 
Trastuzumab ADCs only at high concentrations could be detected on HER2-negative cells. Illustrated are exemplary cell viability graphs 
with data points of two replicates from at least three independent experiments. 
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The HER2-overexpressing cell lines used comprised HCC1954, SKBR-3, BT-474, NCI-N87 as positive cell lines 
and as HER2-negative cell line MDA-MB-468. MMAE was selected as a well established and characterized 
microtubule inhibiting agent that targets mainly fast dividing cells. 
MMAE is connected to the linker dipeptide valine-citrulline-PABC, which ensures predominantly intracellular 
toxin release by lysosomal enzymes like cathepsin B. As reference constructs, the approved ADC Kadcyla 
(Trastuzumab emtansine, T-DM1) was used and as an isotype control anti-Dig x MMAE that was also 
conjugated by sortase A. For evaluation of the activity of MMAE-based ADCs, serial dilutions of the samples 
were added to the respective cancer cell lines and incubated at 37°C, 5% CO2 for 72 h. Tmab CL x MMAE + 
MT-SP1 was preincubated with matriptase for 24 h, resulting in cleaved products. Exemplarily illustrated are 
the cell viability curves of the constructs on HER2-positive cells SKBR-3, HCC1954, BT-474 and on 
HER2-negative cells MDA-MB-468 (Figure 30). Trastuzumab nCL x MMAE and Trastuzumab natural x 
MMAE as well as Kadcyla and other controls are shown in Appendix 25. 
Cytotoxicity of MMAE-conjugated constructs showed on SKBR-3, HCC1954 and BT-474 cells a strong cell 
killing in the nanomolar to subnanomolar range that was comparable to the benchmark Kadcyla (Table 10). 
In Appendix 26 cytotoxicity of Trastuzumab MMAE ADCs on NCI-N87 cell line is listed. The strongest 
activity was observed on HCC1954 with Trastuzumab CL x MMAE + MT-SP1 having an IC50 of 0.19 nM that 
was comparable to full-length MMAE ADCs (0.24 to 0.34 nM). 
ADCs with a DAR of approximately 2 exhibit consistent IC50 values in the subnanomolar range on SKBR-3 and 
HCC1954. Also Trastuzumab CL x MMAE + MT-SP1 and Trastuzumab Fab His x MMAE, which both have 
a DAR of nearly 1 exert similar cytotoxicity. As a general trend, Trastuzumab oa SEED x MMAE always 
displayed less cyototoxic activity than Trastuzumab Fab His x MMAE, except on BT-474. 
 
Table 10: Overview of cytotoxicity of Trastuzumab MMAE ADCs. 
Depicted are cellular potencies of MMAE ADCs in different formats on several HER2 cancer cell lines. ADCs in the IgG format have a 
DAR of nearly 2 (Kadcyla has a DAR of 3.5), whereas antibody fragments and cleaved ADC with matriptase displays a DAR of 1. Used 
control ADCs comprised Kadcyla and anti-Dig x MMAE. Mean IC50 in nM from at least three independent experiments were used. 
 
Construct DAR HCC1954 SKBR-3 BT-474 MDA-MB-468 
Tmab CL x MMAE 1.9 0,24 ± 0,15 0,30 ± 0,14 0,23 ± 0,07 > 100 
Tmab nCL x MMAE 1.8 0,22 ± 0,10 0,38 ± 0,19 0,48 ± 0,15 > 100 
Tmab natural x MMAE 1.8 0,34 ± 0,13 0,50 ± 0,17 0,73 ± 0,01 > 100 
Tmab CL x MMAE + MT-SP1 0.8 0,19 ± 0,03 0,31 ± 0,07 0,58 ± 0,01 > 100 
Tmab Fab His x MMAE 0.9 0,50 ± 0,24 0,47 ± 0,19 2,31 ± 0,53 50,54 ± 35,53 
Tmab oa SEED x MMAE 0.8 0,90 ± 0,33 1,17 ± 0,09 1,91 ± 0,05 > 100 
Kadcyla 3.5 0,29 ± 0,26 0,35 ± 0,22 3,06 ± 1,82 42,64 ± 36,18 
MMAE - 0,12 ± 0,04 0,32 ± 0,23 0,43 ± 0,06 0,70 ± 0,45 
DM-1 - 0,39 ± 0,13 1,11 ± 0,40 3,82 ± 0,97 0,99 ± 0,32 
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Cytotoxic activity on BT-474 was slightly decreased for all constructs compared to HCC1954, but Kadcyla was 
even 13-fold less active than Trastuzumab CL x MMAE on BT-474. On HER2-negative cell line MDA-MB-468 
only at higher concentrations Trastuzumab Fab His x MMAE showed at 50.54 nM cell killing, but that was 
similar to Kadcyla with an IC50 of 42.64 nM. In all tested cell lines, non-related isotype control ADC, anti-Dig 
x MMAE, did not indicate a significant reduction in cell viability. 
For small molecules MMAE and DM-1, cell and target independent cytotoxic effects in the range from 0.12 to 
3.82 nM were observed, indicating a free diffusion and cell permeable payload.  
To better differentiate in vitro between only cell killing that is more related to bystander effect by cell permeable 
toxin MMAE or real tumor penetration, constructs conjugated with MMAF as a more cell impermeable payload 
were used. Therefore, comparison of a bystander molecule in the case of MMAE and a non bystander molecule 
like MMAF was investigated. Generally, all used MMAF constructs displayed increased potencies than MMAE 
ADCs and as shown in all cell viability graphs the small molecule MMAF is much less active (Figure 31). 
 
 
 
Figure 31: Cytotoxicity of Trastuzumab x MMAF ADCs on cancer cell lines. 
Trastuzumab ADCs with cleavable ValCit-PABC-MMAF linker drug conjugated to light chains were incubated on HER2-
overexpressing SKBR-3 (A), HCC1954 (B) and BT-474 cells (C) as well as on HER-2 negative cells MDA-MB-468 (D) for 72 h. Cell 
viability was analyzed by measurement of ATP-levels using the CellTiter-Glo assay. High cytotoxic activity was observed on HER2-
overexpressing cells with subnanomolar potencies (IC50 values), whereas cell killing by Kadcyla only at high concentrations could be 
detected on HER2-negative cells. Illustrated are exemplary cell viability graphs with data points of two replicates from at least three 
independent experiments. 
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Table 11: Overview of cytotoxicity of Trastuzumab MMAF ADCs. 
Depicted are cellular potencies of MMAF ADCs in different formats on several HER2 cancer cell lines. ADCs in the IgG format have a 
DAR of nearly 2, whereas antibody fragments and cleaved ADC with matriptase displays a DAR of approximately 1. Used control ADCs 
comprised Kadcyla and anti-Dig x MMAE. Mean IC50 values in nM from at least three independent experiments were used. 
 
Construct DAR HCC1954 SKBR-3 BT-474 MDA-MB-468 
Tmab CL x MMAF 1.7 0,13 ± 0,07 0,17 ± 0,13 0,31 ± 0,31 > 100 
Tmab nCL x MMAF 1.8 0,12 ± 0,06 0,20 ± 0,17 0,58 ± 0,37 > 100 
Tmab natural x MMAF 1.9 0,10 ± 0,05 0,21 ± 0,15 0,32 ± 0,13 > 100 
Tmab CL x MMAF + MT-SP1 0.7 0,10 ± 0,03 0,23 ± 0,03 0,46 ± 0,23 > 100 
Tmab Fab His x MMAF 0.7 0,28 ± 0,22 0,34 ± 0,14 0,60 ± 0,33 > 100 
Tmab oa SEED x MMAF 0.8 0,44 ± 0,27 0,54 ± 0,10 0,78 ± 0,47 > 100 
Kadcyla 3.5 0,32 ± 0,22 0,42 ± 0,22 2,45 ± 0,25 36,96 ± 45,34 
Tmab natural x MMAF DAR 3.5 3.5 0,12 ± 0,08 0,42 ± 0,23 1,81 ± 0,21 > 100 
MMAF - - - - - 
DM-1 - 0,42 ± 0,13 0,66 ± 0,45 2,51 ± 1,26 1,09 ± 0,34 
 
 
An overview of the cytotoxicity results is shown in Table 11. Trastuzumab CL x MMAF + MT-SP1 and 
Trastuzumab natural x MMAF ADCs potently killed HCC1954 cells with an IC50 of 0.10 nM, and thus were 
3-fold more potent than Kadcyla with an IC50 of 0.32 nM. On SKBR-3 and BT-474 cells, Trastuzumab CL x 
MMAF and Trastuzumab natural x MMAF showed the highest potencies ranging from 0.17 to 0.32 nM, 
surpassing slightly Kadcyla. Another construct termed Trastuzumab natural x MMAF DAR 3.5, was also tested 
with the MMAF ADCs that bears 4 MMAF payloads and showed a pronounced effect with an IC50 of 0.12 nM 
on HCC1954 and 0.42 nM on SKBR-3 cells. In this case, payloads are conjugated again to light chains by sortase 
A and also to the heavy chains that carry a LPETGS recognition motif. On HER-2 negative cells MDA-MB-468 
of the ADCs only Kadcyla showed at higher concentrations (36.96 nM) cell killing, whereas all MMAF-based 
ADCs where inactive in the evaluated concentration range and did not show any unspecific cell killing. The cell 
viability graphs of full-length constructs Trastuzumab CL x MMAF, Trastuzumab nCL x MMAF and 
Trastuzumab natural x MMAF can be found in Appendix 27. 
For all cytotoxicity assays, evaluation of the target inhibition on cell viability was investigated using 
unconjugated antibodies analogously. Antibodies without toxins showed no significant activity on cell viability, 
but when conjugated with a toxin, strong cytotoxic activity was achieved. 
When comparing the DAR with the obtained IC50 values of tested anti-HER2 ADCs and FDCs, similar IC50 
values on HCC1954 of higher DAR and low DAR ADCs in the case of MMAF as a payload were observed. 
In vitro cytotoxicity of the cleaved ADC and FDC are equipotent to higher DAR Trastuzumab natural x MMAF 
DAR 3.5 and Kadcyla (Figure 32). 
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Figure 32: Comparison of IC50 and DAR of Trastuzumab x MMAF ADCs on HCC1954 cell line. 
Cytotoxic activity of Trastuzumab ADCs and FDCs conjugated with MMAF on HCC1954. Plotted are the obtained IC50 values against 
the DAR of the respective construct. Strong cytotoxicity is observed by cleaved ADC and FDC despite the low drug load of 
approximately 1. 
 
Furthermore, analogous to the clevable antibodies and antibody fragments that were based on Trastuzumab, 
cell viability was also analyzed with Cetuximab-based ADCs conjugated to MMAE on EGFR-overexpressing 
cell lines. Cetuximab x MMAE ADCs displayed strong cytotoxicity on EGFR-positive A431 and MDA-MB468 
cells, whereas no unspecific cell killing was observed on EGFR-negative MCF-7 cell line. 
An overview of the IC50 values of Cetuximab x MMAE ADCs is shown in Appendix 28 and cell viability curves 
are depicted in Appendix 29. 
As cytotoxicity of generated cleavable ADCs and FDCs is maintained, a suitable approach to investigate tumor 
distribution and penetration of solid tumors is necessary. For evaluation of tumor localization, antibody-
fluorophore conjugates will be used for imaging studies. 
 
5.6. Tumor spheroid distribution and penetration 
To investigate tumor distribution and penetration in vitro, tumor spheroids were prepared. Spheroids represent 
spherical clusters of growing, self-adhered cancer cells that mimic the three-dimensional environment and 
structure of a solid tumor. 
Due to the fact that tumor cell killing is not directly related to an improved penetration, the different formats 
of antibody molecules were prepared as antibody-fluorophore conjugates using Alexa Fluor 488 as a green 
fluorescent dye. Alexa Fluor 488-conjugates contain a triple-glycine motif and a noncleavable C5-spacer in the 
linker structure of Alexa Fluor 488. The antibody-fluorophore conjugate Trastuzumab CL N297A x AF488 x 
BHQ10 was generated by a dual conjugation method. 
In the case of Alexa Fluor 488, sortase A conjugation was used to attach the fluorophore to the light chains, 
whereas dark soluble BHQ-10 is conjugated to Q295 in the heavy chain by transglutaminase reaction (Figure 
33). In the intact IgG form, the green fluorescence is quenched by BHQ-10, which has a broad quenching range 
for emission maxima at 516 nm. Upon cleavage in the hinge region fluorescence is activated, because of the 
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separation of the Fc part with BHQ-10 from Fab-Alexa Fluor 488. All other formats carry the fluorophore on 
the light chains and an overview of antibody-fluorophore conjugates is shown in Table 5. 
 
 
Figure 33: Structure of Trastuzumab CL N297A x AF488 x BHQ-10 using Alexa Fluor 488 as the fluorophore and BHQ-10 as 
a quencher. 
Cleavable antibody-fluorophore conjugate Trastuzumab CL N297A x AF488 x BHQ-10 was generated by sortase A conjugation of Gly3-
C5-AF488 to the light chains of the antibody. BHQ-10 was conjugated to Q295 by transglutaminase reaction (A). The whole intact 
construct is cleaved in the hinge region, releasing the Fab fragments with the fluorophore attached to it (B). 
 
 
For analysis of efficient fluorescence activation, measurements were performed with Trastuzumab CL x AF488 
x BHQ-10 alone, with enzymes uPA and matriptase, as well as control samples. Control samples comprised 
Trastuzumab CL x BHQ-10 only with quencher conjugated as well as Trastuzumab natural x AF488. Prior to 
enzyme cleavage experiments, a calibration curve was carried out by measuring solely increasing AF488 
concentrations. The obtained correlation coefficient R2 with 0.9383 was significant enough for analytical 
evaluation and indicated a proportional increase of the relative fluorescence units (RFU). For the cleavage of 
Trastuzumab CL x AF488 x BHQ-10 with matriptase a strong increase in RFU was observed from early time 
points with 320203 RFU to 511733 RFU at 24 h. Compared to the cleavage with matriptase, incubation with 
uPA resulted in a less increase of fluorescence intensity at 24 h with 382340 RFU (Figure 34). 
These results displayed that fluorescence of the Trastuzumab CL x AF488 x BHQ-10 construct is increased 
upon efficient separation of the Fab fragment containing Alexa Fluor 488 from the Fc portion bearing the 
BHQ-10 quencher. Moreover, control samples Trastuzumab CL x AF488 x BHQ-10 as well as Trastuzumab 
natural x AF488 remained unchanged in their RFU over time. 
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Figure 34: Alexa Fluor 488 calibration and fluorescence intensity over time of different antibody-fluorophore conjugates. 
Alexa Fluor 488 was analyzed for an increasing, proportional fluorescence with varying concentrations (A). Alexa Fluor 488 was 
conjugated to Trastuzumab CL N297A antibody with the quencher BHQ-10 and was incubated with tumor proteases uPA and 
matriptase. Increasing RFU were observed for both samples over time, indicating a sufficient separation of the Fab fragment with the 
fluorophore from the Fc portion bearing the quencher (B). Control samples Trastuzumab CL x AF488 x BHQ-10 (without enzyme), 
Trastuzumab CL x BHQ-10 (only with quencher) and Trastuzumab natural x AF488 (only with fluorophore) were used. Samples were 
measured in triplicates with EnVision multiplate reader. RFU = Relative Fluorescence Units, AF488 = Alexa Fluor 488, BHQ-10 = 
Black Hole Quencher-10 
 
 
As the basic principle for fluorescence activation was confirmed, imaging experiments were carried out with 
tumor spheroids. Cancer cell lines HCC1954, SKBR-3 and MDA-MB-468 were used to form spheroids, as these 
cell lines express matriptase. Spheroid formation was checked with IncuCyte S3 Live-Cell Analysis System and 
was unfortunately only successful with HCC1954 at a cell density of 3000 cells/well, indicated by the presence 
of an extracellular matrix (Appendix 30). Spheroids had an average diameter size of approximately 300 µm and 
were grown within 48 h. HCC1954 spheroids were treated for 14 h with antibody-fluorophore conjugates 
Trastuzumab CL x AF488 x BHQ-10 (with and without matriptase), Trastuzumab nCL x AF488 and 
Trastuzumab Fab x AF488 to evaluate size-dependent tumor distribution and penetration in an in vitro model. 
Live cell imaging was carried out over the time and green fluorescence was detected. 
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Figure 35: Spheroid distribution and penetration with antibody-fluorophore conjugates. 
Depicted are HER2-overexpressing HCC1954 spheroids at a cell density of 3000 cells/well. Antibody-fluorophore conjugates were 
applied with a concentration of 6.25 nM and cells were imaged over time for 14 h. Trastuzumab CL x AF x BHQ-10 was applied without 
enzyme to ensure matriptase cleavage is achieved by tumor cells. Control samples that are applied as Fab fragments attached to Alexa 
Fluor 488 comprised Trastuzumab CL x AF488 x BHQ-10 + MT-SP1 and Trastuzumab Fab x AF488. Trastuzumab nCL x AF488 
remains unchanged in the intact IgG form. Scale bar = 400 µm 
 
Imaged time points were 2 h, 6 h, 10 h and 14 h and are illustrated in Figure 35. When comparing the results 
of Trastuzumab CL x AF488 x BHQ-10 (with and without matriptase) and Trastuzumab Fab x AF488, 
comparable green fluorescence is observed over the spheroid area at 14 h. This indicates that functional 
Trastuzumab CL x AF488 x BHQ-10 is cleaved by present tumor protease on tumor cell surface and the cleaved 
Fab-fluorophore conjugate distributes and penetrates evenly into the spheroid core, reaching almost all cancer 
cells. In contrast to that, Trastuzumab nCL x AF488 predominantly localizes at exterior fractions compared to 
the other tested constructs and is not able to reach the central region. 
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In another experiment with the fluorescence microscope EVOS FL Auto 2 Imaging System, the penetration of 
the conjugates with fluorophore along the z-stack was monitored and reveales that inside the tumor core a 
stronger fluorescence is observed for Trastuzumab CL x AF488 x BHQ-10 and Trastuzumab Fab x AF488. 
Exemplarily images are shown in Appendix 31. 
Taken together, results of cleaved Trastuzumab CL x AF488 x BHQ-10 as well as Trastuzumab Fab x AF488 
showed that these constructs significantly better localize across the tumor spheroids and even within the tumor 
core, leading to an improved tumor distribution and penetration in vitro. 
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6. Discussion 
 
6.1. Protease-cleavable ADCs with prolonged half-life as a novel format 
Efficient, site-specific and uniform delivery of antibody-based therapies to solid tumors remains a major 
challenge. Previous studies have demonstrated a strong correlation between the size and penetration ability of 
targeting agents and hence a novel ADC design is pursued in this study to address the penetration issue while 
retaining advantages of the full-length antibody.157,167 
In the course of this study, smaller-drug conjugates that are released by an ADC through cleavage in the hinge 
region were utilized to improve the tumor penetration and accumulation while maintaining long-half life by the 
intact ADC in systemic circulation. Thus, rapid clearance of the Trastuzumab CL compound would be avoided 
but as the toxin-based fragment is generated, faster penetration but also rapid renal clearance of the fragment 
would be achieved. Moreover, such rapid clearance could be a potential benefit for reducing toxic exposure to 
healthy cells. 
The purpose of this study was to compare the tumor penetration and localization of hinge cleavable 
Trastuzumab ADCs with a noncleavable counterpart as well as with Trastuzumab Fab control constructs. 
Fab fragments exhibit a typical plasma half-life of 12 - 20 h, which make them more appropriate for diagnostic 
and imaging applications rather than for therapeutic use.203 Nomerous strategies are described for prolonging 
the half-life of therapeutic agents in drug development. The most prominent approaches are the PEGylation of 
molecules (like Certolizumab pegol with 2 x 40 kDa PEG residues or PEGylated interferon alfa-2a with 2 x 
20 kDa PEG) or association of targeting agents with albumin.204–206 However, for PEGylation a high amount of 
PEG chains is necessary to achieve an extended half-life, leading to a higher molecular weight and hence an 
impaired tumor penetration. In the case of albumin, this 67 kDa protein has no targeting ability and only one 
payload molecule per native albumin can be achieved, resulting in a restricted cargo loading. As albumin already 
exceeds the molecular weight of a 50 kDa Fab fragment and has to be modified with a targeting molecule, no 
improved tumor penetration is assumed. PEGylated Fab fragments exhibit potential advantages over IgG 
antibodies like a lack of any undesirable Fc-mediated effects. Elimination of effector functions is considered in 
many cases as this leads to reduced side-effects. For example, these immune effects are associated with 
exaggerated cytokine secretion after antibody therapy or off-target toxicities in the case of ADCs.207 The long 
circulatory half-life of antibody-based drugs leads to elevated blood concentration, often resulting in bone 
marrow toxicity even before therapeutic activity in a solid tumor is reached.157 In addition to that, Fc-fusion 
proteins are also an important alternative for prolonging the half-life.208 
All ADCs and FDCs generated for this work are homogeneous and site-specific by way of their predefined 
attachment sites for the payload on the C-termini of light chains of antibodies and antibody fragments. Site-
specific conjugation is superior compared to chemical conjugation in terms of defined pharmacokinetics, safety, 
stability and efficacy profile. All Trastuzumab ADC conjugations with sortase A displayed good yields with a 
DAR of 1.6 to 1.9 and conjugation efficiency was in the range of 60 - 70%. In contrast to that, Cetuximab ADCs 
achieved a lower DAR of 1.1 to 1.3, leading to the assumption that conjugation is not efficient. This could be 
due to the heterogeneous mixture of Cetuximab, which is present with different glycoforms that might have a 
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negative impact on the conjugation reaction. As the same linker-drug structure like for Trastuzumab ADCs was 
used for the generation of Cetuximab ADCs, no interference of the Gly3-ValCit-PABC-MMAE substrate with 
the enzyme’s active site is conceivable. Possibly, steric hindrance for sortase A to reach the LPETGS motif on 
Cetuximab could also lead to an inefficient conjugation reaction. 
To improve the tumor penetration and simultaneously make use of the well established conventional IgG 
format, a protease cleavable site is engineered in the hinge region. Desnoyers and colleagues deployed the 
protease site when they used its amino acid sequence as a cleavable linker between a masking peptide and the 
N-terminus of the antigen binding site of an antibody. This approach abolishes binding to the target and the 
tumor-specific activation of the tested probody by tumor proteases was verified in an in vivo study.198 In such 
case, the protease site was exposed at the surface of the antibody and no steric hindrance was expected, whereas 
in this work the protease site was buried within the hinge region. Nevertheless, it could be demonstrated that 
the hinge region is still accessible to tumor proteases as Fab cleavage was observed upon matriptase and uPA 
addition. As shown by ESI-MS analysis, the selective cleavage site of the proteases is between arginine and 
serine within the 8 amino acid sequence. This is in accordance with Yang et al., where the linker sequence was 
used for another approach.197 The expression of such enzymes like matriptase in several cancer cell lines was 
confirmed by Western Blot anaylsis, as also evidenced by other research groups.202 
These data reveal that the antigen HER2 and matriptase are expressed on selected cancer cell lines, which are 
both crucial for this concept. Moverover, matriptase overexpression is mainly restricted to malignant cells, 
whereas in normal cells minor amounts are present for physiological functions. This could lead to a suitable 
application that is preferentially in tumor tissue and results in more cleaved fragments that accumulate within 
the tumor. The overexpression compared to cancer cells is more likely, because a greater split in safety could be 
achieved. 
 
6.2. Evaluation of cleavage reactions, cellular binding and internalization 
The hinge region of IgG antibodies with its high flexibility is susceptible to specific cleavage by proteases in 
vitro and various modifications like reductive cleavage of interchain groups, cysteinylation and glutathionylation 
are known to affect the stability of mAbs. Particularly, the IgG3 subclass with its short half-life of 7 days and 
its extended hinge region that is prone to cleavage, is not used as a therapeutic.83 The evaluation of the designed 
cleavable IgG1 antibodies revealed that the elongated hinge region is not impeding the structural integrity and 
functionality of the antibody. Cleavage reactions that occur in the upper hinge region can impact epitope binding 
due to the loss of bivalency, whereas cleavage reactions in the lower hinge region lead to impaired Fc effector 
function.199,209 
The time-dependent cleavage results demonstrated that a fast and efficient cleavage reaction in the hinge region 
of Trastuzumab CL constructs is achieved with tumor proteases uPA and matriptase, whereas matriptase 
displays a significant faster proteolytic cleavage than uPA. These results are consistent with earlier 
observations, where kinetic parameters of substrate conversion for matriptase were kcat/Km 2200 ± 424 M-1 s-1 
and for uPA kcat/Km 500 ± 79 M-1 s-1.198 A fast cleavage rate is important for this work, because otherwise the 
full-length ADC can be internalized in a short period of time and thus would not be anymore available for the 
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extracellular protease cleavage, targeting the tumor only in the IgG-ADC form. As the quantitative and fast 
cleavage rate of matriptase is obvious, this enzyme was used for all subsequent experiments where preincubated 
samples are of importance as controls. 
Besides that, it is generally assumed that ADC internalization into tumor cells is required in order to exert 
pronounced therapeutic activity.64,165 In contrast to that, ADCs against CD20, CD21, CD22 and fibronection 
exhibited activity even when antibodies and antigens are poorly internalized.210,211,212 Moreover, such 
experiments showed that non-internalizing ADCs carrying the cytoxic drug by means of disulfide linkers are 
cleaved in the tumor microenvironment. Recent investigations by Neri and colleagues also revealed that the 
non-internalizing F16 antibody is able to release cytotoxic drugs at the extracellular tumor site, resulting in 
anti-cancer activity in preclinical studies of U87 and A431 xenografted tumors. The human F16 antibody targets 
the non-internalizing antigen tenascin-C (splice isoform) and was generated as an ADC by conjugation of 
ValCit-PABC-MMAE to cysteine residues. In these experiments, unexpected extracellular proteolytic cleavage 
of the ValCit dipeptide linker was observed, leading to the conclusion that such peptide linker is not selectively 
cleaved by cathepsin B in intracellular compartments.213,214 
Taken together, previous studies showed that non-internalizing ADCs with a dipeptide linker release efficiently 
the payload. As efficient drug release of ADCs at the tumor site is not only achieved by reductive conditions, 
but also by extracellular proteases, this approach can also be used for the protease site used in this work. uPA 
and matriptase sensitive cleavable linker could be utilized for the design of non-internalizing ADCs to release 
cytotoxic payloads in the extracellular regions of tumor cells. Such an application expands the ADC target space 
to non-internalizing cell membrane proteins offering potential therapeutic advantages for the treatment of 
further antigens. Consistent with previous reports and impaired solid tumor penetration of antibodies that are 
mainly located in the perivascular region, the release of drugs in the extracellular space enables diffusion and 
subsequently penetration of the tumor.167 
In principle, many extracellular proteolytic enzymes that reside in the tumor microenvironment can influence 
activity and stability of ADCs. Elevated expression levels of many proteases in the tumor microenvironment are 
evident, especially the activity of several MMPs.209 In this work, analysis of Western Blots confirmed the 
selectivity of the protease site to uPA and matriptase due to the fact that no upper or lower hinge cleavage was 
observed with the Trastuzumab nCL construct upon incubation with cancer cell lines. 
As affinity and avidity play a critical role, cellular binding of monovalent and bivalent constructs was tested and 
showed only slight differences on HER2-overexpressing cells. As monovalent Trastuzumab Fab has no avidity, 
marginal altered binding interaction to the single antigen might result from loss of bivalency. Binding strength 
of the tested constructs correlated with expression levels of the antigen on different cancer cell lines. 
Furthermore, no unspecific binding was detected for bivalent and monovalent constructs for HER2-negative 
cell line MDA-MB-468. 
Parameters that influence the internalization rate are less understood. However, the choice of target antigen, 
kinetic parameters as association and dissociation rates for the antibody-antigen interaction as well as processing 
and intracellular events such as recycling to the cell surface rather than lysosomal degradation play a key role.175 
Previous observations with high affinity anti-CEA scFv molecules showed that affinity and avidity had no 
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dramatic impact on internalization rates and the internalization rate of mAb and antibody fragment is probably 
largely dependent on recycling of the respective antigen.157 In this case, an equivalent uptake of monovalent and 
bivalent scFvs was observed, leading to the assumption that crosslinking of CEA antigens on cell surface 
displays only a minor effect on trafficking.215 The internalization results shown here for Trastuzumab antibodies 
and antibody fragments are in accordance with these observations, displaying that Trastuzumab Fab has 
comparable internalization rates like commercial Herceptin and bivalent construct Trastuzumab CL. All 
evaluated antibodies and antibody fragments were internalized in HER2-positive cells with a relative 
internalization rate of 34 to 39 % after 48 h on MCF-7 cells and on SKBR-3 cells even 38 to 52 % after 48 h. 
Based on these results, the prerequisite for payload delivery in the context of ADCs is met with a sufficient 
internalization. As Trastuzumab Fab has no Fc portion and hence is not able to bind FcRn for recycling, 
probably better processing and trafficking is achieved of this molecule. In contrast to that, other groups 
demonstrated that Herceptin undergoes a very fast and extensive recycling via early endosomes of about 85 % 
within 30 min.216 
Similar investigations of researchers concerning internalization with different mAbs concluded that different 
properties of the targeting molecule have no effect on internalization and that this process is totally dependent 
on the antigen of interest.217 
 
6.3. In vitro serum stability and thermal stability 
Due to concerns regarding the hinge stability in serum from different species, in vitro serum stability of ADC 
samples in mouse and human serum were analyzed and displayed mainly unchanged total antibody 
concentrations. As the stability graphs of Trastuzumab CL x MMAE and Trastuzumab nCL x MMAE display 
comparable results over time, the stability of the cleavable protease site in the hinge region can be assumed. 
Only Trastuzumab Fab His x MMAE showed a strong decrease at early time points in human serum that could 
result from the missing second Fab fragment and Fc portion that contribute to full-length antibody stability. 
Regarding the drug-linker stability in mouse serum, results showed expected cleavage of the dipeptide linker 
valine-citrulline that is attributed to murine carboxylesterase 1c and is in accordance with previous studies.218 
This structure related cleavage that leads to release of active toxin can be mitigated by simply using another 
release mechanism like hydrophilic ß-glucuronide linkers or non-cleavable linkers.138,141 
Regarding the thermal stability, individual domains of antibodies are susceptible to thermal unfolding. The first 
transition point represents the CH2 domain and the second one the Fab fragment.219 Evaluation of glycosylated, 
unconjugated Trastuzumab constructs as well as ADCs with MMAE, showed that no alteration in the transition 
temperatures of both CH2 domains and Fab domains were observed. Therefore, both domains were not 
negatively affected by toxin conjugation with sortase A to the light chains. For further concept evaluation, 
deglycosylated Trastuzumab N297A constructs were used for the generation of antibody-fluorophore 
conjugates. N-glycosylation is an important posttranslational modification that not only affects structural 
properties of the Fc part of antibodies but also plays a key role for effector functions and pharmacokinetics, and 
therefore also modulates the efficacy and safety of these drugs.220,221 The conserved N-glycosylation at N297 
position in the Fc part stabilizes the CH2 domain of antibodies, as shown by deglycosylated antibodies that are 
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thermally less stable and more susceptible to thermal induced unfolding. Additionally, deglycosylation makes 
antibodies less hydrohphilic and prone to aggregation.222 This derives from the assumption that several 
hydrophobic amino acid residues are masked by the glycan structure and by removing the glycans, these residues 
are exposed. Moreover, the removal of the glycan structure from the CH2 domain of antibodies may also increase 
the protease accessibility to the hinge region.222 The measured melting temperatures of the CH2 domain of the 
deglycosylated Trastuzumab N297A constructs appear to be approximately 10°C lower than for glycosylated 
antibodies, which is in good agreement with previous literature reports. 
 
6.4. Cleavable ADCs and FDCs exhibit high potency in vitro 
After the comprehensive functional characterization of designed antibodies and ADCs, in vitro cytotoxicity was 
evaluated for all constructs. First, the MMAE-based Trastuzumab ADCs were tested on HER2-overexpressing 
cell lines. Currently, most of the published ADC formats show an average DAR of 2 to 4. This is mainly based 
on several observations. Investigations demonstrated that by increasing the DAR of ADCs, the in vitro potency 
increases as well. But higher DAR ADCs are not only associated with advantages as their plasma clearance is 
also accelerated, resulting in a reduced exposure and poor in vivo efficacy. Previous studies by Lyon et al. showed 
that such accelerated clearance correlates with ADC hydrophobicity, which they demonstrated by using several 
hydrophilic (PEG and glucuronide) drug-linkers and ADCs with different DARs.223,224 Moreover, higher drug 
loading of ADCs often lead to poor tolerability, which is observed by various toxicities.225  
Aforementioned reasons and characteristics of ADC drug load led to the conclusion, that for the present study 
conjugates with a DAR of 1 to 2 are sufficient.  Hence, when using highly potent payloads, the low DAR should 
be appropriate to struck the balance between a pronounced cytotoxic activity while preserving tolerability of 
produced ADCs. 
Cytotoxicity of Trastuzumab x MMAE ADCs on high expressing HER2-positive cell lines were tested head-
to-head with Kadcyla. The cytotoxic compound MMAE is frequently used as an ADC payload and its beneficial 
properties like high solubility and remarkable potency resulted in the approved ADC Adcetris. MMAE acts 
similar like the payload DM1 of Kadcyla as an antimitotic agent by inhibiting microtubule assembly and 
subsequently preventing mitosis.124,130 Trastuzumab CL x MMAE and Trastuzumab CL x MMAE + MT-SP1 
samples exhibited on all tested cell lines superior potency in comparison to Kadcyla. Moreover, a better safety 
profile was also obtained with these constructs due to the fact that Kadcyla showed higher off-target toxicity on 
HER2-negative MDA-MB-468 cell line. These results might be due to several differences that probably will 
have a stronger influence, at least in vivo. Firstly, Kadcyla is a heterogeneous mixture generated by lysine 
conjugation with different DAR species, which impact all ADC properties like efficacy, safety, pharmacokinetics. 
For Trastuzumab CL x MMAE ADC a site-specific conjugation with defined DAR species was achieved. 
Secondly, Kadcyla utilizes a non-cleavable linker with a different release mechanism, which depends on complete 
degradation of the antibody.118 Upon degradation the resulting DM1-containing lysine derivative that is 
released, is cell impermeable. In contrast to that, Trastuzumab CL x MMAE relies upon lysosomal cleavage of 
the cleavable dipeptide valine-citrulline linker to release the payload in a traceless manner without any amino 
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acid attached. Once MMAE is released, the cell permeable toxin can diffuse to neighbouring cells.226 Therefore 
MMAE is able to induce bystander killing of HER2-positive cells as well as antigen-negative cells. 
Despite the low drug load of cleaved Trastuzumab CL x MMAE + MT-SP1 and Trastuzumab Fab x MMAE 
of 0.8 and 0.9 respectively, remarkable potency was observed. Such cytotoxic activity can be associated with the 
high receptor densities on HCC1954, SKBR-3 and BT-474. Other reports with single drug conjugated products 
FabTRA-bisAlk-vc-MMAE (PolyTherics) targeting HER2 and anti-HER2 ADC SYD985 (Synthon) with 
duocarmycin as a payload obtained comparable results for in vitro potency.134,227 Furthermore, an increasing 
interest in the development of small-format drug conjugates by several pharmaceutical and biotechnological 
companies (e.g. Bicycle Therapeutics and Tarveda) paved the way for first clinical investigations for such new 
modalities. Most of the molecules are evaluated in preclinical R&D (e.g. Seattle Genetics) and the typical 
molecular weight of these conjugates range from 1 kDa up to 80 kDa.173 
When comparing the herein presented design to other small-format drug conjugates in development, most 
approaches might exploit an improved tumor penetration, but the molecules are still lacking a prolonged half-
life. Therefore, the pharmacokinetic properties negatively influence the potential benefit of the small format.173 
The hinge cleavable ADCs used in this work might show the potential benefit for a long half-life in systemic 
circulation, while achieving a better tumor penetration by released Fab-drug conjugates at the tumor site. 
When tested as MMAF-based ADCs, Trastuzumab constructs achieved stronger efficacy and showed slightly 
greater potency than MMAE counterparts. MMAF was chosen as an additional payload, because it is cell 
impermeable and hence it is not able to cross biomembranes and can not induce bystander effect, leading to a 
more precise assessment of tumor penetration in vitro. Therefore, only cells that are reached by the delivery 
vehicle are efficiently killed. 
Interestingly, when comparing the IC50 values of the higher DAR ADCs with that of lower DAR ADCs, no 
dramatic change is observed. As ADC exposure-response correlation is not well understood, this suggests that 
a certain threshold of intratumor payload concentration is needed to exert efficacy. Above this concentration a 
plateau effect is reached, where excessive levels of payload to tumors are not able to enhance the efficacy even 
cause toxicity. This is in line with observations by Zhang and colleagues, where DAR changes of a PBD-ADC 
could not rationalize observed efficacies.228 
Regarding the deglycosylated Trastuzumab N297A constructs, when tested in the toxin-based format with 
MMAE, similar values for in vitro cytotoxicity compared to glycosylated variants were observed (personal 
communication Merck KGaA, Darmstadt, Germany). Therefore the lack of glycosylation has probably no 
influence on cell binding or internalization  
In summary, the cytotoxicity results of the presented study show that hinge cleavable ADCs can be generated 
that are homogeneous, highly efficacious on different cancer cell lines while being stable against unspecific 
cleavage and degradation. 
 
6.5. Relationship between molecular size and tumor spheroid penetration and distribution 
Although full-length antibodies with a long half-life can accumulate in tumor tissues and bind target cells, 
restricted distribution is common to the tumor cell surface, eventually resulting in poor solid tumor penetration. 
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On the other hand, antibody fragments with a low half-life could accumulate less efficiently, but tumor 
penetration is more efficiently compared to antibodies.94,95,166,167 
Since solid tumors are exposed to various microenvironments as well as to a large concentration gradient, a 
spheroid model was preferred over a monolayer culture approach. Tumor spheroids reflect many properties of 
solid tumors. These include beside the concentration gradient, a nutrient gradient, the development of an 
extracellular matrix and tight junctions between cells.159 Although limitations like the geometry of drug 
penetration towards the spheroid centre is not identical to the in vivo situation, such a spheroid model can be 
useful to evaluate the distribution of antibody-based molecules. 
The three-dimensional spheroid model provides a useful evaluation to complement in vitro experiments for solid 
tumor penetration and distribution studies of therapeutic antibodies and antibody fragments. In 
autoradiography experiments, Sutherland and colleagues tested the penetration of 125I-labeled anti-CEA mAb 
and Fab in spheroid models in vitro. In their study, Fab fragments were bound at surface area of tumor spheroids 
and additionally penetrated about eight to ten cell layers into the spheroid core, whereas intact full-length mAb 
was localized predominantly at exterior fractions of the spheroid surface.229 These observations from previous 
experiments are similar to the used cleavable antibody-fluorophore conjugates in this study, which showed an 
increased tumor penetration and distribution in vitro. 
The improved in vitro spheroid penetration of the Fab fragment is also in accordance with in vivo experiments 
with Co 112 xenografts in nude mice that revealed a deeper penetration of antibody fragments compared to 
intact antibodies and resulted in the greatest tumor to normal tissue ratio.230 Moreover, another study confirmed 
also a better tumor penetration in vivo by antibody fragments in nephrectomized mice to exclude renal clearance 
related aspects.231 
This study demonstrated that Trastuzumab CL x AF488 x BHQ-10 and Trastuzumab Fab x AF488 constructs 
had remarkable differences in tumor penetration and distribution properties in vitro compared to full-length 
antibody Trastuzumab nCL x AF488. 
Despite better distribution, toxin-based ADCs Trastuzumab CL x MMAE and Trastuzumab Fab x MMAE 
exhibited nearly equivalent pharmacological characteristics like cellular binding, internalization efficiency as 
well as cytotoxicity against HER2-overexpressing cell lines. 
Tumor spheroid experiments with HC1954 cells revealed that an improved distribution throughout the entire 
tumor spheroid was achieved with Trastuzumab CL x AF488 x BHQ-10 and Trastuzumab Fab x AF488 
constructs, whereas Trastuzumab nCL x AF488 localized only at exterior fractions on tumor cell surface. The 
smaller antibody-fluorophore conjugates fill a shell at the surface of the sphere, moving progressively towards 
the spheroid core. 
In summary, the results indicated that hinge cleavable ADCs and FDCs with a lower molecular weight and 
reduced size can distribute more efficiently within tumor spheroids. Selective localization of hinge cleavable 
antibodies at the tumor site may offer a potential benefit to target the entire solid tumor. It will be interesting 
to see how these early in vitro imaging data will translate into a biodistribution study in vivo. 
The hinge cleavable ADC design described here is universally applicable. This work showed that additionally 
to the auristatins MMAE and MMAF conjugated to glycosylated Trastuzumab formats, also the fluorophore 
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Alexa Fluor 488 with a triple-glycine tag can be conjugated to the light chains of deglycosylated Trastuzumab 
N297A variants using sortase A mediated conjugation. Furthermore, the drug-linker Gly3-ValCit-PABC-
MMAE used here can be attached to different mAbs like EGFR-specific Cetuximab constructs also with a hinge 
cleavable design and consistently delivers highly potent ADCs and FDCs. 
 
6.6. Outlook 
Further investigations are needed to confirm the potential benefit against solid tumors in terms of tumor 
penetration and localization. As it is difficult to establish a relation between tumor shrinkage and tumor 
penetration, in vivo biodistribution studies with antibody-fluorophore conjugates will be performed. The 
constructs that were already tested with tumor spheroids in vitro using Alexa Fluor 488 will be used for imaging 
analysis. Furthermore, the hinge non-cleavable control will be prepared with the red fluorophore Cy5 for a 
better differentiation. Conjugates will be applied in HCC1954 xenografted mice. Imaging of cleavable conjugates 
within a complex, intact tumor microenvironment and with existing vasculature will present valuable insights 
not only for tumor penetration, but also for pharmacokinetics. One major advantage of this work relies in the 
maintained half-life, which can only appropriately tested in vivo. 
The toxin-based ADCs showed remarkable in vitro potency results even with a low DAR. Generally, for an in 
vivo cancer model the tumor cells proximal to the blood vessel are proliferating and viable. Hence, targeting 
with microtubule inhibitors like in the presented study with MMAE and MMAF would be suitable to efficiently 
eradicate perivascular tumor cells. However, cells distant from the vasculature are often not proliferating and 
necrotic. For such case, DNA damaging agents like duocarmycins, PBDs or IGNs should be selected as payloads, 
because these drugs can address also non-dividing tumor cells.120,133 For future investigations it would be 
interesting to see, if these hinge cleavable ADCs with DNA damaging agents can address non-proliferating cells 
properly. 
Besides the therapeutic application, three single Fab fragments are used for diagnostic purposes for SPECT 
(single photon emission computed tomography) imaging. Other approaches were developed for surgical 
navigation in patients like image-guided surgery. Image-guided surgery has become an essential tool in brain 
tumor surgery and neurosurgery. For detection of brain tumors it is very important to localize the exact position 
of the tumor in order to prevent healthy tissue damage and ensure no residual cancer cells left behind. In general, 
Fab molecules or small molecule ligands are used due to the shorter half-life. The cleavable antibody could thus 
be utilized in diagnostic applications, where a longer half-life is needed.100 
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8. Appendix 
 
Appendix 1: Antibody purification of trastuzumab variants using protein A affinity chromatography 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Downstream processing exemplarily depicted for representative mAbs Trastuzmab CL, LC Srt Tag (A) and Trastuzumab nCL, LC Srt 
Tag (B) using HiTrap MabSelect SuRe 5 ml column. Blue line represents UV detection of proteins. Isocratic elution was carried out with 
20 mM acetic acid, pH 3.2 and subsequently desalting step with PBS, pH 7.4. 
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Appendix 2: Preparative SEC of Trastuzumab CL, LC Srt Tag 
 
 
 
 
 
 
 
 
 
 
 
 
 
Selected preparative SEC of Trastuzumab CL, LC Srt Tag using HiLoad Superdex 200 pg column with isocratic elution PBS pH 7.4. UV 
chromatogram (blue) at 280 nm. 
 
 
 
Appendix 3: Purification of Trastuzumab antibody fragments using IMAC  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IMAC purification exemplarily depicted for Trastuzumab Fab His, LC Srt Tag (A) and Trastuzumab oa SEED AG HC His, LC Srt Tag 
(B) with stepwise elution using HisTrap HP 5 ml column and imidazole as elution buffer. UV chromatogram (blue) at 280 nm. 
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Appendix 4: Preparative SEC of Trastuzumab antibody fragments and anti-penta His Western Blot 
 
Preparative SEC of Trastuzumab Fab His, LC Srt Tag (A) and Trastuzumab oa SEED AG HC His, LC Srt Tag (B) with isocratic elution 
using PBS pH 7.4. Non-reduced SDS-PAGE (C) and Western Blot (D) of purified Trastuzumab Fab His, LC Srt Tag and Trastuzumab 
oa SEED AG HC His, LC Srt Tag. SDS-PAGE was stained with InstantBlue and Western Blot was detected with primary mouse IgG1 
anti-Penta His Antibody following goat IgG anti-Mouse IgG (H+L)-Alk. Phos. For Immunodetection, BCIP/NBT was added. 
 
Appendix 5: Purification of Cetuximab antibody fragments using IMAC and anti-penta His Western Blot 
 
 
 
 
 
 
 
 
 
Non-reduced SDS-PAGE (A) and Western Blot (B) of purified Cetuximab Fab His, LC Srt Tag and Cetuximab oa SEED AG HC His, 
LC Srt Tag. IMAC Purification was carried out with His GraviTrap columns. SDS-PAGE was stained with InstantBlue and Western 
Blot was detected with primary mouse IgG1 anti-Penta His Antibody following goat IgG anti-Mouse IgG (H+L)-Alk. Phos. For 
Immunodetection, BCIP/NBT was added. 
 8. Appendix  110 
Appendix 6: Antibody purification of Cetuximab variants using protein A affinity chromatography 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Downstream processing exemplarily depicted for representative mAbs Cetuximab CL, LC Srt Tag (A) and Cetuximab nCL, LC Srt Tag 
(B) using HiTrap MabSelect SuRe 5 ml column. Blue line represents UV detection of proteins. Isocratic elution was carried out with 20 
mM acetic acid, pH 3.2 and subsequently desalting step with PBS, pH 7.4. 
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Appendix 7: Analytical SEC for protein purity of antibody constructs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analytical SEC of Trastuzumab CL, LC Srt Tag (A) and Trastuzumab Fab His, LC Srt Tag (B), Trastuzumab nCL, LC Srt Tag (C), 
Trastuzumab oa SEED AG His, LC Srt Tag (D), Cetuximab Fab His, LC Srt Tag (E), Cetuximab CL, LC Srt Tag (F), Cetuximab oa 
SEED AG His, LC Srt Tag (G) and Cetuximab nCL, LC Srt Tag (H)  using TSK Super SW3000 column and HPLC Agilent 1260. 
Mobile phase was PBS, pH 7.4 or 50 mM sodium phosphate (NaH2PO4, Na2HPO4), 0.4 M sodium perchlorate, pH 6.35. UV 
chromatogram at 214 nm. 
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Appendix 8: Protease cleavage of unconjugated antibody by tumor proteases 
 
 
 
 
 
 
 
 
 
 
 
Incubation of unconjugated Trastuzumab CL, Trastuzumab nCL, and Trastuzumab natural with uPA (A) or matriptase (B) for 24 h at 
37°C. Samples were non-reduced and gels were stained with InstantBlue after SDS-PAGE run. 
 
Appendix 9: Mass confirmation by ESI-MS and analytical HIC of selected ADCs 
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Exemplarily depicted are ESI-MS spectra of Trastuzumab CL x MMAE heavy chain (A) and light chain with payload (B) as well as 
overlay of HIC chromatograms (E) of conjugated (red line) and unconjugated (blue line) molecules. For Trastuzumab nCL x MMAE, 
mass confirmation of conjugated antibody with heavy chain (C) and light chain with payload (D) as well as overlay of HIC chromatograms 
(F). 
 
Appendix 10: General ADC structure with MMAF as payload 
 
 
Depicted is the generic structural composition of MMAF-based ADCs (Antibody-Gly3-ValCit-PABC-MMAF). Site-specific conjugation 
was achieved by sortase A mediated antibody conjugation technology by attaching triple-glycine drug-linker to sortase A recognition 
motif LPETGS C-terminally to light chain of the antibody.  
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Appendix 11: Analytical SEC of selected Trastuzumab x MMAE constructs and Trastuzumab x AF488 
 
 
Analytical SEC of toxin-based Trastuzumab CL x MMAE (A), Trastuzumab nCL x MMAE (B), Trastuzumab Fab His x MMAE (C). 
Fluorophore-labeled Trastuzumab CL HC N297A x Alexa Fluor 488 x BHQ-10 (D), Trastuzumab nCL HC N297A x Alexa Fluor 488 
(E) and Trastuzumab Fab His x Alexa Fluor 488 (F), exemplarily depicted. Purity was assessed with TSK Super SW3000 column and 
HPLC Agilent 1260. Mobile phase was PBS, pH 7.4 or 50 mM sodium phosphate (NaH2PO4, Na2HPO4), 0.4 M sodium perchlorate, pH 
6.35. 
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Appendix 12: Protease cleavage of Trastuzumab CL x MMAF, Cetuximab CL x MMAE and Trastuzumab CL 
HC N297A x Alexa Fluor 488 x BHQ-10 conjugates by uPA and matriptase 
 
 
 
 
 
 
 
 
 
 
 
 
SDS-PAGE analysis of Trastuzumab x MMAF, Cetuximab x MMAE ADCs and Tmab CL HC N297A x AF488 conjugates incubated 
with tumor proteases uPA and matriptase. Protease cleavage of ADC variants with Trastuzumab x MMAF ADCs by uPA (A) and 
matriptase (MT-SP1) (B). Cetuximab x MMAE ADCs incubated with uPA (C) or matriptase (D). Protease cleavage of antibody-
fluorophore conjugates with AF488 by uPA (E) and matriptase (MT-SP1) (F). Incubation of tPA, a homologous enzyme to uPA was also 
tested. Samples Tmab CL x MMAF, Tmab nCL x MMAF, Tmab natural x MMAF, C225 CL x MMAE, C225 nCL x MMAE and C225 
nat x MMAE, Tmab CL HC N297A x AF488 x BHQ-10, Tmab nCL HC N297A x AF488 and Tmab nat HC N297A x AF488 were 
incubated with (+) or without (-) enzyme at 37°C for 24 h and were non-reduced. After SDS-PAGE run, InstantBlue stain was performed 
at least for 30 min. Tmab = Trastuzumab, C225 = Cetuximab, nat = natural, AF488 = Alexa Fluor 488, BHQ-10 = Black Hole Quechner-
10, + = with enzyme, - = without enzyme 
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Appendix 13: Mass confirmation of FDC/Fc and verification of uPA/MT-SP1 cleavage site by ESI-MS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Trastuzumab CL x MMAE was incubated with uPA (A) and with MT-SP1 (B) and cleaved fragments were analyzed by ESI-MS (non-
reduced). In accordance with the expected mass, hinge cleavage releases FDC fragment that correlates to observed mass. 
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Appendix 14: Mass confirmation of FDC/Fc (Trastuzumab CL x MMAF) and verification of uPA/MT-SP1 
cleavage site by ESI-MS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Trastuzumab CL x MMAF was incubated with uPA (A) and with MT-SP1 (B) and cleaved fragments were analyzed by ESI-MS (non-
reduced). In accordance with the expected mass, hinge cleavage releases FDC fragment that correlates to observed mass. 
 
Appendix 15: Mass confirmation of Cetuximab CL x MMAE fragments by uPA/MT-SP1 using ESI-MS 
Cetuximab CL x MMAE was incubated with uPA (A) and MT-SP1 (B) and cleaved fragments were analyzed by ESI-MS (reduced). 
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Appendix 16: RP-MS chromatograms Trastuzumab CL x MMAE cleavage reaction with uPA and MT-SP1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Trastuzumab CL x MMAE was incubated with MT-SP1 (A) and with uPA (B) and cleaved fragments were analyzed by RP coupled to 
MS. Peaks were assigned to the specific fragments according to their detected mass. Used irreversible enzyme inhibitor 1,5-Dansyl-Glu-
Gly-Arg Chloromethyl Ketone (C) to stop the cleavage reaction of uPA and matriptase. 
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Appendix 17: Overlay of RP-HPLC chromatograms Trastuzumab CL x MMAE cleavage reaction with uPA 
and MT-SP1 
 
 
Enyzme kinetics experiments with uPA and MT-SP1. Trastuzumab CL x MMAE was incubated with uPA (A) and MT-SP1 (B) and 
peak assignment of cleaved fragments was achieved in a previous RP run (mobile phase: Water + 0.1% TFA) coupled to MS (see Appendix 
16). Each time point was stopped by small molecule inhibitor 1,5-Dansyl-Glu-Gly-Arg Chloromethyl Ketone. 
 
Appendix 18: Enzyme cleavage reaction of uPA and MT-SP1 with Tmab CL x MMAE at different time points 
Cleaved fragments generated by uPA (A) and MT-SP1 (B) were analyzed by SDS-PAGE and each time point was stopped by small 
molecule inhibitor 1,5-Dansyl-Glu-Gly-Arg  Chloromethyl Ketone. 
 
Appendix 19: Affinity and kinetic analysis of commercial Herceptin and isotype control anti-HEL by BLI 
Herceptin (A) and anti-HEL (B) were analyzed with anti-human Fab-CH1 (FAB2G) biosensors. Interference pattern shift [nm] is 
monitored with varying concentrations of analyte over the time [sec]. 
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Appendix 20: Cellular binding of designed Cetuximab antibodies and antibody fragments to several cancer cell 
lines 
 
 
Binding assay of cetuximab antibodies and antibody fragments by flow cytometry. Constructs displayed no binding to EGFR-negative 
MCF-7 cells for bivalent (A) and monovalent antibodies (D). On high-expressing EGFR cell line MDA-MB-468, binding of all IgG 
antibodies is strongly increased (B), whereas monovalent Trastuzumab Fab His shows a slightly weaker binding compared to IgG 
antibodies (E). For A431 cells a strong binding effect is obtained for conventional antibody format (C) and antibody fragments (F). In all 
cases, binding is comparable to commercial Erbitux. Samples were measured in duplicates. 
 
Appendix 21: Thermal stability raw data of Trastuzumab-based antibodies and ADCs by nanoDSF 
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Melting points of glycosylated antibodies (A), ADCs (B) and deglycosylated antibodies (C) were determined by measuring the maximum 
of the first derivative curve of F330nm/F350nm ratios. 
 
Appendix 22: Terminal % drug load relative to initial conjugated total MMAE for mouse and human serum 
 
 
 
 
 
 
 
 
 
 
 
 
Samples were incubated in mouse serum (A) or human serum (B) at 37°C, 5% CO2 for 96 h. Samples were taken at different time points 
and analysis was performed by LC-MS as triplicates. As a test item MMAE was detected. Depicted are remaining % of drug load relative 
to initial conjugated total MMAE at time point 96 h. 
 
Appendix 23: Drug load as percentage relative to initial conjugated total MMAE for mouse and human serum 
at different time points. 
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Samples were analyzed by LC-MS, using MMAE as a test item. Depicted are exemplarily remaining % of drug load relative to initial 
conjugated total MMAE of Trastuzumab CL x MMAE (A) and Trastuzumab Fab His x MMAE (B) in human serum as well as 
Trastuzumab CL x MMAE (C), Trastuzumab nCL x MMAE (D), Trastuzumab Fab His x MMAE (E) and Trastuzumab oa SEED x 
MMAE (F) in mouse serum. 
 
Appendix 24: Western Blot analysis of Trastuzumab-based antibodies incubated with SKBR-3 cells 
 
 
 
 
 
 
 
 
 
Detection of cleaved Fab fragments was carried out with goat anti-human IgG Antibody, F(ab’)2 specific. Samples were Tmab Fab His, 
Tmab CL + MT-SP1, Tmab CL and Tmab nCL incubated with SKBR-3 cells at 37°C for 72 h. Analysis of 2 h and 6 h incubation was 
performed. For Immunodetection, BCIP/NBT was added. Tmab = Trastuzumab 
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Appendix 25: Cytotoxicity of Trastuzumab x MMAE ADCs on cancer cell lines. 
 
Trastuzumab ADCs generated by enzyme-assisted, site-specific conjugation of ValCit-PABC-MMAE to light chains were incubated on 
HER2-overexpressing SKBR-3 (A), HCC1954 (B) and BT-474 cells (C) as well as on HER-2 negative cells MDA-MB-468 (D) for 72 h. 
Uncojugated antibodies and antibody fragments were used as controls. Cell viability was analyzed by measuring ATP-levels using the 
CellTiter-Glo assay. High cytotoxic activity was observed on HER2-overexpressing cells with subnanomolar potencies (IC50 values), 
whereas no cell killing by Trastuzumab ADCs could be detected on HER2-negative cell. Illustrated are exemplary cell viability graphs 
from at least three independent experiments. 
 
Appendix 26: Overview of cytotoxicity of Trastuzumab MMAE ADCs on NCI-N87 
 
Construct DAR NCI-N87 
Tmab CL x MMAE 1.9 0,39 ± 0,04 
Tmab nCL x MMAE 1.8 0,40 ± 0,14 
Tmab natural x MMAE 1.8 0,38 ± 0,07 
Tmab CL x MMAE + MT-SP1 0.8 44,55 ± 44,41 
Tmab Fab His x MMAE 0.9 32,72 ± 30,25 
Tmab oa SEED x MMAE 0.8 11,33 ± 8,89 
Kadcyla 3.5 0,15 ± 0,05 
MMAE - 0,22 ± 0,02 
DM-1 - 1,22 ± 0,23 
Depicted are cellular potencies of MMAE ADCs in different formats on NCI-N87 cancer cell line. Used control ADCs comprised Kadcyla 
and anti-Dig x MMAE. Mean IC50 values in nM from at least three independent experiments were used. 
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Appendix 27: Cytotoxicity of Trastuzumab x MMAF ADCs on cancer cell lines 
 
 
Trastuzumab ADCs with cleavable ValCit-PABC-MMAF linker drug conjugated to light chains were incubated on HER2-
overexpressing SKBR-3 (A), HCC1954 (B) and BT-474 cells (C) as well as on HER-2 negative cells MDA-MB-468 (D) for 72 h. Also 
unconjugated antibodies were tested. Cell viability of cells was analyzed by ATP-levels using the CellTiter-Glo assay. No cell killing by 
Trastuzumab ADCs could be detected on HER2-negative cells. Illustrated are cell viability graphs from at least three independent 
experiments. 
 
Appendix 28: Overview of cytotoxicity of Cetuximab (C225) x MMAE ADCs and FDCs on cancer cell lines 
 
Construct DAR A431 MDA-MB-468 MCF-7 
C225 CL x MMAE 1.1 0,54 ± 0,23 0,37 ± 0,06 > 100 
C225 nCL x MMAE 1.3 0,49 ± 0,07 0,34 ± 0,13 > 100 
C225 natural x MMAE 1.1 0,56 ± 0,07 0,41 ± 0,15 > 100 
C225 CL x MMAE + MT-SP1 0.8 0,95 ± 0,01 0,79 ± 0,19 > 100 
C225 Fab His x MMAE 0.8 0,71 ± 0,28 0,53 ± 0,22 > 100 
C225 oa SEED x MMAE 0.8 1,05 ± 0,26 0,95 ± 0,44 > 100 
Erbitux - > 100 > 100 > 100 
MMAE - 0,15 ± 0,12 0,46 ± 0,07 0,59 ± 0,10 
DM-1 - 0,99 ± 0,09 0,55 ± 0,03 1,35 ± 0,27 
 
Depicted are cellular potencies of Cetuximab x MMAE ADCs in different formats on A431, MDA-MB-468 and MCF-7 cells. Mean 
IC50 values in nM from at least three independent experiments were used. 
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Appendix 29: Cytotoxicity of Cetuximab x MMAE ADCs and FDCs on cancer cell lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cetuximab ADCs and FDCs generated by sortase A conjugation of ValCit-PABC-MMAE to light chains were incubated on EGFR-
overexpressing A431 (A), MDA-MB-468 (B) cells as well as on EGFR-negative cells MCF-7 (C) for 72 h. Uncojugated antibodies and 
antibody fragments were used as controls and full length ADCs were also tested on A431 (D), MDA-MB-468 (E) and MCF-7 (F) cells. 
Cell viability was analyzed by measuring ATP-levels using the CellTiter-Glo assay. Illustrated are exemplary cell viability graphs from 
at least three independent experiments 
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Appendix 30: Tumor spheroid with HCC1954 cell line 
 
 
 
 
 
 
 
 
 
 
Spheroid formation was successful due to the formation of an extracellular matrix, represented by the black circle surrounding the 
spheroid. Scale bar = 400 µm 
 
Appendix 31: Spheroid distribution and penetration with antibody-fluorophore conjugates using EVOS device 
 
 
HCC1954 spheroids were treated with antibody-fluoropore conjugates with a concentration of 6.25 nM. Trastuzumab CL x AF x BHQ-
10 was applied without enzyme to ensure matriptase cleavage is achieved by tumor cells. Control samples that are applied as Fab 
fragments attached to Alexa Fluor 488 comprised Trastuzumab CL x AF488 x BHQ-10 + MT-SP1 and Trastuzumab Fab x AF488. 
Prior measurement, calibration was carried out with fluorescence microscope EVOS FL 2 and the brightness and coarse (autofocus) were 
adjusted. Objective was used with 20x magnification, pictures were captured along Z stack at 24 h. Images are depicted in greyscale that 
is related to green fluorescence. Scale bar = 50 µm 
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8.1. Abbreviations 
aa Amino acid 
ADC Antibody-drug conjugate 
ADCC Antibody-dependent cellular cytotoxicity 
ADCP Antibody dependent cellular phagocytosis 
AF488 Alexa Fluor 488 
ALCL Anaplastic large-cell lymphoma 
ALL Acute lymphoblastic leukemia 
AMD Age-related macular degeneration 
AML Acute myeloid leukemia 
Amp Ampicillin 
ATP Adenosine triphosphate 
BCA Bicinchoninic acid 
BCR B-cell receptor 
BLI Biolayer interferometry 
BRCA1 Breast cancer susceptibility 1 
BSA Bovine serum albumin 
C225 Cetuximab 
CD Cluster of differentiation 
CDC Complement-dependent cytotoxicity 
CDR Complementarity determining region 
CH1, 2, 3 Constant domain 1, 2, 3 of the heavy chain 
CL cleavable 
CLL Chronic lymphoblastic leukemia 
CML Chronic myeloid leukemia 
CTLA4 Cytotoxic T lymphocyte-associated antigen 4 
CV Column volume 
Da Dalton 
DAR Drug-to-antibody ratio 
dH20 Distilled water 
DHFR Dihydrofolate reductase 
DNA Deoxyribonucleic acid 
ECD Extracellular domain 
E. coli Escherichia coli 
EGF(R) Epidermal growth factor (receptor) 
ELISA Enzyme-linked immunosorbent assay 
Fab Fragment antigen binding 
FACS Fluorescence activated cell sorting 
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Fc Fragment crystallizable 
FcRn Neonatal Fc receptor 
FcγR Fcγ receptor 
FCS Fetal calf serum 
FDA Food and Drug Administration 
FDC Fragment-drug conjugate / Fab-drug conjugate 
FGF Fibroblast growth factor 
FITC Fluorescein 
GIST Gastrointestinal stromal tumors 
gp Glycoprotein 
h Hour 
HC Heavy chain 
HCC Hepatocellular carcinoma 
HER Human epidermal growth factor receptor 
HGF / SF Hepatocyte growth factor, scatter factor 
HGFR Hepatocyte growth factor receptor, mesothelial epithelial transition; c-MET 
HIC Hydrophobic interaction chromatography 
HIF-1a Hypoxia inducible factor-1 alpha 
His-tag Histidine tag, usually composed of six histidines 
HL Hodgkin lymphoma 
HPLC High performance liquid chromatography 
HPV Human papillomavirus 
HRP / POD Horseradish peroxidase 
hu / hs Human / homo sapiens 
Ig Immunoglobulin 
IGN Indolinobenzodiazepine 
IL Interleukin 
IMAC Immobilized metal ion affinity chromatography 
ITAM Immunoreceptor tyrosine-based activating motif 
ITIM Immunoreceptor tyrosine-based inhibitory motif 
ka Association rate constant 
KB Kinetics buffer 
KD Equilibrium dissociation constant 
kd Dissociation rate constant 
LB medium Luria-Bertani medium 
LC Light chain 
mAb / pAb Monoclonal antibody / polyclonal antibody 
MALDI-TOF Matrix-assisted laser desorption/ionization time of flight mass spectrometry 
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MAPK Mitogen-activated protein kinase 
MS Mass spectrometry 
MCS Multiple cloning site 
MES 2-(N-morpholino)ethanesulfonic acid 
MFI Mean fluorescence intensity 
MMAE Monomethyl auristatin E 
MMAF Monomethyl auristatin F 
MMP Matrix metalloproteinase 
mRNA Messenger ribonucleic acid 
MSA Multiple sequence alignment 
mTG Microbial transglutaminase 
MT-SP1 Matriptase 
mu Murine, mus musculus 
MWCO Molecular weight cut-off 
n.d. Not determined 
NC Nitrocellulose 
nCL noncleavable 
NEAA Non-essential amino acids 
NHL Non-Hodgkin lymphoma 
NHS N-hydroxy succinimide 
NK cells Natural killer cells 
NK1 N-terminal HGF fragment 
NSCLC Non-small-cell lung carcinoma 
oa One-armed 
OD Optic density 
PABC Para-aminobenzyloxycarbonyl 
PAGE Polyacrylamide gel electrophoresis 
PAI Plasminogen activator inhibitor 
PAMPs Pathogen-associated molecular patterns 
PBMCs Peripheral blood mononuclear cells 
PBD Pyrrolobenzodiazepine 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PD-1 Programmed cell death protein 1 
PD-L1 Programmed cell death protein ligand 1 
PDB Protein Data Bank 
PDGF Platelet-derived growth factor 
PEG Polyethylene glycol 
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PI Propidium iodide 
PI3K Phosphatidylinositol 3-kinase 
PVDF Polyvinylidene fluoride 
RCC Renal cell carcinoma 
RFU Relative fluorescence units 
RIPA buffer Radioimmunoprecipitation assay buffer 
rpm Revolutions per minute 
RT Room temperature 
RTK Receptor tyrosine kinase 
scFv Single-chain variable fragment 
SCLC Small cell lung cancer 
s.d. Standard deviation 
SDS Sodium dodecylsulfate 
SEC Size exclusion chromatography 
sec second 
SEED Strand exchange engineered domain 
SERM Selective estrogen-receptor modulator 
SHM Somatic hypermutation 
SMCC Succinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate 
SMDC Small molecule−drug conjugate 
Srt Sortase 
TCEP Tris(2-Carboxyethyl)phosphine 
TCR T-cell receptor 
T-DM1 Trastuzumab emtansine 
TFF Tangential Flow Filtration 
TKI Tyrosine kinase inhibitor 
TLR Toll-like receptor 
Tm Melting temperature 
Tmab Trastuzumab 
TME Tumor microenvironment 
TNM T (tumor) N (node) M (metastasis) Classification System for Malignant Tumors 
TNF-a Tumor necrosis factor-a 
tPA Tissue-type plasminogen activator 
Tris Tris(hydroxymethyl)aminomethane 
uPA Urokinase-type plasminogen activator 
uPAR Urokinase-type plasminogen activator receptor 
US United States 
v/v Volume per volume 
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ValCit Valine-citrulline 
vc Valine-citrulline 
VEGF Vascular endothelial growth factor 
VH Variable domain of the heavy chain 
VL Variable domain of the light chain 
w/v Weight per volume 
wt Wild type 
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